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Abstract
Blood pressure homeostasis is controlled via a complex network of cell signaling
mechanisms. Among the broad network of receptors and signaling molecules regulating
blood vessel reactivity, members of the G protein-coupled receptor (GPCR) family are
known to play a central role. GPCR activity represents a delicate, but coordinated balance
between molecular mechanisms governing receptor signaling, desensitization, and resensitization. GPCR kinase 2 (GRK2) modulates multiple cellular responses through
GPCR desensitization and alterations in GRK2 activity are considered to play an important
role in the development of hypertension. The main premise of our study was to test whether
the inhibition of GRK2 expression leads to alterations in vascular reactivity, vascular tone,
and vascular smooth muscle cell (VSMC) signaling. Genetic knockdown of GRK2
expression results in a mouse that shows indications of intrauterine growth retardation
phenotype and becomes spontaneously hypertensive at 8-12 weeks of age due to alterations
in the balance between mechanisms regulating vasodilatation and vasoconstriction. The
extensive loss of GRK2 expression favors an increased in vasoconstriction associated with
an increase in peripheral resistance and this is likely due to the reduced Gαq/11-coupled
receptor desensitization. The vasodilatation in response to GαS-coupled receptor
stimulation was also enhanced, but the increases in vasoconstrictor mechanisms dominate
the physiological phenotype. In addition, VSMCs cultured from shGRK2-knockdown mice
demonstrate an altered ERK1/2 and Akt/PKB signaling with age, as well as age-dependent
increases in cellular proliferation and migration responses linked to Gαq/11-coupled GPCR
activation. Our results indicate that, as blood pressure increases in the shGRK2 mice, the
expression of renal renin angiotensin system (RAS) components increases correspondingly
and this has a strong impact on the regulation of both peripheral vascular resistance and
sodium balance. The chronic activation of RAS also potentiates renal injury by inducing
alteration in glomerular filtration rates and progression of renal fibrosis. Thereby, these
intricate effects complement each other in the onset of hypertension. Finally, to enable
definition of the role of Rab4GTPase on GPCRs re-sensitization, we have developed a
vascular specific inhibitory Rab2S22N transgenic mouse and the documentation of the
hypertensive phenotype is the first evidence for the existence of a causal relationship
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between alteration in Rab4 activity and vascular GPCR signaling. Taken together, our
findings indicate that the balance between mechanisms regulating vascular tone is
significantly modulated by intracellular regulatory proteins underlying GPCR signal
transduction.

Keywords: G protein-coupled receptors, heterotrimeric G proteins, G protein-coupled
receptor kinases, desensitization, Rab4GTPase, re-sensitization, signal transduction,
vascular smooth muscle cells, vascular tone, renin angiotensin system, hypertension
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CHAPTER 1:
INTRODUCTION

1

1.1

G Protein-Coupled Receptor Family

The seven transmembrane-spanning domain or G protein-coupled receptors (GPCRs)
represent the largest and the most diversified protein family of cell surface receptors
(Lander et al., 2001; Latek et al., 2012). Current estimations assert that 1000 up to 2000
distinct receptors might exist if alternate splicing variants are also accounted for. This
broad conformational variety allows GPCRs to be involved in a multitude of physiological
processes including senses, behavioral and mood regulation, hemodynamics and
intermediary metabolism control, as well as cellular growth, differentiation and apoptosis.
Because of this diversity of stimuli to which GPCR respond to, it is not surprising that over
half of all drugs used in the present clinical practice target GPCRs directly or indirectly
(Flower, 1999).
The common trait of all known GPCRs is that they share a common central core
domain comprised of seven transmembrane helices joined by three intracellular and three
extracellular loops. The two additional cysteine residues that are present in most GPCRs
are assumed to play an important role in packing as well as in the stabilization of certain
conformations of the GPCRs. The extracellular region – characterized by a high structural
diversity but a small movement during activation – plays a significant role in ligand binding
Unlike the relatively stable shape of the extracellular zones, intracellular regions are known
to be characterized by broad conformational modifications following receptor activation
(Katritch et al., 2012). Due to their localization within the inner cellular structure,
intracellular regions interact extensively with a multitude of G proteins, arrestins as well
as many other downstream effectors (Lefkowitz, 2000; Palczewski et al., 2000;
Palczewski, 2006; Cherezov et al., 2007; Jaakola et al., 2008; Rasmussen et al., 2011b).
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When it comes to the taxonomy of the GPCRs, several classification systems have
been proposed. While an unitary classification scheme would have been advantageous
from a variety of perspectives, the challenge to be overcome is related to the broad
discrepancies in sequences that exist between invertebrate and mammalian GPCRs
(Broeck, 2001). Some classifications are grouping the ligands based on how they are
binding, while others rely on both physiological and structural characteristics. One of the
common classifications – applicable to both vertebrates and invertebrates – is based on
classes (involving letters from A to F) and subclasses (involving roman numbers) (Attwood
and Findlay, 1994; Kolakowski, 1994; Bockaert and Pin, 1999; Josefsson, 1999; Graul and
Sadee, 2001; Joost and Methner, 2002; Fredriksson et al., 2003).
According to the widespread GRAFS taxonomy (Schioth and Fredriksson, 2005),
the GPCR superfamily is split into five families, namely: glutamate (former class C),
rhodopsin (former class A), adhesion (part of former class B), frizzled/taste2 (former class
F), and secretin (part of former class B). Former classes D (fungal mating pheromone
receptors) and E (cyclic AMP receptors) are not part of the GRAFS classification system,
and that is essentially because they do not include human receptors.
Interestingly, not all receptors captured by the GRAFS classification are believed
to signal through heterotrimeric G proteins, such that – at least when looking from this
particular angle – the conventional “G protein-coupled receptor” term could be perceived
as a somewhat of a misnomer, since in reality completely different signaling mechanisms
could be activated. One of the well-described examples in this category is represented by
the Frizzled receptors.
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1.2

G Protein-Coupled Receptor Signaling

1.2.1

Receptor Structure-Function Relationship
The transmembrane localization and disposition of GPCRs – exposed to both extra-

and intracellular stimuli – enable them to become a critical component for the transduction
of the incoming extracellular messages into downstream intracellular responses. The
presence of multiple enzymatic steps along the signaling pathway creates the premises for
strong signal amplifications that occur even at low (5%) receptor occupancy rates
(Arshavsky et al., 2002).
Early

studies

proposed

that

the

binding

between

agonist

and

transmembrane/extracellular domains of GPCR is accompanied by conformational
changes of the receptor that are transmitted to its intracellular domains in contact with the
G protein complex (Gether and Kobilka, 1998; Ridge et al., 2003). These conformational
changes can take either the form of a high-affinity “ternary complex” among the agonistreceptor-G protein or that of a low-affinity state (when G protein is absent) (De Lean et al.,
1980). However, more recent works have further enhanced this model in order to account
for constitutively active GPCRs as well as full, partial, neutral, antagonist, and inverse
agonists (“extended ternary complex model”) (Samama et al., 1993). The primary
difference between these types of agonists resides in the preferred equilibrium state of the
GPCR that can vary between active (R*) (full agonist binding to R* conformation),
inactive (R) (inverse agonist binding to R), or unselective (neutral antagonist binding to
either R* or R) (Lefkowitz et al., 1993).
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To account for all aspects of GPCR function, more comprehensive models
(Kenakin, 2002; Kenakin, 2003) advocate for the existence of an “alternative ternary
complex” that oscillates between a conformation required for G protein activation and a
second one needed for receptor internalization. This model, originally proposed for β2adrenergic receptor activation (Swaminath et al., 2004) has been later endorsed by the
discovery of β-arrestin-dependent angiotensin AT1a receptor internalization and signaling
that continued to be present even when G protein coupling was lacking (Wei et al., 2003).
1.2.2

G Protein-Dependent Signal Transduction

G proteins act as molecular switches for the intracellular signaling cascades and provide
the link between the external stimulus and the intracellular effector enzymes.
Heterotrimeric G proteins are a group of GTPases that share a common multi-subunit
structure comprised of a guanosine triphosphate GTP-binding Gα subunit and a linked
heterodimeric Gβγ subunit (Neer, 1995). Based on sequence homology, the Gα subunits
were grouped into four main families, namely Gαs, Gαi, Gαq and Gα12. Alongside with Gα,
five Gβ and twelve Gγ subunits were also identified.
The innate GTPase activity of the Gα subunit determines the hydrolysis of GTP to
GDP and in turn, this will return the Gα to an inactive state that is characterized by a high
Gβγ affinity. Because the re-association of Gβγ with Gα-GDP will cancel all effector
interactions, the lifetime of Gα is believed to have a direct control over the signaling time
of both Gα-GTP and free Gβγ (Siderovski and Willard, 2005). Since the activated GPCR
catalyzes the exchange of GDP for GTP that occurs on the Gα subunit, one GPCR is
capable to activate multiple G proteins. After dissociation, the free Gα-GTP and Gβγ
subunits contribute to the regulation of “second messengers” that in turn control the activity
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of protein kinases with role in intermediary metabolism (Fig. 1.1). For instance, the
activation of Gαs is known to stimulate the production of adenylate cyclase that in turn
upregulates cAMP formation and consequent protein kinase A (PKA) phosphorylation
leading to smooth muscle relaxation and hence increases vasodilatation. Conversely, Gαi
has a Gαs-antagonistic effect culminating with reduced vasodilatation. On the other hand,
Gαq activates phospholipase C (PLC) and induces vasoconstriction either via Ca2+ releases
from intracellular stores or via protein kinase C (PKC) phosphorylation. Finally, Gα12/13 is
capable to activate the Rho kinase leading to smooth muscle contraction via myosin light
chain phosphatase activity (MLCP) (Rhee, 2001; Noma et al., 2006).
1.2.3

G Protein-Independent Signal Transduction

The known versatility of certain GPCRs to bind either directly to enzymatic effectors, or
indirectly through adaptor proteins has prompted the idea that GPCRs might signal by
coupling to non-G protein-regulated effectors. Such mechanisms would likely involve βarrestins and alternative ternary complex formation for GPCR signaling (DeFea et al.,
2000; Luttrell et al., 2001; Miller and Lefkowitz, 2001; Perry and Lefkowitz, 2002; Ahn et
al., 2003). Typical examples in this category are angiotensin antagonist [Sar1Ile4Ile8]AngII binding to wild type AT1 receptor (Luttrell et al., 2001) or propranolol binding to
β2-adrenergic receptor (Azzi et al., 2003), both leading to extracellular signal-regulated
kinase (ERK1/2) activation in the absence of G-protein activation. While G proteins trigger
a rapid and transient nuclear translocation of ERK phosphorylation, β-arrestin-mediated
ERK activation is slower but more persistent and restricted to the cytoplasm (DeFea et al.,
2000; Luttrell et al., 2001; Ahn et al., 2004). Both transient and sustained activated
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Figure 1.1: The schematic diagram of GPCR-G protein-effector model of GPCR
signaling
At rest, the subunits the G protein complex are associated with each other while both
receptor and the complex are not associated. Gαβγ complex is bound to GDP (1). Upon
agonist activation, Gαβγ associates with the receptor, followed by GDP-GTP exchange (2).
Then, Gαβγ dissociates from the receptor into a GTP- Gα subunit and Gβγ heterodimer
leading to the activation of downstream signaling (3 & 4). Within seconds of agonist
binding, GPCRs are phosphorylated by GRKs, followed by subsequent β-arrestin binding.
β-arrestin bound receptors are prepared for endocytosis and sorted for either recycling or
degradation. Simultaneously, RGS bind to the Gα subunit leading to GTP hydrolysis and
resetting the receptor to its initial resting state (5 & 6).
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Gβγ

ERK1/2 pathways have been shown to regulate cell growth and differentiation (Sasagawa
et al., 2005).
1.2.4

Receptor Phosphorylation-Dependent Mechanism

If GPCRs are subjected to prolong activation, the receptor itself becomes a target for
negative regulation. The processes responsible for the regulation of GPCR levels are
typically divided into desensitization, internalization and downregulation. Collectively,
these processes control the uncoupling of the receptor from G proteins, removal of
receptors from plasma membrane followed by recycling or degradation, and reduced
synthesis of new receptors. GPCR desensitization following agonist binding starts off with
receptor phosphorylation that involves mainly the Ser and Thr residues (carboxyl-terminal
tail and third intracellular loop) where the newly added large phosphates will interfere with
G protein-coupling and will facilitate the recruitment of adaptor proteins with role in
internalization (Ferguson and Caron, 1998; Lefkowitz, 1998; Kohout and Lefkowitz,
2003).
Phosphorylation of the receptor can be performed either heterologously via second
messenger-dependent protein kinases (PKA or PKC) or homologously via GPCR kinases
(GRKs) (Ferguson, 2007). Activation of second messenger-dependent protein kinases
desensitize receptors that have not bound agonist thus agonist occupancy of the GPCR is
not necessary for this process. In some situations, PKA phosphorylation can also alter the
G protein-coupling selectivity and this will trigger the PKA-phosphorylated receptor to
reverse the direction (Daaka et al., 1997; Lawler et al., 2001; Zamah et al., 2002). The
switch in coupling from Gαs to Gαi subunit might also tilt the balance towards alternate
signaling pathways (Lefkowitz et al., 2002).
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Homologous desensitization involves phosphorylation of receptors that are in the
agonist-occupied conformation. GRKs-mediated desensitization is a two-step process in
which receptor phosphorylation is followed by arrestin binding. Furthermore, arrestin
binding to receptor domains fulfils three main functions: to blocks GPCR-G protein
interactions, to tag GPCR for chathrin-mediated endocytosis, and to couple GPCRs to G
protein-independent signaling cascades. In this context, the primary role of GRKs in GPCR
desensitization is to increase receptor affinity for arrestins, one example in this sense being
GRK2-induced phosphorylation of β2 adrenergic receptor that increases by 10-30 fold its
affinity for β-arrestin 1 (Lohse et al., 1992).
1.2.5

Receptor Phosphorylation-Independent Mechanism

Since phosphorylation is not an absolute prerequisite for GPCR desensitization,
phosphorylation-independent mechanisms also exist and they are typically mediated by
GRKs (Pao and Benovic, 2002; Shenoy and Lefkowitz, 2003; Sterne-Marr et al., 2004).
GRK2 can bind directly to free Gαq/11 subunits through its RGS homology domain
(Carman et al., 1999). Crystallographic analysis has shown that GRK2 might be able to
simultaneously interact with the receptor, free Gαq/11, and Gβγ subunits (Lodowski et al.,
2003). Thereby, desensitization occurs as a consequence of Gβγ sequestration by receptorbound GRK2 that hinders the re-association of receptor with GDP-bound Gαq/11 (Dhami
et al., 2004).
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1.3

GPCR Trafficking

1.3.1

Receptor Internalization

GPCR internalization or endocytosis – is a process slower than desensitization since it
involves a period of few minutes after agonist binding. The internalization of the GPCRs
may occur either in a constitutive or an agonist-stimulated manner (Ferguson, 2001). While
endocytosis can take place via several different avenues, the most commonly employed
one is mediated by clathrin. The two events that “prepare the field” for clathrin-dependent
internalization are GRK-mediated GPCR phosphorylation and β-arrestin binding. The
latter is usually regarded as one of the integral components of GPCR endocytosis,
intracellular trafficking, and downregulation (Goodman et al., 1996; Lefkowitz, 1998).
Depending on their pattern of interaction with β-arrestin isoforms, GPCRs can be
grouped in two classes. “Class A” has a higher affinity for β-arrestin 2 than for β-arrestin1
and it has a transient interaction since upon internalization, the receptor-β-arrestin complex
dissociates. Some of the most typical components of the “class A” are β2 and α1 adrenergic
receptors.
On the other hand, “class B” receptors bind β-arrestin 2 and β-arrestin 1 with equal
affinity and two of the representative members of this class are angiotensin AT1a and
neurotensin 1 receptors. While for class A receptor, the process of internalization is tightly
connected to the lifecycle of an unstable receptor-β arrestin complex, class B receptors
involve a stable receptor-β arrestin compound that internalizes as a unit to be subsequently
processed by the endosomes (Barak et al., 1997; Oakley et al., 2000; Oakley et al., 2001).
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1.3.2

Early Endosomal Sorting and Trafficking

There are two mechanisms that are involved in the recycling pathway and the major
contributor to the selection of one over the other is represented by the stability of the
GPCR–β-arrestin interaction. Certain receptors, such as the β2 adrenergic receptor that
dissociates fast from β-arrestin, can return rapidly to the plasma membrane via recycling
endosomes. On the other hand, when more stable bounds between receptors and β-arrestins
are formed, such is – for instance – the case of AT1R, recycling tends to be a much slower
process that concludes with the degradation of the receptors (Pitcher et al., 1995). The root
cause of this behavior could be tracked down to β-arrestin dissociation that allows protein
phosphatases to cleave receptor phosphates and thus enable its recycling. When
dissociation does not occur – as is the case the case of stable complexes – resensitization
will certainly be hindered (Ferguson and Caron, 1998; Ferguson et al., 1998).
1.3.3

Receptor Recycling and Downregulation

Re-initialization of signal transduction via recycling of the internalized receptors is a more
effective approach than the de novo receptor synthesis. Sorting of the GPCRs back into the
recycling occurs either through a default mechanism via a “bulk” membrane flow or
through a regulated process via Rab GTPases (Gruenberg, 2001; Dale et al., 2004;
Maxfield and McGraw, 2004).
The persistent loss of cell surface receptors – also known as downregulation represents the least understood part of GPCR responsiveness. While the information stored
at the transcriptional level is important, receptor internalization followed by either resensitization or degradation also plays a major role on the control of receptor density on
the cell surface, particularly during the early stages of downregulation.
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1.4

G Protein-Coupled Receptor Kinase Family

1.4.1

Structural Organization
There are seven genes involved in the encoding of the mammalian GRKs, a family

of serine/threonine kinases with common structural and functional characteristics (Pitcher
et al., 1998a; Kohout and Lefkowitz, 2003). All GRKs share a similar basic structure that
includes a well-conserved central catalytic domain (~ 270 aa) that is flanked by an amino
terminal (~ 185 aa), and a carboxyl terminal with a variable length (~ 105-230 aa) (Penela
et al., 2003) (Fig. 1.2). The N-terminal domain plays an important role in receptor
recognition (e.g., the α-actinin-binding domain of GRK2) and intracellular membrane
anchoring (e.g., the calmodulin-binding domain of GRK5) (Palczewski et al., 1993; Penn
et al., 2000). Furthermore, the amino terminus of GRK2 has been shown to be homologous
to G-protein signaling at the Gαq/11 binding RH domain and to inhibit GPCR-Gαq by
sequestering the Gαq/11 subunits. By contrast, the C-terminal domain contributes to their
subcellular localization and agonist-dependent translocation by facilitating their interaction
with lipids and other membrane proteins (Inglese et al., 1992; Pitcher et al., 1992; Koch et
al., 1993; Kohout and Lefkowitz, 2003; Penela et al., 2003; Penela et al., 2006; Reiter and
Lefkowitz, 2006).
Based on the homology of their sequences, GRKs can be categorized into three
main groups: rhodopsin kinase or visual subfamily (GRK1 and GRK7), the β-adrenergic
receptor kinases subfamily (GRK2 and GRK3), and GRK4 subfamily (GRK4, GRK5 and
GRK6). While certain common traits exist between all GRKs, each of them fulfils specific
regulatory properties.
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Figure 1.2: Linear diagram illustrating the three domain structures of GRK family
All GRK isoforms share a similar basic structure with a central catalytic domain, flanked
by an amino terminal containing a regulated of G protein signaling (RGS) and a carboxyl
binding domain of variable length. Aminoacid numbers – at the start and end of the
structure – were shown to indicate the particular size of each isoform.
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Furthermore, their anatomical localization is extremely diverse and inconsistent since
GRK1 and GRK7 are expressed in retinal rods and cones, GRK4 is expressed in testis,
cerebellum and kidney while GRK2, 3, 5, and 6 are ubiquitously expressed in mammalian
tissues (Sallese et al., 1997; Virlon et al., 1998; Sallese et al., 2000b).
With respect to their cellular localization, GRKs are mainly present in the
cytoplasm or in the proximity of the plasma membrane. For instance, GRK1 and GRK7
are connected directly to the membrane due to their short COOH-terminal prenylation
sequence that facilitates the attachment of lipid molecules acting as anchors to the cell
membranes (Inglese et al., 1992; Iaccarino et al., 1998).
GRK2 and GRK3 are located in cytosol and bind within their C-terminus to the
membrane-anchored Gβγ subunits of G protein complex (Pitcher et al., 1992; Carman et
al., 2000). Since free Gβγ subunits are produced by ligand-bound receptors, the Gβγ will
recruit the GRK2 and GRK3 isoforms. This will largely enhance the GPCR
phosphorylation only when the fidelity of the desensitization process is critical in case of
agonist-activated receptors. On the other hand, the specific interactions of GRK2 with the
membrane-anchored Gβγ will also assist with the preservation of a membrane-bound
GRK2 prior to the agonist-dependent GRK2 translocation (Penela et al., 2003). However,
in addition to their cytosolic localization, GRK2 was also found in mitochondria, even
though this is a rather uncommon possibility (Fusco et al., 2012; Chen et al., 2013).
GRK4 and GRK6 possess both post-translational palmitoylation sites and lipidbinding positively charged elements that determine their constitutive membrane
localization (Stoffel et al., 1994; Premont et al., 1996; Loudon and Benovic, 1997; Pitcher
et al., 1998a; Stoffel et al., 1998). Both GRK4 and GRK6 have multiple splice-variant
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forms that determine different structural domain organizations (Premont et al., 1999; Vatter
et al., 2005). GRK5 is also found attached to the plasma membrane via its PIP2 binding
domain even though lacks the classical palmitoylation site (Pronin et al., 1998;
Thiyagarajan et al., 2004). One interesting case is that GRK6A splice variant includes
elements that both promote and inhibit membrane localization. Furthermore, even though
both cytoplasm and nucleus contain non-palmitoylated forms of GRK6A, its nuclear
function remains unknown (Jiang et al., 2007). However, nuclear localization sequences
are common in all members of the GRK4 subfamily (Johnson et al., 2004; Johnson et al.,
2013).
To a certain extent, the functional specificity of GRKs for a certain receptor can be
explained through the differential subcellular targets and tissue expression levels that could
be indeed one of the ways in which GRKs manage to accomplish different tasks in different
tissues. However, a number of questions remain still open since variable expression levels
of different GRK isoforms are unable to fully explain the receptor-kinase specificity. While
receptor phosphorylation “bar coding” (Nobles et al., 2011), cell-specific expression or
structural characteristics have all emerged as viable explanations of the receptor specificity,
the complete picture remains unclear.
1.4.2

Regulation of GRKs Activity and Mechanism of Action

The first and well described function of GRKs is the ability to phosphorylate active GPCRs
(Wilden, 1995) and to allow binding of arrestins to block the cytoplasmic surface of
receptors (Krupnick et al., 1997) thus preventing their interaction with effector enzymes
(Palczewski et al., 1991; Chen et al., 1993). The only exception from this overall functional

17

pattern of GRKs is GRK4α that was shown to be capable of phosphorylating the
unstimulated GPCRs (Menard et al., 1996; Rankin et al., 2006).
GRKs were found to phosphorylate many other targets at the membrane as a
response to receptor activation (Binder et al., 1990; Binder et al., 1996) that occurred with
non-cognate pairs, as is the case of GRK2 that phosphorylates rhodopsin in a lightdependent manner (Benovic et al., 1986). The shared activation characteristics allow few
GRKs to be capable of phosphorylating virtually hundreds of GPCRs (Palczewski, 1997).
The two conditions to be met for GRK-mediated phosphorylation of GPCRs are the
presence of negatively charged lipids as well as the formation of a GRK docking pocket
(inaccessible in the active state) in the cytoplasmic surface of the active receptor (Choe et
al., 2011; Rasmussen et al., 2011a; Standfuss et al., 2011).
In addition to GPCRs, GRKs are also capable of phosphorylating a broad variety
of proteins such as single transmembrane domain tyrosine kinases (PDGFRβ), single
transmembrane domain serine/threonine kinases, toll-like receptors, transcription factors
and adapter proteins. The first non-GPCR protein identified was tubulin and both GRK2
and GRK5 were found to phosphorylate it (Carman et al., 1998; Haga et al., 1998; Pitcher
et al., 1998b).
However, GRKs were found to modulate cell functions that are independent of
phosphorylation and this can be attributed mainly to their ability to interact with many
signaling and trafficking proteins such as, actin (Freeman et al., 1998), actinin (Freeman
et al., 2000), caveolin (Carman et al., 1999; Gildea et al., 2009), clathrin (Shiina et al.,
2001), Gα (Carman et al., 1999), Gβγ (Pitcher et al., 1992), PI3K (Naga Prasad et al.,
2001), tubulin (Carman et al., 1998). In addition, GRKs modulate multiple cellular
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responses such as cell migration (Penela et al., 2008), cell survival (Chen et al., 2013) and
metabolism (Usui et al., 2004; Cipolletta et al., 2009; Ciccarelli et al., 2011).
Many mechanisms have been proposed to explain the cytoplasmic regulation of
GRKs. Even though it became soon clear that while a common component exists, kinase
activity tends to be extremely specific to each GRK subtype. For instance, in HEK cells,
PKA binds and phosphorylates GRK2 and this enhances Gβγ biding and promotes
membrane translocation (Cong et al., 2001). Similarly, PKC phosphorylation was found to
augment GRK2 activity (Chuang et al., 1995; Winstel et al., 1996; Krasel et al., 2001).
Because GRK2 is a short-lived protein that is polyubiquitinated and degraded in
response to β2ARs (Penela et al., 2001), it is natural to believe that transcriptional
regulation might play an important role in GRK control, although very little is known about
the mechanisms involved in the modulation of GRK mRNA levels. A different mechanism
proposed for GRK2-specific regulation involves S-nitrosylation: when nitric oxide (NO) is
abundant, this causes the inhibition of GRK2 activity towards GPCRs (Whalen et al.,
2007). Furthermore, GRK2 was found to have a bidirectional inhibitory relationship with
endothelial NO synthase (eNOS) that is practically dependent on eNOS bioavailability
(Huang et al., 2013). GRK2 was also found to be phosphorylated by p38 protein (Liu et
al., 2013) and mitogen-activated protein (MAP) kinases (Pitcher et al., 1999) that results
in reduced phosphorylation of the active receptor and accentuated GRKs degradation
(Elorza et al., 2003; Chen et al., 2013). However, phospholipids are also known to play a
role in GRK activity modulation, typically via the PH domain of GRK2 and GRK3
(Onorato et al., 1995; Pitcher et al., 1996; Pronin et al., 1998; Carman et al., 2000).
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1.4.3

GRKs and GPCR-Biased Signaling

The main mechanism responsible for GPCR downregulation is GRK-mediated
phosphorylation followed by the binding of the β-arrestin (Premont et al., 1995; SterneMarr and Benovic, 1995) acting as a clathrin adaptor with role in receptor internalization
(Goodman et al., 1996). However, it is possible that – prior to receptor downregulation –
activated GPCRs become “biased” towards G protein or β-arrestin-mediated signaling.
Furthermore, the pattern of receptor phosphorylation will determine a specific β-arrestin
functionality according to the so-called “bar code” model (Nobles et al., 2011). For
instance, GRK6-mediated receptor phosphorylation leads to β-arrestin recruitment and
activation of ERK1/2 signaling whereas GRK2-mediated phosphorylation determines
signaling fading and/or receptor internalization (Kim et al., 2005; Ren et al., 2005; Kara et
al., 2006; Shenoy et al., 2006; Jones et al., 2007; Zidar et al., 2009; Nobles et al., 2011).
Another aspect of GPCR signaling is that some ligands that normally function as
antagonists to block G protein signaling pathways may also function as agonists on
alternative signaling pathways in the same cell (Galandrin et al., 2007; Kenakin, 2007).
This so-called “biased agonism” is particularly important with respect to β-arrestin
signaling and is a target for the treatment of heart failure and hypertension. For example,
it has been demonstrated that the β-blocker carvedilol, antagonizes the Gαs-coupling of
β2ARs, but stimulates GRK2-mediated phosphorylation of the receptor, β-arrestin
recruitment, and ERK1/2 phosphorylation (Wisler et al., 2007; Lee et al., 2008). This has
led to the hypothesis that the unique efficacy of carverdilol in the treatment of heart failure
may be related to the activation of β-arrestin-signaling (Wisler et al., 2007). Biased
agonism is not unique to Gαs-coupled receptors since the AT1AR antagonist
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[Sar1,Ile4,Ile8]Ang II fails to activate G protein signaling, but effectively promotes βarrestin2-dependent ERK1/2 activation (Wei et al., 2003; Rakesh et al., 2010).
1.4.4

GRK2 and Hypertension

Among the seven GRKs, GRK2 seems to be the only isoform that is critical for the
embryonic development (Jaber et al., 1996), while gene ablation of the other kinases results
in much more elusive phenotypes (Jaber et al., 1996; Peppel et al., 1997; Lyubarsky et al.,
2000; Gainetdinov et al., 2003; Walker et al., 2004). More importantly, the physiological
functions of GRK2 extend beyond the embryonic development since this kinase has been
found to be involved with cell cycle progression, migration, and differentiation (Kahsai et
al., 2010; Chen et al., 2011). Moreover, the GRK2-mediated desensitization is also
dependent on selective protein-protein interactions (Lodowski et al., 2003; Tesmer et al.,
2005) that might occur outside of the cell membrane (Fusco et al., 2012).
One of the interesting observations about GRK2 is that its N terminus has the ability
to selectively interact with Gαq. This interaction leads to sequestration of Gαq and further
inhibition of Gαq-mediated activation of PLC (Carman et al., 1999; Sallese et al., 2000a).
The C terminus of GRK2 contains a pleckstrin homology (PH) domain capable of binding
to phosphatidylinositol 4,5-biphosphate (PIP2) and free Gβγ subunits. The latter interaction
is responsible for agonist-mediated translocation of GRK2 to the plasma membrane
followed by the enhanced phosphorylation of the activated GPCRs. The C terminus of
GRK2 also binds to clathrin and this leads to the internalization of certain GPCRs followed
by their co-localization in endosomes along with GRK2 (Ruiz-Gomez and Mayor, 1997;
Shiina et al., 2001) ( Fig. 1.3).
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Figure 1.3: Schematic representation of the GRK2 interactions
In addition to its canonical role to phosphorylate active GPCRs, GRK2 can phosphorylate
diverse non-GPCR substrates such as transcription factors and adaptor proteins. GRK2 also
displays a complex network of functional interactions with signaling and trafficking
proteins. (APC, Adenomatous polyposis coli protein; RalA, Ras like proto-oncogene A;
Mdm2, Mouse double minute 2; GIT1, G protein-coupled receptor kinase-interacting
protein; MEK1, Mitogen-activated protein kinase kinase 1; PI3K, phosphatidylinositol-3kinases; EGFR, Epidermal growth factor receptor; Ezrin aka Cytovillin; ENaC, Epithelial
sodium channels; p38 MAK, Mitogen-activated protein kinases; DREAM, Downstream
regulatory element antagonist modulator; NEDD4, Neural precursor cell expressed
developmentally down-regulated protein 4; SMADS3,4, Mothers against decapentaplegic
homolog 3, 4;
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MEK1

GRK2 was also shown to be involved in the negative modulation of the immune
responses (Penela et al., 2014), and this is accomplished by means of the phosphorylationindependent interactions that occurs with a large – and perhaps yet to be identified –
number of proteins with roles in receptor internalization and signaling. For instance, GRK2
modulates MAPK signaling via direct association with MEK with further consequences on
chemotactic responses (Jimenez-Sainz et al., 2006).
Alterations in GRK2 expression and activity were found associated with a broad
spectrum of pathologies including heart failure (Iaccarino et al., 2005), multiple sclerosis
(Vroon et al., 2005), rheumatoid arthritis (Lombardi et al., 2001). GRK2 levels in
peripheral blood lymphocytes were positively correlated with impaired vascular GRK2
expression and hypertension (Gros et al., 1997; Gros et al., 1999; Gros et al., 2000).
Alterations in GRK2 expression and activity have been described in both human and
animal models of hypertension. GRK2 overexpression in VSMCs in vivo results in mice
that show impaired β-adrenergic-mediated vasodilatation, impaired cAMP accumulation
and a modest increase in blood pressure (Eckhart et al., 2002). However, vascular-specific
knockdown of GRK2 expression(via genetic ablation or peptide inhibition) did not reduce
hypertension even though β-adrenergic-mediated vasodilatation was improved (Cohn et
al., 2008).
Beyond GRK2, other GRKs were found to play complex and intricate roles with
respect to blood pressure regulation. Vascular GRK5 overexpression in transgenic mice
was associated with a hypertensive phenotype (Keys et al., 2005). Low levels of GRK3 in
human lymphocytes were associated with high blood pressure, a result that was also
confirmed through a murine model (Oliver et al., 2010).
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On the other hand, overexpression of both GRK3 and GRK5 in HEK293 cells was found
to desensitize dopamine D1 receptors (Tiberi et al., 1996), while inhibition of GRK6
decreased receptor desensitization (Fraga et al., 2006). The levels of GRK6 in kidney were
found lower in hypertensive rather than normotensive subjects.
To add to this picture, a growing body of work have suggested that GRK4
participates in the adverse responses observed in patients under antihypertensive
medication (Bhatnagar et al., 2009; Liu and Xi, 2012; Rayner et al., 2012; Vandell et al.,
2012; Wagner et al., 2012). This behavior is probably a consequence of the counterbalance
that exists between the regulating role played by GRK4 on both dopamine-mediated
natriuresis and renin-angiotensin system (RAS)-mediated antinatriuresis (Zeng et al.,
2008). GRK4 isoform is constitutively activated under basal conditions partially due to its
capacity to bind to inactive GαS and Gα13 subunits (Keever et al., 2008). So far, four splice
variants were identified for GRK4 (Premont et al., 1996) and all are expressed abundantly
in human renal proximal tubules (Felder et al., 2002; Villar et al., 2009). GRK4 expression
is also characterized by organ specificity, since its renal cortical expression was found
increased in animal models of hypertension (Sanada et al., 2006). Furthermore, the renal
expression of GRK4 was found to be both mouse strain and salt intake-dependent (Escano
et al., 2009). Increased renal GRK4 activity was detected in hypertensive patients (Felder
et al., 2002) and alterations in various GRK4 gene variants were observed in subjects with
different ethnic backgrounds (Bengra et al., 2002; Zhu et al., 2006; Venkatakrishnan et al.,
2013). Moreover, meta-analyses conducted on human studies revealed that while the
GRK4-A486V gene variant is inversely correlated with hypertension among East Asians,
it is positively associated with hypertension among Europeans.
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1.5

Rab Family of Small GTPases

1.5.1

Structure of Rab Proteins

Rab proteins are the largest family of Ras superfamily of monomeric GTPases-binding
proteins. Rab GTPases are small-molecular sized (21–25 kDa) proteins that are involved
in many cellular functions including growth, trafficking, transduction, and fusion of
membrane-bound organelles (Chavrier and Goud, 1999; Pereira-Leal and Seabra, 2000).
Since their initial cloning in late 1980s, about 70 different members of Rab (i.e., “Ras-like
in rat brain”) have been identified and characterized in humans (Pereira-Leal and Seabra,
2000; Zerial and McBride, 2001; Colicelli, 2004). Rab proteins enclose a compact,
globular, GTP binding and hydrolysis domain that is linked to an unstructured C-terminus
domain that tends to be the extremely diverse across Rab GTPase sequences (Itzen and
Goody, 2011). Rab proteins undergoes conformational change when switching from the
active, GTP-binding form to its inactive, GDP-binding counterpart. Mutations targeting
GTP binding and hydrolysis are usually responsible for alter Rab4 function and thereby
hinder the intracellular vesicular transport (Zerial and McBride, 2001).
1.5.2

Subcellular Localization and Microdomains

Rab proteins participates in the regulation of several endocytic, transcytic and exocytic
transport pathways and they are commonly located to the cytoplasmic surface of
membrane-bound organelles (Chavrier et al., 1991; Ferro-Novick and Novick, 1993; Zerial
and Stenmark, 1993; Ullrich et al., 1996; Novick and Zerial, 1997). In addition to their
predominant organelle-attached location, a minor fraction of each Rab protein is found in
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cytosol in a complex with the guanine dissociation inhibitor (GDI) (Garrett et al., 1993;
Soldati et al., 1993; Ullrich et al., 1993).
While the majority of Rab proteins are expressed ubiquitously, some of them have
a more specific tissue/cell type dissemination. For instance, Rab3 is expressed in the
synaptic vesicles of neurons, Rab17 is localized in epithelial cells (Lutcke et al., 1993),
and Rab22 has been found mostly in hematopoietic cells (Hume et al., 2001). The pathway
regulated by Rab proteins is generally correlated with their subcellular location (Zerial and
McBride, 2001). To exemplify, Rab6 and Rab8 were originally found to regulate the
transport of newly synthetized membrane proteins (Huber et al., 1993), while Rab4 and
Rab15 seem to be involved with cargo transports (van der Sluijs et al., 1992; Zuk and
Elferink, 1999; McCaffrey et al., 2001).
Rab proteins are characterized by domain structures in order to fulfill the spatial
distribution of membrane proteins. The endosome domains are comprised of combinations
of Rab proteins that dynamically change over time, but do not typically mix with each
other. Therefore, three main endosomal domains were identified: one with Rab5 alone, one
with combination of Rab4 and Rab5, and one containing Rab4 and Rab11 (Sonnichsen et
al., 2000; Zerial and McBride, 2001). These Rab populations have distinct biochemical
and functional characteristics with specific pharmacological sensitivity. Generation of Rab
endosomal domains depends not only on protein-lipid interactions (Simons and Ikonen,
1997; Mukherjee and Maxfield, 2000; Zerial and McBride, 2001), but also on the amount
of energy generated during GTP hydrolysis which regulates the kinetics and limits the
extension of effector recruitment (Zerial and McBride, 2001)
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1.5.3

Rab Proteins in the Trafficking Pathway

Rab proteins cycle from their GDP-bound inactive to GTP-bound active forms between
cytosol and membranes, respectively. This continuous cycle of activation, inactivation, and
translocation is regulated by at least three key molecules: guanine nucleotide exchange
factors (GEPs), GTPase activating proteins (GAPs) and GDP dissociation inhibitors
(GDIs) (Pfeffer, 2005). Post-synthesis, Rab proteins associate with the cytosolic Rab escort
protein (REP) to form a stable (GDP-bound) complex (Andres et al., 1993; Wilson et al.,
1996).
The primary role of Rab proteins is to regulate each of the four major intracellular
membrane trafficking steps: vesicle formation/budding, vesicle motility/delivery, vesicle
tethering, and fusion of the vesicle membrane with that of the target compartment. Each of
these different steps are being carried out with assistance from Rab effectors that bind to
specific GTP-bound Rabs. Since a single Rab can interact with multiple effectors, it can be
inferred that one Rab protein can regulate various biochemical reactions occurring at
different sites along the pathway between two organelles.
Among all intracellular pathways, the endocytic one plays a key role during the
transport and recycling of proteins. The functionality of the several Rabs located along the
endocytic pathway has been characterized. The endocytic pathway works in a sequence of
steps that start with the formation of clathrin-coated endocytic vesicles (“pits”) to later
become endosomes. Within them, the endocytosed components are then sorted to their
different/final destinations involving either degradation or sorting (Gruenberg and Kreis,
1995; Gruenberg and Maxfield, 1995; Mellman, 1996). Different Rab proteins regulate
each of the steps along the endocytic pathway (Chavrier et al., 1990; Olkkonen et al., 1993;
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Ullrich et al., 1996). For instance, Rab5 mediates trafficking from plasma membrane to
early endosomes (Bucci et al., 1992) while Rab4 mediates the fast recycling from early
endosomes and recycling endosomes (van der Sluijs et al., 1992; Daro et al., 1996;
Kouranti et al., 2006) back to the plasma membrane.
Contrasting with endocytic pathways, the exocytic ones participate in the regulation
of biosynthetic protein secretion and various Rab proteins are involved with different
exocytic steps (Novick and Zerial, 1997). To exemplify, Rab1 and Rab2 govern trafficking
from the endoplasmic reticulum (ER)-to-Golgi, Rab6 regulates the intra-Golgi traffic
(Tisdale et al., 1992), while Rab8 and Rab11 mediate the transport from the trans-Golgi
network (TGN) to the surface (Huber et al., 1993). Furthermore, the exocytic function of
Rab11 seems to also be implicated in the development of the photoreceptor cells in
embryos (Pelissier et al., 2003; Satoh et al., 2005; Giansanti et al., 2007).
Newer theories have started to suggest that endosomes are in fact dynamic sites for
the activation of GPCR-G proteins in a sense that RabGTPases were identified downstream
of various signaling pathways and they influence gene expression and growth control.
Along these lines, β2AR-mediated induction of cAMP-dependent genes was found to be
dysregulated by endocytic inhibitors (Tsvetanova and von Zastrow, 2014). Rab25 and
Rab11a seem to participate in EGFR and TGFβ signaling as well as trafficking in the
context of cell differentiation and proliferation (Lapierre and Goldenring, 2005; Nam et
al., 2010).
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1.5.4

Rab4-Modulated Recycling of GPCRs

There are two isoforms associated with Rab4 protein, each of them being encoded by
Rab4A and Rab4B genes (chromosomes 1 and 19). Rab4 isoforms are ubiquitously
expressed and are characterized by a 93% homology, although their tissue expression is
quite different. For instance, Rab4A is localized in the brain while Rab4B appears in B
cells (Krawczyk et al., 2007; Hoogenraad et al., 2010).
With respect to its intracellular location, Rab4 resides in the endosomal system, in
a sub-compartment with role in fast recycling to the plasma membrane (van der Sluijs et
al., 1992; Daro et al., 1996), and only a relatively small (5%) amount was found in the
Golgi complex. This latter localization suggests that Rab4 might also be involved in the
traffic between endosomes and Golgi complex (de Wit et al., 2001).
Neither the transport to the late endosomes nor the endocytic internalization are
influenced in any way by the inhibitory Rab4-N121I mutant (Gerez et al., 2000).
Dephosphorylation of β2AR occurs during the transit of the receptor between the Rab5and Rab4-positive early endosomal compartments. While the overexpression of wild type
Rab4 neither alters the rate of β2AR nor accelerates the recycling of the receptor back to
the surface of the cell, it appears that the overexpression of Rab4-N121I mutant is in fact
capable to block β2AR recycling and resensitization. In addition, the expression of either
Rab4-N121I or wild type Rab4 does not prevent β2AR phoshphorylation (Seachrist et al.,
2000).
The transgenic overexpression of Rab4 in mouse myocardium leads to significant
increases of β-ARs in the plasma membrane as well as augments basal cAMP production
in response to isoproterenol stimulation. In addition, the cardiac-specific overexpression of
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Rab4 is also responsible for mild cardiac hypertrophy (Filipeanu et al., 2006). Conversely,
the cardiomyocyte-specific transgenic expression of an inhibitory Rab4-S27N mutant was
found to reduce the β2AR-regulated cardiac contractile function, primarily through βAR
reallocation. Moreover, the Rab4-mediated recycling of internalized βARs is required for
resensitization after agonist-binding as well as to maintain normal cardiac catecholamine
responsiveness (Mohrmann and van der Sluijs, 1999; Somsel Rodman and WandingerNess, 2000; Odley et al., 2004).
Rab4 protein was found to co-localize with internalized AT1R whose recycling is
also controlled by Rab11 (Hunyady et al., 2002; Seachrist and Ferguson, 2003; Dale et al.,
2004). As such, it was proposed that AT1R recycling pathway is mediated by both Rab4
and Rab11 (Li et al., 2008). The precise function(s) of Rab4 are still unclear, but it was
speculated that it might facilitate the transported AT1R vesicles to fuse with Rab11-positive
perinuclear compartments, such that after fusion, Rab4 and Rab11 will form common
recycling endosomes. Then, the AT1R sorted for recycling will bud off via Rab11 and it
will be eventually recycled back to the plasma membrane (Li et al., 2008).
Dephosphorylation of AT1R is facilitated by the overexpression of wild type Rab4
(but not Rab11), whereas a constitutively active Rab4-Q67L mutant will promote AT1R
resensitization (Esseltine and Ferguson, 2013). The association between various Rab
GTPases and the AT1R carboxyl-terminus typically leads to different functional outcomes.
To exemplify, Rab5 is capable to promote the sequestration of AT1R in early endosomes
(Seachrist et al., 2002), Rab7 has a role in the trafficking of the AT1R to lysosomes (Dale
et al., 2004), while Rab4 was found to promote the resensitization of the AT1 receptor.
Even though Rab11 can co-immunoprecipitate more effectively with AT1R, Rab4 is in fact
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capable to displace Rab11. Therefore, it could be inferred that small differences in Rab4
expression might translate into dramatically different alterations in AT1R activity.

1.6

Pathogenesis of Hypertension

Hypertension or high blood pressure represents a complex, multifactorial disease that
constitutes a major cause of morbidity and mortality worldwide affecting more than 1
billion people (Lawes et al., 2008). Recent statistics estimate that 19 in 20 Canadians will
develop hypertension over an average life span (Public_Health_Agency_of_Canada,
2010). Even though high blood pressure might not have immediate negative health
consequences, its increased values over prolonged periods of time leads to deterioration of
a number of vital organs such as heart, brain, or kidney. The associated pathologies –
cardiac hypertrophy and failure, stroke, nephropathy – were identified as root causes of the
increased

morbidity

and

mortality

associated

with

chronic

hypertension

(No_authors_listed, 1967). While current therapeutic approaches focused on blood
pressure reductions are generally capable to avert the progression of the pathologies
associated with hypertension (No_authors_listed, 1967; No_authors_listed, 1979;
No_authors_listed, 1985), extensive data collected suggest that hypertensive treatments
have reduced blood pressure to target levels in less than 50% of cases . Despite significant
improvements in the effectiveness of hypertensive treatments, the incidence of
uncontrolled or resistant hypertension remains high. Under these circumstances, a better
understanding of the molecular and cellular mechanisms responsible for the pathogenesis
of hypertension represents one of the priority avenues to be pursued towards the
development of improved therapeutic strategies.
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When it comes to the etiology of hypertension, several major hypotheses have been
proposed and among them the “mosaic theory” of hypertension seems to be the prevailing
dogma. Over the last decades ongoing research attempted to determine which one of the
“myriad” of alterations in blood pressure regulatory systems occurs earliest in the process
and which ones are critical in the maintenance of the hypertensive state.
One of the favored hypothesis asserts that the arteriolar injury is primary and this
increases peripheral resistance, leading to cardiac hypertrophy and kidney strain (Gull and
Sutton, 1872). This initial idea was later refined to add that reduction in the luminal
diameter of small vessels is the hallmark of blood pressure increases that are associated
with idiopathic hypertension (Folkow, 1987).
Another hypothesis revolved around for a key role for the kidney in pathogenesis
of hypertension (Johnson, 1872). The primary “culprit” of this hypothesis is the “pressure
natriuresis” mechanism whose dysfunctionality leads to hypertension (Borst and Borst-De
Geus, 1963; Guyton et al., 1972). According to the theory proposed by Guyton et al.
(1972), the majority of systems causing elevation in blood pressure would only induce
temporary increases, whereas the prolonged ones require important alterations of the
pressure natriuresis curve. Subsequent studies on this topic have largely supported this
hypothesis (Hall et al., 1990; Cowley and Roman, 1996; Wang et al., 2000). Further
endorsements of the renal involvement in hypertension came from a series of kidney
transplantation studies performed both on human patients (Curtis et al., 1983) and animal
models (Bianchi et al., 1974; Dahl and Heine, 1975; Rettig et al., 1990). In this regard,
when kidneys from normotensive, salt-resistant rats were reciprocally transplanted into
hypertensive rats characterized by salt-sensitivity, the blood pressure was either
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normalized (in case of the hypertensive recipients) or increased (in case of the
normotensive recipients) (Bianchi et al., 1974; Dahl and Heine, 1975; Kawabe et al., 1978).
Similar blood pressure normalization patterns were also observed in hypertensive patients
who received kidneys from normotensive donors (Curtis et al., 1983). The primary role of
the kidney is also further reinforced by the genetic studies that have established correlations
between the disorders associated with abnormal blood pressure and fluid reabsorption
along the nephron (Lifton et al., 2001). Evidently, the larger emphasis placed on the kidney
in the context of the hypertension does not exclude the role of non-renal mechanisms that
could intervene either by means of AT1R-mediated vasoconstriction (Crowley et al., 2005)
or systemic nervous system (Naraghi et al., 1994). There are a number of vasoactive
systems that have been suggested as key contributors to the hypertensive process, namely:
increases in intrarenal vasoconstrictors (e.g., angiotensin II (Navar et al., 2003),
endothelin-endothelin A receptor (Noll et al., 1996)) or reductions in intrarenal
vasodilators (e.g., kallikrein–bradykinin (Ardiles et al., 2003), endothelin–endothelin B
receptor (Kohan, 2006), dopamine (Hermann et al., 2006; Katori and Majima, 2006; Jose
et al., 2010).
A long standing debate argued that hypertension is in fact determined by a complex
of genetic and environmental factors (“mosaic hypertension”) because an increased
frequency of hypertension was observed in families of index patients (Page, 1967).
Another hypothesis proposed that neural mechanisms are a major contributor to
hypertension. Following the initial idea that the activation of sympathetic nervous system
leads to the onset of essential hypertension, a number of subsequent studies have shown
that patients with activated sympathetic nervous system (SNS) exhibit an increased basal
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cardiac pace, elevated blood pressure in response to stimuli and increased catecholamine
levels (Julius and Schork, 1978; Goldstein, 1983; Mancia et al., 1999). Multiple
mechanisms appear to be involved in this neural hypothesis, including faulty
autoregulation of the baroreceptors (Mancia et al., 1999), increased hypothalamic
responses (Mancia et al., 1997), stimulation of renal sympathetic leading to the activation
of the adrenergic pathways for the central nervous system (Campese and Park, 2006) or
increased thoracolumbar sympathetic activity (Smithwick, 1949).
Despite the century-long research on the molecular basis of hypertension, it is clear
that – similar with other chronic pathologies – the picture is still unclear and far from being
complete. While the long-term regulation of blood pressure is undoubtedly the outcome of
a collaborative/overlapping activity between neuronal, renal and circulatory systems, with
few exceptions (Joyner et al., 2008; Coffman, 2011; Charkoudian and Wallin, 2014), the
majority of the studies tend to (over)emphasize one of the three components on the expense
of the other two. In this context, the terms that have been coined for the two major theories
in the field are neurocentric (Navar, 2010) and renocentric (Jelakovic and Mayer, 1995;
Joyner et al., 2008). According to the former one, the overactivity of the SNC is involved
in both initiation and maintenance of the blood pressure in patients with essential
hypertension (DeQuattro and Miura, 1973; Esler et al., 1977; Grassi, 2010; Fisher and
Paton, 2012; Esler, 2014; Mancia and Grassi, 2014; Grassi et al., 2015). By contrast, the
renocentric supporters argue that while the kidney is the main long-term regulator of blood
pressure, the nervous system plays an important role in short term regulation (Borst and
Borst-De Geus, 1963; Guyton and Coleman, 1969; Coffman and Crowley, 2008; Brands,
2012; Hall et al., 2012; Coffman, 2014; Ivy and Bailey, 2014).
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1.6.1

Adrenergic System and Vascular Tone

The sympathetic nervous system plays a key role in the regulation of peripheral vascular
resistance and capacitance of the vascular system. Peripheral resistance reflects a net
balance between vasoconstrictor and vasodilator mechanisms. As part of this systemic
activity, vascular tone is mediated by G-protein-coupled receptor signaling pathways.
Previous studies support the assumption that hypertension is in part due to dysregulation
and desensitization of GPCRs linked to vasodilation (Feldman and Gros, 1998; Feldman
and Gros, 2006; Ferguson and Feldman, 2014).
The major mechanism mediating the hormonal regulation of vasodilatation is via
the activation of one or more of the nine known subtypes of adrenergic receptors of which
β – adrenergic receptors (βAR) are the prototype. While the β1A receptors are only present
in certain smooth muscle cells such as in coronary vessels, β2-adrenergic receptors are
express in the most vascular cells and their action involves both endothelial- and vascular
smooth muscle-mediated regulation of vascular tone (Orlov et al., 1996).
One of the key contributors to the regulation of the blood pressure is constituted by
the vascular smooth muscle (VSM) in a sense that the hypercontractive state of VSM is
usually regarded as the hallmark of essential hypertension. Alterations in β2-adrenergic
receptors lead to reduced adenylyl cyclase activity and cAMP formation that in turn
prevents VSM relaxation (Kamikawa et al., 1980; Feldman et al., 1987; Anand-Srivastava
et al., 1991). Interestingly, Gαi (a major inhibitor of adenylyl cyclase) was found
upregulated in VSM and myocardium of hypertensive humans and animal models. β2AR
may couple to Gαi and potentially switch the signal leading to activation of alternative
regulatory pathways (Feldman and Gros, 2006).
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1.6.2

Renin Angiotensin System and Vascular Tone

One of the most powerful regulators of blood pressure is the renin-angiotensin system
(RAS) (Kobori et al., 2007; Navar et al., 2011). From a clinical perspective, it has been
established that RAS is a key regulator of blood pressure and fluid balance, particularly
since the untimely activation of RAS – that is quite common in renal artery stenosis – has
been linked with profound cardiovascular morbidity and hypertension (Lonn et al., 1994).
In addition, studies performed on patients with essential hypertension who do not have
typical signs of RAS activation have shown that angiotensin-converting enzyme (ACE)
inhibitors and angiotensin receptor blockers (ARBs) are capable to successfully diminish
blood pressure, suggesting that dysregulation of RAS was responsible for the increased in
blood pressure (Hansson et al., 1999; Yusuf et al., 2000; Dahlof et al., 2002).
From a mechanistic perspective, RAS is a potent modulator of the renal pressurenatriuresis balance and this directly affects the characteristics of the blood pressure levels
in both normal and pathologic conditions (Hall, 1986; Hall et al., 1999). In this regard,
while the chronic infusion of Ang II shifts the pressure-natriuresis curve to the right –
meaning that RAS activation requires higher blood pressures for a certain amount of
sodium excretion – the administration of ACE inhibitors has an opposite effect, essentially
meaning that the excretion of the sodium in urine is facilitated at lower blood pressures
levels (Hall, 1986).
1.6.2.1 Components of the Renin Angiotensin System
The functionality of RAS relies on a multi-enzymatic cascade of processes according to
which angiotensinogen (AGT) is sequentially converted, by means of a two-step enzymatic
reaction, into Ang II. Renin is a key-rate limiting enzyme whose expression/secretion is
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controlled by a renal baroreceptor mechanism working in conjunction with sodium chloride
concentration to the macula densa (Carey et al., 1997). However, in addition to its
regulatory role in RAS activity-renin through its pro-renin and renin receptors expressed
by renal glomeruli as well as vasculature-stimulates both pro-fibrotic and proinflammatory pathways independently of Ang II (Nguyen and Muller, 2010).
Through a “feed-forward” mechanism, Ang II has the potential to augment the
angiotensinogen synthesis in the kidney with impact on RAS activity. Simultaneous
upregulation of intrarenal AGT at both mRNA and protein levels is present in multiple
animal models of Ang II-mediated hypertension (Schunkert et al., 1992; Kobori et al.,
2001; Kobori et al., 2007; Gonzalez-Villalobos et al., 2008). The increase in the intra-renal
AGT levels can be reversed by means of AT1 receptor blockers, suggesting that the
activation of AT1R has a promoting role that in turn accelerates the progression of the
hypertensive disease. The long-term increases in systemic or renal Ang II levels will
stimulate the hypertensive pathogenic factors, including growth factors, pro-inflammatory
cytokines, oxidative and mechanical stress (Ruiz-Ortega et al., 2002) and in turn, they will
all cooperate to boost the expression of angiotensinogen in kidney. Thus, the urinary
angiotensinogen level might be used as a clinical indicator of the renal RAS activation in
hypertensive patients (Kobori et al., 2009; Konishi et al., 2011).
1.6.2.2 Role of Renal RAS
A growing body of research has shown that in addition to its core functionality as RASmediator (Bader et al., 2001), Ang II can induce glomerular growth and sclerosis (Mezzano
et al., 2001). Furthermore, increased levels of Ang II in the kidney are associated with
albuminuria and elevated glomerular collagen deposition (Muller et al., 2002). Several
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studies have suggested that blocking RAS would slow down or even stop the progression
of renal fibrosis (Brewster and Perazella, 2004). Treatment with the ARB-losartan was able
to regress the pathologic increases of collagen I and IV gene/protein expressions (Boffa et
al., 2003), while the administration of ACE inhibitor-enalapril was associated with
reversions of the tubulointerstitial and glomerulosclerosis (Adamczak et al., 2003).
Angiotensin II was also known to modulate immune responses largely by inducing
the expression of pro-inflammatory cytokines that in turn can potentiate renal injury
(Crowley et al., 2008). Previous studies have shown that AT1 receptors as well as other
RAS components are present in several mononuclear cell populations with
immunomodulatory roles (Nataraj et al., 1999; Jurewicz et al., 2007). To further reinforce
the strong link between the immune and angiotensin system, Muller et al. (2002) have
shown that immunosuppression is capable to reduce inflammatory cell infiltration in the
kidney, renal structural damage, and albuminuria in the Ang II-induced hypertension.
Previous studies have shown that AT1 receptor plays a critical role in mediating the
Ang II-dependent mechanism of hypertension. AT1R is a member of the GPCR family
capable to couple with Gαq/11 and Gαi (Higuchi et al., 2007). As shown in Fig. 1.4, once
Ang II activates AT1R, a cascade of events is being triggered. As a result, different second
messengers are activated via G protein-dependent pathways and this further translates into
vasoconstriction induction, changes in gene transcription, promotion of cell growth and
migration, etc. (Touyz and Berry, 2002; Higuchi et al., 2007; Mehta and Griendling, 2007;
Miyata et al., 2014). The activation of AT1 receptors are responsible for the internalization
of the ligand-receptor complex that in turn triggers intracellular Ang II increases (Zou et
al., 1996; Zou et al., 1998; Zhuo et al., 2002).
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Figure 1.4: Schematic of the proposed mechanisms of Ang II-mediated hypertension
Ang II-activated AT1Rs trigger the activation of a cascade of downstream second
messengers that further translate into vasoconstriction and changes in gene transcription.
As explained in the text, increased levels of Ang II indirectly lead to accumulation of
intrarenal cytokines and synergistically add to increase proximal tubular (PT)
angiotensinogen expression levels.
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Approximately half of the intra-renal increases in Ang II levels are due to AT1R-mediated
uptake of circulating Ang II (Higuchi et al., 2007; Shao et al., 2009). The AT1 receptor
blockade leads to important increases in glomerular filtration rate, renal blood flow and
profound increases in sodium excretion. Taken together, all these observations demonstrate
the canonical role played by the activated intra-renal AT1 receptors in the regulation of
renal function, electrolyte and body fluid homeostasis, and blood pressure homeostasis.

1.7

Hypothesis and Specific Objectives

GPCR activity represents a delicate, but coordinated balance between molecular
mechanisms governing: receptor signaling, desensitization, and resensitization (Ferguson,
2001). However, these processes do not occur in isolation, rather they occur simultaneously
with each cycle of receptor-ligand interaction and the patterns of desensitization and
resensitization differ between GPCR subtypes. It is now clear that alterations in the balance
between GPCR signaling, desensitization and resensitization are associated with both
cardiac failure and hypertension (Ungerer et al., 1993; Gros et al., 1997; Feldman and Gros,
1998; Gros et al., 2000; Wu et al., 2001; Eckhart et al., 2002; Odley et al., 2004; Harris et
al., 2007; Raake et al., 2008).
Over the past years, our group has identified many molecular mechanisms
underlying differences in GPCR signaling, desensitization and resensitization in
heterologous cell culture systems (Oakley et al., 1999; Zhang et al., 1999; Anborgh et al.,
2000; Oakley et al., 2000). This includes the GRK2-and β-arrestin-dependent and independent regulation of GPCR desensitization and endocytosis (Ferguson et al., 1995;
Ferguson et al., 1996; Zhang et al., 1997; Dhami et al., 2002; Dhami et al., 2004; Dhami
et al., 2005), along with the role of Rab GTPases in regulating the trafficking of GPCRs
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between distinct intracellular membrane compartments (Seachrist et al., 2000; Seachrist et
al., 2002; Dale et al., 2004; Esseltine et al., 2011).
Alteration in GRK2 expression has been noticed in both cardiac failure and
hypertension, and GRK2 overexpression in VSMCs in vivo results in mice that show a
modest increase in blood pressure. By contrast, the consequence of reduced GRK2 activity
on vascular function has not been addressed. Previous studies indicate that Rab4 expression
is increased in cardiac hypertrophy and failure. However, the contribution of Rab4 to the
regulation of GPCR activity in VSMCs and hypertension has not been analyzed.
We hypothesize that alterations in both GRK2 and Rab4 expression/activity
modulate vascular GPCRs signaling and thereby play an essential role in the mechanism
of hypertension. Specifically, the aims of this thesis are to:
1. Assess the molecular alterations that contribute to onset of hypertension in a
mouse model of GRK2 inhibition.
2. Determine whether GRK2 inhibition leads to alteration of renal function and
stimulation of renal-mediated mechanisms of hypertension.
3. Examine whether modulation of Rab4GTPase activity influences vascular
GPCRs signaling and blood pressure homeostasis.
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2.1

Introduction

Blood pressure homeostasis and vascular reactivity is controlled via a complex network of
cell signaling mechanisms. Among the broad network of receptors and signaling molecules
regulating blood vessel reactivity, members of the GPCR family are known to play a central
role. Since GPCRs expressed on vascular smooth muscle cells (VSMCs) fine tune and
maintain the balance between constriction and relaxation of blood vessels, their modulation
has been a primary target in hypertension. Indeed, approximately one third of the
cardiovascular drugs used in current clinical practice directly target GPCR signaling and
function in one way or the other (Siryk-Bathgate et al., 2013). GPCRs function to modulate
vascular tone by transducing hormonal signals into changes in intracellular second
messenger levels, effector enzymes and channel activity (Lefkowitz, 2013).
Agonist activation of GPCR signaling is counteracted by intrinsic cellular
mechanisms that turn off or dampen the agonist-generated signal, a phenomenon referred
to as receptor desensitization or G protein-uncoupling. This provides an essential
physiological “feedback” mechanism that protects against both acute and chronic GPCR
over-stimulation.

The

classical

paradigm

for

GPCR

desensitization

involves

phosphorylation of agonist activated receptors by G protein-coupled receptor kinases
(GRKs), which promote the binding of β-arrestin proteins that function both to uncouple
the receptor from the G protein and target receptors for clathrin-dependent endocytosis and
internalization (Goodman et al., 1996; Krupnick and Benovic, 1998; Laporte et al., 1999;
Ferguson, 2001). GRK-mediated phosphorylation followed by β-arrestin binding not only
contributes to GPCR desensitization and endocytosis, but also couples GPCRs to the
activation of G protein-independent receptor signals (Gesty-Palmer and Luttrell, 2008).
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GRK2 is ubiquitously expressed in the body, regulates the vast majority of GPCRs,
and partakes in several cellular processes like cell cycle progression, migration and
differentiation. The GRK2 RH domain comprises a Gαq/11 binding site that binds
specifically to Gαq/11 subunit (Carman et al., 1999; Ferguson, 2007). Consequently, it has
been demonstrated that Gαq/11-coupled GPCR signaling can be attenuated in a GRK2
phosphorylation-independent manner via the association of the GRK2 RH domain with
Gαq/11 (Dhami et al., 2002; Dhami et al., 2004; Willets et al., 2004; Iwata et al., 2005).
From a mechanistic perspective, alterations in GRK2 expression and activity have
been detected in both human and animal models of hypertension (Gros et al., 1997; Gros
et al., 1999; Gros et al., 2000; Eckhart et al., 2002; Harris et al., 2007; Cohn et al., 2008;
Izzo et al., 2008; Cohn et al., 2009; Morris et al., 2010; Napolitano et al., 2012; Avendano
et al., 2014). Specifically, GRK2 protein expression is elevated in lymphocytes from
hypertensive patients and is correlated with reductions in the β-adrenergic receptor (βAR)stimulated vasodilation (Gros et al., 1997). The increased GRK2 expression might be an
important prerequisite in the impairment of βAR-mediated vasodilation associated with
hypertension, especially since the increases in lymphocyte GRK2 are paralleled by those
in vascular GRK2 (Gros et al., 2000). Moreover, increases in systolic blood pressure in
humans correlate well with increases in GRK2 mRNA expression, but not with either
GRK3 or GRK5 levels (Cohn et al., 2009). Cardiac overexpression of GRK5 results in
marked β2AR desensitization, whereas GRK2 overexpression in cardiac muscle leads to
significant impairment of Ang II-mediated cardiac contractility (Rockman et al., 1996).
Thus, it is possible that GRK2 may preferentially regulate the signaling of Gαq/11-coupled
GPCRs due to the fact that GRK5 does not have a functional RH domain (Ferguson, 2007).
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GRK2 may have the unique capacity to block Gαq/11-coupled GPCR signaling via its
interaction with Gαq/11. Consequently, alterations in GRK2 expression are proposed to
induce a shift in the balance between vasoconstrictor and vasodilator mechanisms
suggesting that GRK2 may function as a potential molecular mediator contributing to the
induction of hypertension.
Given the important role played by GRK2 in regulating both phosphorylationdependent and -independent GPCR desensitization and endocytosis, as well as β-arrestin biased cellular signaling (Jaber et al., 1996; Zhang et al., 1997; Luttrell and Kenakin,
2011), the primary goal of this study was to clarify the link between changes in GRK2
expression and altered vascular GPCRs signaling.
We have successfully derived a line of viable shGRK2 transgenic mice with
significant reduction of GRK2 protein expression in the aorta, heart, liver and kidneys.
These mice are intrauterine growth retarded, are spontaneously hypertensive and have
impaired vascular reactivity. In addition, VSMCs cultured from shGRK2-knockdown mice
demonstrate reduced Gαs- and Gαq/11 GPCR desensitization, altered extracellular regulated
kinase 1/2 (ERK1/2) and Akt signaling with age, as well as age-dependent increases in
cellular proliferation and migration in response to AT1, but not β2AR, activation. Our data
indicate that the loss of GRK2 expression shifts the balance of GPCR-regulated vasodilator
and vasoconstrictor mechanisms in the favor of Gαq/11 that at least in part could be
responsible for the hypertensive phenotype observed in shGRK2 transgenic mice.
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2.2

Experimental Procedure

2.2.1

Development and Characterization of shGRK2 Transgenic Mice

The shGRK2 transgenic mouse strain was generated using a U6 RNA polymerase III
promoter to drive ubiquitous GRK2-shRNA AATCTTTGACTCCTATATTAT (shGRK2)
expression and was subcloned HindIII/BamHI into the pSilencer 2.0-U6 vector. A 766 bp
fragment containing both the U6 promoter and shGRK2 was excised by digestion with
PvuII and microinjected into B6C3F1 mouse embryos that were transferred to pseudopregnant recipients. After weaning offspring were examined for integration of the genomic
DNA by polymerase chain reaction (PCR) analysis and positive offspring backcrossed onto
a C57Bl/6 background for 10 generations. Animals were housed in an animal care facility
in cages of 2 or more animals, and were maintained on a 12-hour light/12-hour dark cycle
at 24°C. Mice received food and water ad libitum. The experimental protocol involving
animals was approved by the Animal Use Subcommittee of Western University, according
to the guidelines of the Canadian Council on Animal Care.
2.2.2

Assessment of Blood Pressure

Blood pressures and heart rates were recorded from conscious mice at 4-5, 8, 12-14 and
24-25 weeks old, using the non-invasive CODA tail-cuff blood pressure system (Kent
Scientific, Torrington, CT, USA). To assess the possible influence of anxiety on blood
pressure, non-invasive tail-cuff blood pressures and heart rates were obtained in 12-week
old anesthetized (ketamine/xylazine 100/10 mg/kg intraperitoneal) mice. Invasive arterial
blood pressures and heart rates were recorded in 12-week old anesthetized
(ketamine/xylazine) mice after cannulating the right carotid artery with a Millar-tip
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transducer catheter (model SPR-261, 1.4F; Millar Instruments, Inc., Houston TX). To
assess in vivo vasoconstrictor responsiveness, mice were injected with 1 mg/kg
phenylephrine intraperitoneal and blood pressures were recorded.
2.2.3

Indirect Calorimetry, Activity and Inactivity

Assessment of metabolic and activity parameters were obtained using the Comprehensive
Laboratory Animal Monitoring System (CLAMS) metabolic chamber (Columbus
Instruments, Columbus, OH, USA).
2.2.4

Vasomotor Studies

Vascular reactivity was assessed in second-order mesenteric arteries obtained from 12-14
week old wild-type and shGRK2 mice were mounted on a pressure myograph (Living
Systems Instrumentation, St. Albans, Vermont). Passive and active vessel diameter
perfusion pressure relationships (20-120 mm Hg) were obtained. The set-point was defined
as the lowest perfusion pressure at which significant myogenic constriction was first
observed. Extent was defined as the magnitude of the percent myogenic tone at a given
perfusion pressure, and strength was defined as the slope of the active diameter-pressure
relationship. Contractile responses to phenylephrine (1 nmol/L to 10 μmol/L) or KCl (10
to 120 mmol/L) (Sigma-Aldrich, Oakville, ON, Canada) were recorded in vessels
pressurized to 60 mm Hg. To examine Ca2+ sensitivity, vessels were washed twice in Ca2+free physiological salt solution (1 mmol/L EGTA) and placed in Ca2+-free physiological
salt solution (PSS) containing 120 mmol/L KCl. Contractile responses to increasing
extracellular CaCl2 (0.5 to 3.0 mmol/L) were recorded. Vasodilatory response to
isoproterenol (1 nmol/L to 10 μmol/L) or sodium nitroprusside (0.1 nmol/L to 10 μmol/L)
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were performed in 60 mm Hg pressurized vessels pre-contracted with 3 μmol/L of
phenylephrine.
2.2.5

H&E and Connective Tissue Staining of Aorta

Paraffin-fixed aortic tissues were sectioned (8μm) and placed on positively-charged
microscope slides. After deparaffinization and rehydration through serial decreases of
ethanol concentration (100%, 95%, and 70%), slides were subjected to a general H&E
staining protocol. Collagen deposition was visualized by means of Masson’s trichrome
staining (Trichrome Stain-Kit, Abcam, Cambridge, MA, USA) and Movat penthachrome
staining (Penthachrome Stain Kit, Nordic BioSite, Plymouth Meeting, PA, USA).
2.2.6

Primary VSM Cell Culture

Vascular smooth muscle cells (VSMCs) were isolated by enzymatic digestion from
thoracic aortas of 4-12-24 week old GRK2 shRNA transgenic and age-matched C57Bl/6
male mice and maintained in primary culture for a subsequent number of 7 passages. Cells
were grown as a monolayer in Dulbecco's Modified Eagle Medium (Life Technologies,
Burlington, ON, Canada) supplemented with 10% fetal bovine serum (BioShop,
Burlington, ON, Canada), 50 μg/ml PDGF-B (Sigma-Aldrich, Oakville, ON, Canada) in a
humidified incubator with 5% CO2 at 37oC.
2.2.7

Cyclic Adenosine Monophosphate (cAMP) - Glo Assay Analysis

The cAMP GLO assay (Promega, Fitchburg, WI, USA) was carried out according to the
manufacturer’s protocol. VSMCs were seeded into a Poly-D-lysine coated, white, clearbottom 96-well plates (∼10.000 cells per well) and incubated overnight. Cells were treated
with increasing concentrations of agonists for 15 min and lysed with cAMP-GLO Lysis
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Buffer. Then, cAMP-GLO detection solution containing protein kinase A was added for
20 min, followed by the addition of Kinase-Glo reagent. Luminescence was measured
using a Victor plate reader (PerkinElmer Life Sciences, Billerica, MA, USA).
2.2.8

Fura - 2 Florescence Ca2+ Imaging

VSMCs grown on 25 mm round glass cover ships were loaded with 5 µM Fura-2
acetoxymethyl ester (Invitrogen, Mississauga, ON, Canada) at 37 C for 20 minutes in
Krebs Ringers buffer (pH = 7.4). Cells were then washed and incubated for another 10
minutes in Krebs Ringers buffer. Fura-2 dual excitation and emission was accomplished
using 340- and 380-nm excitation filter and a Photon Technology International DeltaRam
V imaging system. The coefficients required for [Ca2+] calculations were calibrated by
means of the method described by Grynkiewicz et al. (1985).
2.2.9

Western Blot Analysis

VSMCs were plated at 2x105/well in 6 well plates. Next day, cells were serum starved by
culturing them in serum free medium for 48 hours. Prior to the protein extraction, cells
were incubated in the absence (negative control) and presence of either isoproterenol
(10μM), angiotensin II (100nM) or with their biased agonists carvedilol (10μM) and
SIIAngII (100μM) over) over different time intervals (5, 15, 30, 60, 90, 120, 150, and 180
minutes). For preparation of the protein lysate, cells were treated with M-PER®
Mammalian Protein Extraction Reagent supplemented with HALT Protease Inhibitor
Cocktail and Phosphatase Inhibitor Cocktail (Thermo Scientific, Rockford, IL, USA).
Fifteen micrograms of total protein were electrophoresed per well on a 10% SDSpolyacrylamide gel and transferred onto Immobilon-FL PVDF membranes (Millipore,
Billerica, MA, USA). Immunoblotting was performed with the following primary
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antibodies: monoclonal anti-actin and smooth muscle α-actin antibody, p44/p42 (ERK1/2)
rabbit polyclonal antibody, phospho-p44/p42 (ERK1/2) rabbit polyclonal antibody,
phospho-Akt (Ser 473) rabbit monoclonal antibody, Akt (pan) mouse monoclonal antibody
(Cell Signaling Technology) diluted in a solution consisting of 3% BSA in TBST (20mM
tris-base, 0.14M NaCl, 0.01% Tween, pH 7.4) overnight at 4oC. Blots were probed
afterwards with a mixture of IRDye polyclonal secondary antibodies (1:10000) (LI-COR
Biosciences, Lincoln, NE, USA) for one hour. Images were read with an Odyssey infrared
imaging system and the average density of each band was quantified using the Image
Studio software (LI-COR Biosciences, Lincoln, Nebraska USA). For quantitative analysis
of the protein levels, the average densities of target bands were quantified using the
application software of the Odyssey infrared imaging system. For each condition, the band
density of analyzed protein was normalized to the band density of the corresponding total
protein (total-ERK1/2, AKT) or loading control (GADH).
2.2.10 Boyden Chamber Assay Analysis
VSMCs migration was assessed with Boyden chambers using Transwell® inserts (Corning
Life Sciences, Oneonta, NY, USA)). Polycarbonate membrane inserts with 8 μm pore
opening placed within 24-well plates were used. A two hundred microliter suspension of
serum-starved cells at a concentration of 2x105/ml was added in the upper chamber while
various concentrations of agonists were added to serum-free media in the lower chamber.
The assembled chamber inserts were then incubated at 37C, 5% CO2 for 24 hours. VSMCs
were then fixed with methanol and stained with eosin/thiazine. Direct microscopic
counting at 40X magnification (Leica DFC 295, Leica Microsystems, Germany) of cells
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that have migrated to the lower side of the membrane was performed and a mean value for
each sample was calculated.
2.2.11 Trypan Blue Exclusion Assay
VSMCs at 2x105/ml were seeded into T25 flasks for 48 and 96 hours and then harvested
with Trypsin-EDTA combined with media, spun down, and suspended with Trypan Blue
(1:1). In order to generate a growth curve, an automated cell counter (Invitrogen,
Burlington, ON, Canada) was used to calculate total cell number, live cells, dead cells, and
viability.
2.2.12 Cell Proliferation ELISA, BrdU Assay Analysis
Serum-starved VSMCs cells to a final concentration of 2x105 cells/ml were seeded onto
96-well tissue-culture microplates, treated with different type of agonists for 24 hours, and
a cell proliferation ELISA BrdU (colorimetric) assay (Roche Applied Science,
Indianapolis, IN, USA) was performed according to manufacturer’s instruction. For
signaling studies, serum starved VSMCs were pretreated with various concentrations of
PI3 kinase inhibitor (LY294002) (Cell Signaling Technology, Danvers, MA, USA), Akt
inhibitor (Akti-1/2) (Abcam, Cambridge, MA, USA), and MEK 1/2 inhibitor (U0126) (Cell
Signaling, Danvers, MA, USA). After incubation, the reaction product was measured with
a plate reader, Infinite M200 (TECAN, Morrisville, NC, USA) at wavelength of 370 nm.
2.2.13 Statistical Analysis
Statistical calculations were performed using GraphPad Prism software version 5
(GraphPad Software, La Jolla, CA, USA). All parametric data were analyzed with one-way
Analysis of Variance followed by Tukey-Kramer or Dunnett post-hoc comparisons. When

88

two data sets were compared, a Student’s t-test was used. Statistically relevant differences
between mean values were determined based on p < 0.05 criterion.

2.3

Results

2.3.1

shGRK2 Mice Are Smaller and Have Reduced Body Weight

We employed shRNA, using a U6 mouse polymerase III promoter as a transgene, to
universally knockdown, but not knockout, GRK2 protein expression in transgenic mice.
The GRK2 shRNA transgene incorporated into the Y chromosome resulting in only viable
transgenic male mice. Thus, age-matched C57BL/6 male mice were used as controls. The
resulting shGRK2 transgenic mice had reduced GRK2 protein expression in all tissues
tested including: the aorta, heart, lungs, liver, kidneys, and brain (Fig. 2.1A). Our timecourse observation also documents a significant decreased in GRK2 mRNA expression
level in aortic arteries of shGRK2 mice when compared with age-matched control
C57BL/6 mice (Fig. 2.1B). Male shGRK2 transgene positive pups at E17.5 were
significantly smaller in size and had lower body weight as compared to female in utero
wild-type littermates (Fig. 2.1C and 1D). Despite the smaller body weight at E17.5 for
shGRK2 positive male pups, the percentage of male versus female pups at this stage was
equal. At the time of weaning (4 weeks of age), we observed that the percentage of male
versus female was significantly lower suggesting a significant post-natal loss of shGRK2
mice (Fig. 2.1E). The lower body weight of shGRK2 male mice was still apparent at both
12 and 24 weeks of age (Fig. 2.1F). Similarly, assessment of body length (nose to tip of
tail) revealed that shGRK2 mice are significantly smaller in body size at 12 weeks of age
(shGRK2: 16.5 ± 0.1 cm, n=6 vs. C57Bl/6: 18.1 ± 0.1 cm, n=5, p<0.05).
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Figure 2.1: Characterization of shGRK2 transgenic mice
(A) Western blot was used to validate GRK2 protein expression in a variety of tissues
isolated from C57Bl/6 and shGRK2 transgenic mice. Glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) was used as an internal control for differences in protein
expression. (B) Quantitative RT-PCR analysis of GRK2 mRNA expression in aortic tissues
isolated from C57Bl/6 and shGRK2 mice. Expressions levels are normalized to actin
(ACTB). (C) Digital image of wild-type female and male shGRK2 pups outlining the
difference in body size. (D) Quantification of body weight measurements for wild-type
female, male shGRK2 and male C57Bl/6 pups at E17.5 days (n=20). (E) Proportion of
male shGRK2 and female wild-type mice at E17.5 (female, n=22; male, n=20) and 4 weeks
of age (female, n=108; male, n=44). (F) Quantification of body weight measurements in
male mice at 3 (n=13) and 6 months (n=6) of age. * Indicates statistical significant
differences versus female littermate (p < 0.05). ** Indicates statistical significant
differences versus C57Bl/6 male mice (p < 0.05).
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2.3.2

Metabolic Parameters, Activity and Inactivity Are Altered in shGRK2 Mice

We assessed indirect calorimetry, activity and inactivity measurements in both 12-week
old shGRK2 and wild-type C57Bl/6 mice using metabolic cages. No significant differences
in O2 consumption, CO2 production, respiratory exchange ratio, energy expenditure, and
food or water consumption between shGRK2 and wild-type mice were observed during the
light cycle (Fig. 2.2A-F). However, both O2 consumption and CO2 production were
significantly increased in shGRK2 mice during the dark/active cycle (Fig. 2.2A and 2.2B).
Interestingly, assessment of inactivity (sleep) and activity revealed that shGRK2 mice had
a significant reduction in their sleep time during the dark/active cycle, as well as a
significant increase in both total and ambulatory activity measurements (Fig. 2.2G-I).
2.3.3

shGRK2 Mice Develop Hypertension with Age

No significant differences in systolic and diastolic blood pressure or heart rate were
observed between shGRK2 and wild-type mice at 4-5 weeks of age using the non-invasive
tail-cuff method (Fig. 2.3A). Interestingly, systolic blood pressure was significantly higher
in 8-week old shGRK2 mice as compared to age-matched wild-type mice (Fig. 2.3B).
Hypertension was established in 3 month-old shGRK2 mice as compared to wild-type
controls with significant increases in both systolic and diastolic blood pressures
(Fig. 2.3C). The elevated blood pressures were still evident in shGRK2 mice at 6 months
of age (Fig. 2.3D). To eliminate the possibility of a stress/anxiety-induced elevation in
blood pressure, we obtained blood pressures and heart rates in lightly anesthetized mice
using the tail-cuff methods and both systolic and diastolic blood pressures were
significantly elevated in shGRK2 mice (Fig. 2.3E). We also assessed hemodynamic
parameters via invasive Millar catheterization and found that both systolic and diastolic
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Figure 2.2: Assessment of metabolic parameters, activity and inactivity in shGRK2
transgenic mice
Representative graphs of different parameters from 3 month-old wild-type and shGRK2
mice monitored by means of metabolic cages showing: (A) volume of O2, (B) volume of
CO2, (C) respiratory exchange ratio, (D) energy expenditure/heat, (E) food, (F) water, (G)
sleep, (H) total activity, and (I) ambulatory activity. Data is represented as the mean ± SD
of 8 mice in each group. *Indicates significant differences as compared with C57Bl/6 mice
(p < 0.05).
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Figure 2.3: Assessment of blood pressures and heart rates in shGRK2 transgenic mice
Blood pressures and heart rates of C57Bl/6 and shGRK2 mice, as measured by noninvasive tail cuff CODA method at (A) 4-5 weeks, (B) 8 weeks, (C) 3 months and (D) 6
months of age. (E) Blood pressures and heart rates in lightly anesthetized 3 month-old mice
using the tail-cuff method. (F) Blood pressures and heart rates measured via invasive Millar
catheterization at 3 months of age. (G) Blood pressure responsiveness in Millar cannulated
3 month-old mice after phenylephrine administration. Data are represented as the mean ±
SD of 5 independent experiments. * Indicates statistically significant differences versus
C57Bl/6 mice (p < 0.05).
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blood pressures were significantly higher in shGRK2 mice as compared to wild-type
controls (Fig. 2.3F). In Millar cannulated mice, phenylephrine (PE, 1 mg/kg) injection
significantly elevated systolic blood pressure in both wild-type and shGRK2, but the
change in systolic blood pressure was significantly higher in shGRK2 mice as compared
to wild-type controls (Fig. 2.3G).
2.3.4

GRK2 Deficiency Results in Altered Vascular Reactivity

To assess the role of GRK2 inhibition in the regulation of GPCR expression, the mRNA
levels of several GPCRs were measured. shGRK2 seems to have a stimulatory effect on
GPCRs with role in vasoconstriction such as AT1R, α1AR, and 5HT-2bR as well as on
vasodilatatory β2A receptors (Fig. 2.4A). Mesenteric arteries from shGRK2 mice
demonstrated enhanced myogenic tone development with a significant increase in the
extent of myogenic constriction (Fig. 2.4B). Additionally, the set-point of the myogenic
response was significantly reduced in mesenteric arteries from shGRK2 mice when
compared to wild-type controls (80 vs. 100 mmHg, P < 0.05) (Fig. 2.4B). Similarly, we
observed a significant increase in the contractile responses to phenylephrine in arteries
obtained from shGRK2 mice (EC50: 85.2 ± 12.8 nM, n = 5) when compared to wild-type
controls (EC50: 247 ± 25 nM, n = 5) (Fig. 2.4C). To determine if the increase in receptormediated vasomotor response was generalized to all constrictor agents, we examined the
response to increasing doses of potassium chloride (KCl). No significant differences in
KCl-mediated constriction were observed between shGRK2 and wild-type mouse arteries
(Fig. 2.4D). To determine whether the enhanced vasomotor responses observed in arteries
from shGRK2 mice was attributable to heightened Ca2+ sensitivity of the contractile
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Figure 2.4: Assessment of vascular reactivity in mesenteric arteries obtained from
wild-type and shGRK2 mice
(A) Quantitative RT-PCR analysis of several GPCRs mRNA expression in aortic arteries.
Expressions levels are normalized to ACTB. (B) Myogenic responses of second-order
mesenteric arteries collected from 3 month-old C57Bl/6 and shGRK2 mice as assessed by
pressure myography. Contractile responses of mesenteric arteries to (C) phenylephrine,
(D) potassium chloride and (E) calcium chloride. Vasodilatatory responses of mesenteric
arteries to (F) isoproterenol and (G) sodium nitroprusside. Data points are represented as
the mean ± SD. * Indicates statistically significant differences versus C57Bl/6 (p < 0.05).
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apparatus, we assessed KCl-mediated constriction in the presence of increasing
concentrations of extracellular calcium. No significant differences in Ca2+ sensitivity were
observed in mesenteric arteries obtained from shGRK2 and wild-type mice (Fig. 2.4E). To
determine if GPCR-stimulated vasodilator pathways were altered in shGRK2 mice, we
examined receptor-mediated vasodilation in response to isoproterenol in phenylephrine
pre-constricted arteries. Isoproterenol-mediated vasodilation was significantly enhanced at
100 nM and greater doses (Fig. 2.4F, wild-type control EC50: 107 ± 13 nM, n = 5 versus
shGRK2 EC50: 70 ± 7 nM, n = 5, p < 0.05). However, the non-receptor mediated
vasodilation in response to sodium nitroprusside was not significantly different between
shGRK2 and wild-type mouse arteries (Fig. 2.4G). In addition, the assessment of aortic
arteries through H&E, Movat, and Masson staining has revealed that while control aortas
from wild type mice have a normal tunica media characterized by a wavy look of the elastic
lamina, GRK2 aortas are collapsed and have a straight elastic lamina (Fig. 2.5). On the
other hand, no differences in collagen and elastin deposition were observed between
shGRK2 and control aortas.
2.3.5

Heterotrimeric G Protein-mediated Signaling is Altered in shGRK2 VSMCs

Smooth muscle α-actin was expressed at relative constant levels over six different passages
(Fig. 2.6A and 2.6B). To assess the effectiveness of shGRK2 knockdown with increasing
passage in vitro, we examined GRK2 protein expression in passaged VSMCs and found
that GRK2 knockdown was maintained in cultured shGRK2 VSMCs when compared to
wild type VSMCs (Fig. 2.6C and 2.6D).
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Figure 2.5: Histological analysis of aortas
Representative histological images of H&E, Movat staining, and Masson staining of aortic
sections from shGRK2 and wild type C57BL/6 mice. Images were taken at 20x
magnification and scale bar = 100 µm.
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Figure 2.6: Assessment of GRK2 knockdown and heterotrimeric G protein mediated
signaling in primary VSMCs
(A) Representative immunoblot for smooth muscle α-actin and GAPDH in VSMCs
cultured from C57Bl/6 and shGRK2 mice. (B) Densitometric analysis of smooth muscle
α-actin expression in C57Bl/6 and shGRK2 VSMCs over 2-6 passages in culture. A10 and
HEK293 cells were used as positive and negative controls, respectively. Data is represented
as the mean ± SD of 3 independent experiments. (C) Representative immunoblot for GRK2
and GAPDH in VSMCs cultured from C57Bl/6 and shGRK2 mice. (D) Densitometric
analysis of GRK2 expression in wild-type and shGRK2 VSMCs over 2-6 passages in
culture. A10 and HEK293 cells were used as positive and negative controls, respectively.
Data is represented as the mean ± SD of 3 independent experiments. * Indicates statistically
significant differences compared to time matched C57Bl/6 GRK2 expression (p < 0.05).
Dose response curves for cAMP production in C57Bl/6 and shGRK2 VSMCs in response
to treatment with increasing concentrations of (E) isoproterenol (Iso) and (F) forskolin.
Data points are represented as the mean ± SEM of 4 independent experiments. (G)
Representative Ca2+ tracers for changes in intracellular Ca2+ concentration in C57Bl/6
versus shGRK2 VSMCs cultures in response to treatment 100 nM AngII, (H) Graph shows
the area under the curve (AUC) for integrated Ca2+ responses to agonist treatments. Data
are represented as the mean ± SD of 6 independent experiments and the total number of
cells analyzed is shown in the graph.
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To determine whether alteration in GRK2 expression could exert an effect in Gαs-mediated
signaling, cyclic adenosine monophosphate (cAMP) accumulation in response to the β2AR
agonist isoproterenol was assessed. The EC50 for isoproterenol-stimulated cAMP
accumulation in VSMCs prepared from 3 month-old mice was significantly reduced in
shGRK2 VSMCs when compared to wild-type VSMCs (Fig. 2.6E).
In contrast, forskolin-stimulated cAMP formation was unchanged in shGRK2
versus control VSMCs (Fig. 2.6F). Thus, a loss of GRK2 expression appeared to lead to
decreased desensitization of β2-adrenergic receptor signaling. The release of Ca2+ from
intracellular stores in response to treatment with 100 nM Ang II was assessed in VSMCs
prepared from both 3 and 6 month-old shGRK2 and wild-type mice. We found that Ang II
treatment elicited a significantly greater Ca2+ release from VSMCs cultured from 3 and 6
month-old shGRK2 mice, when compared to wild-type VSMCs (Fig. 2.6G and 2.6H).
Taken together, these results indicated that GRK2 expression not only played a significant
role in regulating GPCR desensitization in VSMCs, receptor responsiveness was
significantly altered with age.
2.3.6
We

Effect of GRK2 Knockdown on ERK1/2 Phosphorylation
compared

isoproterenol-stimulated

ERK1/2

phosphorylation

with

ERK1/2

phosphorylation responses elicited with the biased agonist carvedilol in VSMCs derived
from 3 month-old shGRK2 and wild-type mice. Isoproterenol treatment (10 µM) of both
wild-type and shGRK2 VSMCs elicited a rapid increase in ERK1/2 phosphorylation at 5
and 15 min of agonist treatment, but ERK1/2 phosphorylation responses were significantly
greater in the VSMCs derived from shGRK2 mice (Fig. 2.7A). A second wave of ERK1/2
phosphorylation was also observed at 90-150 min of agonist stimulation in shGRK2, but
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Figure 2.7: Assessment of Gαs-mediated ERK1/2 signaling in primary VSMCs
Representative immunoblots and densitometric analysis showing time course for ERK1/2
phosphorylation with corresponding total ERK1/2 immunoblots from VMSCs derived
from 3 month-old wild-type (C57Bl/6) and shGRK2 mice in response to either (A) 10 µM
isoproterenol or (B) 10 µM carvedilol. Data are represented as the mean ± SD of 4
independent experiments expressed as percentage of basal ERK1/2 phosphorylation
normalized. Representative immunoblots and densitometric analysis showing time course
for ERK1/2 phosphorylation with corresponding total ERK1/2 immunoblots from VMSCs
derived from 6 month-old wild-type (C57Bl/6) and shGRK2 mice in response to either (C)
10 µM isoproterenol or (D) 10 µM carvedilol. Total ERK1/2 was used as internal control.
Data are represented as the mean ± SD of 4 independent experiments expressed as
percentage of basal ERK1/2 phosphorylation.  Indicates statistically significant
differences compared to unstimulated C57Bl/6 control (p< 0.05). * Indicates statistically
significant differences compared to time matched C57Bl/6 ERK1/2 (p < 0.05).
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not wild-type VSMCs (Fig. 2.7A). Carvedilol treatment (10 µM) also resulted in an
increase in ERK1/2 phosphorylation that was enhanced and prolonged in VSMCs derived
from shGRK2 mice when compared to wild-type mice (Fig. 2.7B). In contrast, for VSMCs
derived from 6 month old mice, the pattern of isoproterenol-stimulated ERK1/2
phosphorylation was significantly altered, with increases in ERK1/2 phosphorylation
observed at latter time points of agonist treatment (Fig. 2.7C). Isoproterenol-stimulated
ERK1/2 phosphorylation at later time points in VSMCs derived from 6 month-old shGRK2
mice was significantly impaired when compared with wild-type VSMC cultures
(Fig. 2.7C). However, carvedilol did not elicit increased ERK1/2 phosphorylation in
VSMCs derived from either 6 month- old shGRK2 or wild-type mice (Fig. 2.7D).
ERK1/2 phosphorylation in response to 100 nM Ang II treatment was also
significantly increased and prolonged in shGRK2 versus wild-type VSMCs derived from
3 month-old mice (Fig. 2.8A). A similar response profile was observed in response to the
treatment of 3 month-old shGRK2 and wild-type cultures with the biased angiotensin
receptor agonist [Sar1, Ile4, Ile8] Ang II (SII), except that a second later phase of ERK1/2
phosphorylation was observed in wild-type VSMCs that was not observed in response to
Ang II treatment (Fig. 2.8B). Similar to what was observed for isoproterenol treatment of
VSMCs derived from 6 month-old shGRK2 mice, Ang II-stimulated ERK1/2
phosphorylation was delayed (Fig. 2.8C). However, unlike what was observed for
carvedilol, SII treatment mediated a modest biphasic increase in ERK1/2 phosphorylation
in shGRK2 VSMCs that was not observed in wild-type VSMCs (Fig. 2.8D). Taken
together, these data indicate that changes in GRK2 expression modulate ERK1/2 activity
in response to both full and biased agonists and that these responses were altered with age.
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Figure 2.8: Assessment of Gαq-mediated ERK1/2 signaling in primary VSMCs
Representative immunoblots and densitometric analysis showing time course for ERK1/2
phosphorylation with corresponding total ERK1/2 immunoblots from VMSCs derived
from 3 month-old wild-type (C57Bl/6) and shGRK2 mice in response to either (A) 100 nM
AngII or (B) 100 µM SII. Data are represented as the mean ± SD of 4 independent
experiments expressed as percentage of basal ERK1/2 phosphorylation. Representative
immunoblots and densitometric analysis showing time course for ERK1/2 phosphorylation
with corresponding total ERK1/2 immunoblots from VMSCs derived from 6 month-old
wild-type (C57Bl/6) and shGRK2 mice in response to either (C) 100 nM Ang II or (D) 100
µM SII. Total ERK1/2 was used as internal control. Data are represented as the mean ± SD
of 4 independent experiments expressed as percentage of basal ERK1/2 phosphorylation.
 Indicates statistically significant differences compared to unstimulated C57Bl/6 control

(p< 0.05). * Indicates statistically significant differences compared to time matched
C57Bl/6 ERK1/2 (p < 0.05).
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2.3.7

Effect of GRK2 Knockdown on Akt Phosphorylation

β-Arrestins also couple GPCRs to the activation of Akt (Beaulieu et al., 2005). Therefore,
because GRK2 knockdown altered ERK1/2 phosphorylation responses following either
β2AR or AT1R activation, we assessed Akt signaling in VSMCs derived from 6 month-old
wild-type and shGRK2 mice. We find that isoproterenol treatment of wild-type VSMCs
resulted in a modest increase in Akt phosphorylation following 15 and 30 min agonist
stimulation, whereas isoproterenol treatment of shGRK2 VSMCs results in a more robust,
sustained and biphasic activation of Akt phosphorylation (Fig. 2.9A). In contrast,
carvedilol did not induce Akt phosphorylation in wild-type VSMCs and provoked only a
modest increase in Akt phosphorylation in shGRK2 VSMCs following 15, 30 and 180 min
agonist treatment (Fig. 2.9B). Ang II and SII treatment of wild-type VSMCs did not
significantly promote Akt phosphorylation (Fig. 2.9C and 2.9D). The stimulation of
shGRK2 VSMCs with Ang II elicited the same robust, sustained and biphasic activation
of Akt phosphorylation observed following isoproterenol treatment, and SII treatment
induced a modest, but significant, increase in Akt phosphorylation (Fig. 2.9D). Taken
together, these observations indicated that a loss of GRK2 expression favored increased
Akt phosphorylation selectively in response to full receptor agonists. In addition, the
phosphorylation status of both EKR1/2 and Akt signaling was assessed in response to
stimulation with AngII and its biased agonist in VSMCs isolated from 6 week-old shGRK2
(Fig. 2.10). Thus, Ang II and SII treatment of both wild-type and shGRK2 VSMCs did not
elicit an increase in ERK1/2 and Akt phosphorylation supporting the observation that the
alteration of short and long term downstream signaling pathways is a consequence of the
hypertensive phenotype.
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Figure 2.9: Assessment of Akt signaling in primary VSMCs
Representative immunoblots and densitometric analysis for Akt phosphorylation at Ser 473
in primary VSMCs derived from 6 month-old wild-type (C57Bl/6) and shGRK2 mice in
response to treatment with either (A) 10 µM isoproterenol, (B) 10 µM carvedilol, (C) 100
nM Ang II or (D) 100 µM SII. Total Akt was used as internal control. Data are represented
as the mean ± SD of 3 independent experiments expressed as percentage of basal Akt
phosphorylation.  indicates statistically significant differences compared to unstimulated
C57Bl/6 control (p< 0.05). * Indicates statistically significant differences compared to time
matched C57Bl/6 Akt (p < 0.05).
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Figure 2.10: Assessment ERK1/2 and Akt signaling in 6 week-old primary VSMCs
Representative immunoblots and densitometric analysis showing time course for ERK1/2
phosphorylation with corresponding total ERK1/2 immunoblots from VMSCs derived
from 6 week-old wild-type (C57Bl/6) and shGRK2 mice in response to either (A) 100 nM
AngII or (B) 100 µM SII. Data are represented as the mean ± SD of 3 independent
experiments expressed as percentage of basal ERK1/2 phosphorylation. Representative
immunoblots and densitometric analysis showing time course for Akt phosphorylation with
corresponding total Akt immunoblots from VMSCs derived from 6 week-old wild-type
(C57Bl/6) and shGRK2 mice in response to either (C) 100 nM Ang II or (D) 100 µM SII.
Data are represented as the mean ± SD of 3 independent experiments expressed as
percentage of basal Akt phosphorylation.  Indicates statistically significant differences
compared to unstimulated C57Bl/6 control (p< 0.05). * Indicates statistically significant
differences compared to time matched C57Bl/6 (p < 0.05).
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2.3.8

Effect of GRK2 Knockdown on VSMC Proliferation

We found that wild-type and shGRK2 VSMCs derived from 3 month old mice exhibited a
limited proliferation rate (Fig. 2.11A). In contrast, VSMCs derived from 6 month-old wildtype and shGRK2 mice exhibited a more robust proliferative phenotype than VSMCs
derived from 3 month old mice, with shGRK2 VSMCs exhibiting a significantly greater
proliferation rate that wild-type VSMCs (Fig. 2.11A). Agonist treatment with either 10 µM
isoproterenol, 10 µM carvedilol, 100 nM Ang II or 100 μM SII elicited a significant
increase in 5-bromo-2-deoxyuridine (BrdU) incorporation in VSMCs derived from 3
month-old wild-type and shGRK2 mice when compared with serum free medium
(Fig. 2.11B). For cells derived from 6 month-old mice, neither isoproterenol, carvedilol,
Ang II nor SII treatment increased BrdU incorporation into wild-type VSMCs, whereas
only Ang II and SII treatment increased BrdU incorporation into shGRK2 VSMCs
(Fig. 2.11C). Treatment of shGRK2 VSMCs with either an Akt inhibitor (Akti-1/2),
phosphatidylinositol 3-kinase (PI3K) inhibitor (LY294002) or ERK1/2 inhibitor (U0126)
inhibited Ang II-stimulated BrdU incorporation (Fig. 2.11D). These data suggested that the
activation of AT1 receptor in shGRK2 mice selectively activates cell proliferation of older
VSMCs in a PI3K/Akt/ERK-dependent manner.
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Figure 2.11: Assessment of proliferation responses for primary VSMCs
(A) Growth curves over 96-hour course time of primary VSMCs cultured from either 3 or
6 month-old wild-type (C57Bl/6) and shGRK2 mice. Data are represented as the
mean ± SD (n = 4). (B) Proliferation responses of VSMCs cultured from 3 month-old wildtype (C57Bl/6) and shGRK2 treated for 24h with serum free medium (SFM), 10 µM
isoproterenol, 10 µM carvedilol, 100 nM Ang II or 100 µM [Sar1, Ile4, Ile8] Ang II (SII) as
measured by BrdU incorporation in newly synthesized cellular DNA. Data are represented
as the mean ± SD of 4 independent experiments. (C) Proliferation responses of VSMCs
from 6 month old wild-type (C57Bl/6) and shGRK2 treated for 24h with SFM, 10 μM
isoproterenol, 10 µM carvedilol, 100 nM Ang II or 100 µM [Sar1, Ile4, Ile8] Ang II (SII) as
measured by BrdU incorporation in newly synthesized cellular DNA. Data are represented
as the mean ± SD of 4 independent experiments. (D) Cell proliferation responses in VSMCs
cultured from 6 month-old shGRK2 treated with SFM or 100 nM Ang II for 24h in the
presence or absence of either 10 µM Akti-1/2, 50 µM LY294002, or 1 µM U0126
inhibitors. Data are represented as the mean ± SD of 4 independent experiments. *Indicates
statistically significant differences compared to unstimulated control (p< 0.05).
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2.3.9

Effect of GRK2 Knockdown on VSMC Migration

Migration assays for wild-type and shGRK2 VSMCs derived from 3 month old mice
revealed that neither 100 nM Ang II or 100 µM SII stimulated cellular migration when
compared to serum-free medium (Fig. 2.12A and 2.12B). However, the treatment of
VSMCs derived from 6 month-old wild-type and shGRK2 mice with either Ang II or SII
significantly increased shGRK2, but not wild-type, VSMCs migration as compared to
serum-free medium (Fig. 2.12C and 2.12D). The treatment of shGRK2 VSMCs with either
Akt or ERK1/2 inhibitors prevented Ang II-induced shGRK2 VSMCs migration
(Fig. 2.12E). Thus, GRK2 knockdown increased VSMCs migration in response to Gαq/11coupled GPCR activation.

2.4

Discussion

GRK2 contributes to the desensitization of GPCR signaling and generalized increases in
GRK2 expression are linked to the development of essential hypertension in both humans
and experimental animal models (Gros et al., 1997; Gros et al., 1999; Gros et al., 2000;
Eckhart et al., 2002; Harris et al., 2007; Cohn et al., 2008; Izzo et al., 2008; Cohn et al.,
2009; Morris et al., 2010; Napolitano et al., 2012; Avendano et al., 2014). To further
understand the role of the balance between GRK2 expression and vascular reactivity, we
developed a shGRK2 transgenic mouse. The shGRK2 transgenic mice are viable, show
indications of intrauterine growth retardation and become spontaneously hypertensive at
8-12 weeks following birth. GRK2 knockdown both increases vasodilator and
vasoconstrictor responses to GPCR activation in intact tissue and VSMC cultures, but
increase in vasoconstrictor mechanisms appear to dominate the physiological phenotype.
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Figure 2.12: Assessment of migration responses for primary VSMCs
(A) Representative images and (B) quantification of the migration of VSMCs derived from
wild-type (C57Bl/6) and 3 month- old shGRK2 mice treated for 24h SFM, 100 nM Ang II,
or 100 µM [Sar1, Ile4, Ile8] Ang II (SII). Bar graph data represents the mean ± SD of 4
independent experiments. (C) Representative images and (D) quantification of the
migration of VSMCs derived from wild-type (C57Bl/6) and 6 month- old shGRK2 mice
treated for 24h with SFM, 100 nM Ang II, or 100 μM [Sar1, Ile4, Ile8] Ang II (SII). Bar
graph data represents the mean ± SD of 4 independent experiments. (E) Quantification of
cell migration responses of VSMCs cultured from 6 month-old shGRK2 treated with SFM
or 100 nM Ang II for 24h in the presence or absence of either 10 µM Akti-1/2, or 1 µM
U0126 inhibitors. Data represents the mean ± SD of 4 independent experiments. In (A, C)
the microphotographs were taken at 40x magnification and scale bar = 50 µm. *Indicates
statistically significant differences compared to unstimulated control (p < 0.05).
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D)

VSMCs isolated from older hypertensive mice also show alterations in ERK1/2 and Akt
signaling, which are linked to altered cellular proliferation and migration responses to
Gαq/11-coupled GPCR activation.
GRK2/3 are unique with respect to other GRK family members in that they mediate
the

GRK2

RGS

homology

domain-dependent

phosphorylation-independent

desensitization of only Gαq/11-coupled GPCRs (Ferguson, 2007). Consequently, significant
reductions in GRK2 protein expression may preferentially result in enhanced signaling via
Gαq/11-coupled GPCRs leading to increased vasoconstrictor activity and hypertension.
Thus, the current results are not incongruent with previous studies linking increased GRK2
expression to hypertension, as reduced GRK2 expression, given the importance of GRK2phosphorylation-independent desensitization in the regulation of Gαq/11-coupled GPCR
signaling.
GRK2 expression is associated with both enhanced βAR desensitization in
lymphocytes and impaired vascular reactivity in hypertensive humans and increased GRK2
expression in umbilical arteries is correlated with gestational hypertension (Gros et al.,
1997; Gros et al., 1999; Napolitano et al., 2012). VSMC-specific overexpression of GRK2
enhances βAR desensitization, attenuates βAR-mediated vasodilation, increases medial
VSM thickness and results in cardiac hypertrophy (Eckhart et al., 2002). The reduction of
GRK2 expression in hemizygous GRK2 mice also partially protects against Ang IImediated hypertension and vascular remodeling via a mechanism involving the
preservation of nitric oxide availability, but does not affect resting blood pressure
(Avendano et al., 2014). We observed an age-dependent onset of hypertension in shGRK2
knockdown mice with a full onset of hypertension observed at 12 weeks of age, which is
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maintained throughout the lifespan of the animals. The increases in blood pressure are not
confounded by stress and/or anxiety as elevated blood pressure is also observed in lightly
anesthetized mice. We also find that vasodilatation in response to βAR stimulation is
enhanced in the shGRK2 mice, but consistent with the hypertensive phenotype
vasoconstriction in response to PE is also increased and may predominate physiologically.
In addition, myogenic response was increased in shGRK2 mouse mesenteric arteries and
this has been linked to Gαq/11-mediated pathways. These observations suggest that
extensive loss of GRK2 expression favors an increase in vasoconstriction associated with
increases in peripheral resistance likely due to reduced Gαq/11-coupled receptor
desensitization. This is consistent with the observation that inhibition of VSMC-GRK2 by
either the overexpression of the GRK2-ct or VSMC-specific ablation of GRK2 protein
expression increases α1DAR-stimulated vasoconstriction. Consequently, it appears that
either increased or decreased GRK2 expression can lead to a dysregulation in the balance
between vasoconstrictor- and vasodilator-regulated vessel tone. GαS-coupled GPCRs that
mediate vasodilatation are regulated solely by GRK2-mediated phosphorylation, whereas
Gαq/11-coupled receptors are regulated by both GRK2 phosphorylation-dependent and independent mechanisms (Ferguson, 2007). Therefore, GαS-coupled GPCRs may be more
sensitive to small increases in GRK2 expression due to the loss of phosphorylationdependent desensitization, whereas a loss of GRK2 expression increases both GαS- and
Gαq/11-GPCR signaling. Thus, the shGRK2 hypertensive phenotype may be the
consequence of extent of GRK2 suppression achieved in this model, due to the reduction
of the Gαq/11-selective uncoupling of Gαq/11-coupled GPCRs by the, GRK2 RGS homology
domain, which is not observed for Gαs-coupled GPCRs (Ferguson, 2007). Consequently,
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therapeutic strategies that target GRK2 activity, as opposed inhibiting receptor interactions,
may be more effective for the treatment of hypertension.
Consistent with the observation that vasodilatation in response to βAR stimulation
is increased in the shGRK2 mice, isoproterenol-stimulated cAMP formation is enhanced
shGRK2 VSMCs when compared to wild-type mice indicating that βAR desensitization is
reduced. We also observed that Ang II-stimulated Ca2+ release is increased in VMSCs
cultured from shGRK2 mice suggesting that there is reduced GRK2-mediated
desensitization of Gαq/11 signaling. This is similar to what was previously observed for
endothelin receptor signaling in VSMCs transfected with a GRK2-K220R/D110A mutant
that does not mediate receptor desensitization (Morris et al., 2010). Thus, in general,
VSMCs responses recapitulate responses observed in intact tissue.
The ERK1/2 pathway is coupled to enhanced contractile responses and increased
VSMC proliferation and the inhibition of ERK1/2 activity significantly reduces smooth
muscle cell growth (Mii et al., 1996; Dessy et al., 1998; Touyz et al., 2002; Kim et al.,
2005). We also observed alterations in ERK1/2 and Akt signaling. Specifically, we find
that reduced GRK2 expression results in a significant increase in the extent and duration
of Ang II- stimulated ERK1/2 and Akt phosphorylation in VSMC cultures derived from 6
month-old shGRK2 mice. This is in alignment with previous observations that GRK2
expression exerts a negative effect on β-arrestin signaling by competing with GRK5 and
GRK6 for receptor binding (Zidar et al., 2009). The time course for ERK1/2
phosphorylation in response to Ang II shifts with age with more effective activation of
ERK1/2 phosphorylation at early time points in 3 month cultures and a more prolonged
and delayed activation in 6 month cultures. This supports the concept that β-arrestin-
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mediates the prolonged activation of ERK1/2 (Ahn et al., 2004). Carvedilol and SII have
been shown to activate ERK1/2 phosphorylation solely via the β-arrestin-dependent
mechanism (Wei et al., 2003; Wisler et al., 2007). We found that both carvedilol and SII
treatment results in increased ERK1/2 phosphorylation in VSMCs derived from 3 monthold wild-type and shGRK2 mice, but ERK1/2 phosphorylation is selectively increased in
shGRK2 VSMCs. However, the treatment of VSMCs derived from 6 month-old wild-type
mice with either carvedilol or SII does not result in either ERK1/2 or Akt phosphortylation,
whereas in shGRK2 cultures SII, but not carvedilol stimulates ERK1/2 phosphorylation.
In contrast, both carvedilol and SII stimulation elicit Akt phosphorylation in VSMCS
dervied from 6 month old shGRK2 mice. In addition, we observed increases in ERK1/2,
but not Akt signaling in response to Ang II in VSMCs derived from 6 week-old shGRK2
mice prior to the development of hypertension. Thus, it appears that alterations in both
ERK1/2 and Akt are age-dependent and progress with the generation of the hypertensive
phenotype, as pre-hypertensive mice do not exhibit a generalized alteration in both ERK1/2
and Akt activation in response to both Ang II and SII. Taken together, these observations
indicate that GRK2 expression antagonizes ERK1/2 and Akt phosphorylation in VSMCs
and the pattern of responsiveness to drug treatment changes with the development of
hypertension. This suggests that the responsiveness to biased agonists may be reduced with
age and might potentially limit their window of therapeutic effectiveness.
GRK2 plays an inhibitory role in cell cycle progression and GRK2 overexpression
reduces smooth muscle, thyroid cancer and hepato-carcinoma cell growth and that GRK2
and β-arrestin2 regulate cell migration (Peppel et al., 2000; Kim et al., 2008; Metaye et al.,
2008; Lafarga et al., 2012; Liu et al., 2012; Wei et al., 2012). The proliferation and
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migration of VSMCs derived from older shGRK2 mice is significantly increased in
response to Ang II stimulation via an ERK1/2- and Akt-dependent mechanism. β-Arrestin2
deletion reduces both VSMCs proliferation and migration and blocking GRK2 activity
increases neutrophil migration (Kim et al., 2008; Liu et al., 2012). Thus, increased βarrestin signaling in the absence of GRK2 expression promotes VSMCs proliferation and
migration, which may contribute to the age-dependent onset of hypertension in shGRK2
mice. These increased proliferative and migratory responses are only observed following
AT1R activation of VSMCs derived from shGRK2 mice. Thus, the context of the activation
of the ERK/Akt pathway is likely also important in that Gαq/11, but not Gαs, receptor
activation leads to proliferation and may require a concomitant increase in Ca2+ release
from intracellular stores.
In summary, global knockdown of GRK2 expression results in a mouse that
spontaneously develops hypertension, due to alterations in the balance between
mechanisms regulating vasodilatation and vasoconstriction (Fig. 2.13). The loss of GRK2
expression not only results in increases in GPCR responsiveness to both vasodilators and
constrictors, associated with reduced receptor desensitization, VSMC proliferation and
migration are also increased as the consequence of what appears to be β-arrestin-mediated
signaling. This highlights the complexity of the balance between G protein-dependent and
-independent signaling pathways engaged by GPCRs.
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Figure 2.13: Schematic diagram of the proposed role of GRK2-targeted
knockdown expression in the mechanism of hypertension
Vascular smooth muscle cells cultured from shGRK2 knockdown mice show increases in
GPCR-mediated Gαs and Gαq/11 signaling, as the consequence of reduced GRK2-mediated
desensitization. Global knockdown of GRK2 expression shifts the balance of GPCRregulated vasodilator and vasoconstrictor mechanisms in the favor of Gαq/11 that at least in
part is responsible for the hypertensive phenotype observed in shGRK2 transgenic mice.
In addition, agonists and biased agonists exhibited age-dependent alterations in ERK1/2
and Akt signaling pathways that are linked to altered cellular proliferation and migration
responses to Gαq/11-coupled GPCR activation and thereby could be responsible for the
increase in peripheral resistance associated with the hypertensive phenotype.

VASOCONSTRICTION

VASODILATATION
VSMC

Gαq

Gαs

HYPERTENSION

128

These observations indicate that, while partial inhibition of GRK2 may be of
therapeutic benefit, total inhibition of GRK2 expression may lead to alterations in GPCR
signaling that will lead to the development of hypertension or other pathological
conditions.

2.5
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CHAPTER 3:
INHIBITION OF GRK2 EXPRESSION PROMOTES KIDNEY
INJURY AND DYSREGULATION OF RENAL-MEDIATED
MECHANISMS OF BLOOD PRESSURE
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3.1

Introduction

Blood pressure homeostasis is controlled through the interaction of multiple and complex
organ systems. Kidneys play an essential permissive role in the elevation of blood pressure
and dysregulation of the renal excretion function is a prerequisite for hypertension (Guyton,
1991). The strong correlation between genetic disorders affecting blood pressure
homeostasis and those controlling the salt and water reabsorption at the nephron level
(Lifton et al., 2001) can be regarded as an unquestionable validation of the important
modulatory role played by renal excretory function on systemic blood pressure.
The defective renal sodium excretion represents one of the common pathways that
is responsible for the onset of the elevated blood pressure, regardless if induced on a
vascular, neural or inflammatory basis. Along these lines, Aperia et al. (1971) proposed
that elevations of the perfusion pressure in renal artery lead to “pressure natriuresis”, a
phenomenon characterized by rapid escalations of sodium and water excreted by the kidney
in an attempt to restore normal values of the systemic blood pressure (Guyton et al., 1972).
The two main regulatory pathways with a significant effect on sodium balance are
the dopaminergic and renin-angiotensin system (RAS). As expected, these two systems are
characterized by an antagonistic functionality that is modulated by a multitude of
intracellular pathways with role in sodium and water homeostasis.
Any dysregulations and/or sustained activations of the RAS could translate into
hypertension and end-organ damage (Gavras et al., 1971; Brunner et al., 1972; Brunner,
2001), primarily through the activity of AT1 receptors (Lee et al., 1988; Mazzolai et al.,
2000). These receptors are expressed in key tissues (kidney, vasculature, central and
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sympathetic nervous systems) with a strong impact on the regulation of the peripheral
vascular resistance and sodium balance. However, the relative contribution brought by each
of these sites to the overall pathogenesis of the hypertension is difficult to distinguish. Prior
studies have suggested that AT1 receptors expressed by kidney and systemic tissues are
equal and non-redundant contributors to the preservation of the normal blood pressure in
the basal state, typically by protecting fluid body volumes to prevent circulatory collapse
(Crowley et al., 2005). Other studies have suggested that renal AT1 receptors have in fact
a dominant role on sodium retention and hence blood pressure elevation (Crowley et al.,
2006). The kidney cross-transplantation approach with AT1 receptors eliminated from
kidney and/or systemic tissues , suggest that – the absence of renal AT1 receptors alone was
sufficient to protect from AngII-dependent hypertension and cardiac hypertrophy(Crowley
et al., 2006).
Among the seven GRKs, GRK2 is unique with respect to other GRK family
members in that it mediates the RGS homology domain-independent desensitization of
only Gαq/11-coupled GPCRs. Indeed, global knockdown of GRK2 expression results in
mice that show enhanced signaling via Gαq/11-coupled GPCRs leading to increased
vasoconstrictor activity and hypertension (Tutunea-Fatan et al., 2015). GRK2 contributes
to the desensitization of GPCR signaling and it appears that either increased or decreased
in GRK2 expression can lead to a dysregulation in the balance between vasoconstrictorand vasodilator-regulated vessel tone. On the other hand, GRK4 is the only GRK subtype
capable to phosphorylate unstimulated GPCRs due to its capacity to bind to inactive Gαs
and Gβ subunits (Jose et al., 2010). GRK4 gene variants were shown to phosphorylate,
desensitize, and internalize dopamine type 1(D1R) and 3 (D3R) receptors by preventing
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their recycling to the plasma membrane. In addition, GRK4 gene variants were found to be
responsible for stimulation of the AT1 receptor expression (Felder et al., 2002). The
simultaneous elevated levels of GRK4 and AT1R in kidney translate in higher blood
pressure since their concurrent selective renal silencing was associated with increased
sodium excretion and lower blood pressure (Yatabe et al., 2008; Gurevich et al., 2012).
In the present chapter, we have investigated the effects of reduced GRK2
expression on renal function and thereby the contribution of the kidney to the development
of hypertension. The extensive loss of GRK2 expression leads to reduced desensitization
of AT1 receptors – expressed not only by vascular smooth muscle cells but also by kidney
tissue – with a strong impact on the regulation of both peripheral vascular resistance and
sodium balance. Thereby, these intricate effects seem to complement each other in the
onset of hypertension. Our results indicate that as the blood pressure increases, the
expression of renal RAS components increases correspondingly and associates with a
decrease in urinary sodium excretion and thereby could be responsible – at least in part –
for the hypertensive phenotype. The chronic activation of RAS not only leads to defective
renal-sodium excretion but also potentiates renal injury by inducing alteration in
glomerular filtration rates and progression of renal fibrosis. GRK2-mediated hypertension
was also associated with an enhanced in mRNA expression level of different GRKs
subtypes (GRK3, GRK4, and GRK5). Moreover, the pattern of their expression has been
noticed to increase with the generation of the hypertensive phenotype. While GRK5
elevation endeavors a more compensatory role in an attempt to lower blood pressure,
GRK3 and GRK4 upregulation has a more pro-hypertensive action. The effect of GRK4
activation on the dopaminergic-mediated natriuresis might potentiate the alteration of
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sodium excretion and consequently contribute the blood pressure elevation.

3.2

Experimental Procedure

3.2.1

Morphometric Characterization of shGRK2 Kidney

The GRK2 hemizygous (GRK2 +/-) mice were generated on the C57Bl/6 genetic
background as previously described (Tutunea-Fatan et al., 2015). Kidneys (left and right)
were collected, stripped of peritoneal fat and connective tissue and weights were recorded.
Quantification of kidney mass relative to both body weight and tibia length was performed
in a paired manner. All experiments involving animals were approved by the Animal Use
Subcommittee of Western University, according to the guidelines of the Canadian Council
on Animal Care.
3.2.2

Computed Tomography Analysis

Three age-based groups of 3, 6, and 12 month-old GRK2 (+/-) mice and control C57Bl/6
were used in this study. Mice were fed a regular diet and housed on a 12:12 hour light-dark
cycle. Each mouse was anesthetized for the entire duration of the procedure (2 min) by
exposure to 2.5% isoflurane-oxygen gas. A GE eXplore CT 120 scanner was used for 3Dimages acquisition. Data were analyzed with MicroCT Visualization & Analysis software
(MicroView) (Robarts Research Institute). All procedures were performed with the
approval of the Western University Animal Ethics Committee.
3.2.3

Blood and Urine Analysis

The whole blood was collected into BD Microtainer Serum Separator Tubes (BectonDickinson, Franklin, NJ, USA) through cardiac puncture of mice under terminal anesthesia.
Then, blood was allowed to clot at room temperature for one hour. Following
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centrifugation at 1200 x g for 10 minutes, the resulting supernatant was collected, and
stored immediately at -80 C for further biochemical analysis. Urine samples from
conscious, restrained mice were collected in 1.5 ml microtubes and subjected to Chemistrip
urinalysis test (Roche Diagnostics, Laval, Quebec, Canada) to detect the presence of
glucose, protein, and blood. The analysis of biochemical constituents of blood and urine
samples was performed at Mount Sinai Hospital Laboratory (Toronto, Ontario, Canada).
3.2.4

Measurement of Inulin Clearance

The glomerular filtration rate (GFR) was measured in conscious mice by assessing plasma
kinetics of fluorescein isothiocyanate (FITC) labeled inulin (Sigma Aldrich, Saint Louis,
Mo, USA). In short, FITC-inulin solution (2µl/g) was injected into the retro-orbital plexus
of briefly anesthetized mice (isoflurane 2%). Blood samples from non-restrained, awake
mice were collected by tail snip at different time intervals for a total duration of 75 minutes
(8 samples/mouse). FITC-Inulin fluorescence was determined in both standards and
samples by a plate reader with excitation and emission of 490 and 520 nm. A standard
curve was generated from the infused FITC-Inulin solution and GFR was calculated by
employing a two-phase exponential decay function (SigmaPlot 12.0 software).
3.2.5

RNA Extraction from Kidney Samples

To ensure the optimal RNA yield as well as the reduction of lysate viscosity, a total of
30 mg tissue pulverized with liquid nitrogen was subjected to disruption and
homogenization (flash sonication for 5 seconds). Total RNA was obtained by using the
RNeasy Minikit (Qiagen, Valencia, MD, and USA) following manufacturer’s instructions.
To minimize genomic contamination, an on-column DNase digestion step was included in
the protocol. Two micrograms of total RNA were reverse transcribed with a High Capacity
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cDNA Reverse Transcription kit (Applied Biosystems, Carlsbad, CA, USA). Reverse
transcription was performed in a thermal cycler (C1000TM, Bio Rad) under the following
parameters: 25 C for 10 minutes, 37 C for 120 minutes, followed by 85 C for 5 minutes.
3.2.6

Quantitative Real -Time Polymerase Chain Reaction Analysis

To quantify the expression levels of genes of interest, TaqMan® Universal PCR Master
Mix (Applied Biosystems, Foster City, CA, USA) was used. Reaction was performed in
single micro capillary tubes (20 microliters volume) on a LightCycler (Roche Diagnostic,
Laval, QC, Canada) for control and target gene expression primer probes (TaqMan® Gene
Expression Assay, Applied Biosystems, Tab. 3.1). Six serial dilutions (1:10) of each target
and reference genes served as a standard curve and was assayed together with the
corresponding unknown samples on each plate. The quantitative real-time PCR profile was
95 C/15 seconds denature, 58 C/1 minute anneal-extension for 40 cycles. Reactions were
performed in triplicate and delta-delta Ct (ΔΔCt) method was employed to determine the
fold difference (2–ΔΔCt) (Applied Biosystems).
Table 3.1. Primer probe information for quantitative real-time PCR
Target Primer

Probe ID

Grk2/Adrbk1

Mm00804778_m1

Grk3/Adrbk2

Mm00622042_m1

GRK4

Mm01213690_m1

GRK5

Mm00517039_m1

GRK6

Mm00442425_m1

Collagen

Mm00801606_m1

Target Primer

Probe ID
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3.2.7

Sox6

Mm00488393_m1

Renin

Mm02342887_mH

Angiotensinogen

Mm00599662_m1

AT1R

Mm00475056_m1

β2AR

Mm01242584_m1

α1dAR

Mm01328600_m1

5-HT1B

Mm00439377_s1

5-HT2B

Mm00434123_m1

D1R

Mm02620146_s1

ACTB

Mm02619580_g1

Losartan Treatment-Experimental Design

The shGRK2 (+/-) transgenic mice were divided into three age-based groups (3, 6, and 12
month-old) with a number of six mice/group. Age-matched wild type C57Bl/6 mice
(Charles River Laboratories) were used as a control. Treatment groups received
100 mg/kg/day Losartan (Sigma Aldrich) in drinking water for one month. Water alone
was used as a control for all groups of mice. Water intake was measured daily and was
approximately 25 ml/week/mouse. Mice were housed on a 12:12 hour light-dark cycle at
24 C, with free access to food and water. Systolic and diastolic blood pressures were
measured weekly during the one-month treatment period using the non-invasive CODA
tail-cuff blood pressure system (Kent Scientific, Torrington, CT). As a baseline, blood
pressure before and three weeks after the treatment (washout period) was recorded.
To eliminate the influence of circadian rhythm, blood pressure was measured at the same
time of day.
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3.2.8

Plasma Renin Analysis

Plasma renin was measured by an enzyme-linked immunosorbent ELISA assay (Mouse
Ren1-ELISA Kit, Sigma Aldrich) following manufacturer’s instructions. The optical
density at 450 nm was determined for each well using an Infinite M200 (TECAN) plate
reader. Each measurement was done in triplicate and the mean absorbance for standards,
controls and samples was calculated. Standard curve was generated with SigmaPlot
software.
3.2.9

Connective Tissue Staining

In brief, mice were anesthetized with ketamine/xylazine (100/10 mg/kg intraperitoneal),
exsanguinated by saline perfusion and directly perfused with 4% paraformaldehyde
solution via vascular system. Paraffin-fixed tissues were sectioned (4 μm tick) and placed
on positively-charged microscope slides. After deparaffinization and rehydration through
serial decreases of ethanol concentration (100%, 95%, and 70%), slides were subjected to
Masson’s trichrome staining (Trichrome Stain-Kit, Abcam, Cambridge, MA, USA)
following manufacturer’s instructions. Interstitial collagen deposition was visualized by
using a bright-light microscope (20X magnification) and image capture software (Leica
DM RBE, Image Pro Plus 4.5.1 software).
3.2.10 H&E Staining
Formalin-fixed, paraffin-embedded sections were stained with hematoxylin (200 µl/slide,
Sigma Aldrich) for 5 minutes and eosin (400 µl/slide, Sigma Aldrich) for 30 seconds. Then
slides were quickly dehydrated (2 changes of 100% ethanol), cleared in xylene, and
mounted. Assessment of glomerular number was performed by using the point selection
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tool with auto measure of Image J software (Bethesda, MD, USA). The mean glomerular
number per unit area of tissue section (mm2) was calculated from a total number of 160
microscopic fields for both samples and controls.
3.2.11 Immunohistochemistry of Renin
Renin was detected in paraffin-embedded kidney sections (3 μm tick) using a goat antimouse polyclonal antibody (15µg/ml, R&D Systems, Minneapolis, MN, USA). Tissue was
stained with an anti-goat HRP-DAB tissue staining kit (CTS0008, R&D Systems) and
counterstained with haematoxylin. In order to identify non-specific staining of the
secondary antibodies, incubation buffer with no primary antibodies was used as a negative
control. To reduce non-specific hydrophobic interactions between the primary antibodies
and tissue, slides were incubated with a goat serum blocking reagent. To block binding to
endogenous biotin, samples were incubated with avidin blocking reagent and then to block
subsequent binding to the avidin, a biotin blocking reagent was used. A bright-field
illumination microscope (20X magnification) was used to visualize tissue staining.
3.2.12 Statistical Analysis
Statistical differences between groups were performed using GraphPad Prism software
version 5 (GraphPad Software, La Jolla, CA, USA). All parametric data were analyzed
with either Student’s t test or one-way ANOVA followed by Bonferroni post hoc
comparisons. SigmaPlot software version 12.1 (Cincinnati, OH, USA) was used for
regression analysis. Statistical significance between mean values were determined based
on p < 0.05 criterion.
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3.3

Results

3.3.1

Effects of GRK2 Knockdown on Body Fat

To assess the impact of altered GRK2 expression on blood pressure regulation, we used a
transgenic mouse model of systemic downregulation of GRK2 protein expression. The
GRK2 (+/-) transgenic mice are characterized by a lean phenotype since CT analysis of the
whole body scan revealed a significant increase in the lean tissue associated with a
significant reduction of the adipose mass when compared with control wild type C57Bl/6
mice (Fig. 3.1A, 3.1B, and 3.1C). In addition, analysis of retroperitoneal fat, a well-defined
tissue showed more than 60% reduction in shGRK2 mice (Fig. 3.1D).
3.3.2

Effects of GRK2 Knockdown on Kidney Morphometry and Function

The organ weight-to-body weight ratios (heart, lung, and liver) showed no significant
differences between the shGRK2 and control group with the exception of kidneys. A
significant decrease in kidney weight of shGRK2 mice was recorded at 6-weeks, 12-weeks,
and 6-months of age. There was no statistical significance with respect to the mass and
length of both (left-right) shGRK2 kidneys. However, there was a significant difference
between the mean renal length of shGRK2 mice when compared with age-matched
C57Bl/6 mice (Fig. 3.2A, 3.2B, and 3.2C). Measurements of glomerular filtration rate after
a single bolus administration of fluorescent-labelled inulin exhibited characteristics of a
two-compartment system with an initial rapid decay phase, followed by a slower decay
phase. By using nonlinear regression, the plasma elimination of FITC-inulin yielded a GFR
of 232.21 ± 46.75 µl/min for control wild type mice, and a GFR of 76.39 ± 20.79 µl/min
for shGRK2 mice (Fig. 3.2D).
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Figure 3.1: Characterization of shGRK2 mice phenotype
(A) Representative three-dimensional CT images of the whole body scan of shGRK2 and
control C57Bl/6 mice outlining the difference in adipose and lean tissue. (B) and (C)
Comparative quantitative analysis of adipose, lean, and skeletal tissue in shGRK2 and
control mice. (D) Comparative quantitative analysis of retroperitoneal fat in shGRK2 and
control mice at different weeks of age. Data represents the mean ± SD (n = 6). (***)
Significant at (p < 0.001).
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Figure 3.2: Effects of GRK2 knockdown on kidney anatomy and function
(A) Quantification of organ mass relative to body weight in 3 month-old shGRK2 and
C57Bl/6 mice. (B) Digital images of wild-type versus shGRK2 kidneys outing the
difference in size. (C) Quantification of kidney mass (right & left) relative to tibia length
at different months of age. Data represents the mean ± SD of 6 mice. (***) Indicates
statistically significant differences compared to control, age-matched C57Bl/6 mice (p<
0.001). (D) Renal inulin clearance (µl/minute) of shGRK2 and control C57Bl/6 mice under
basal conditions. Data represents the mean ± SD. (*) Significant at (p < 0.05); (**)
Significant at (p < 0.01); (***) Significant at (p < 0.001).
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To assess the effect of GRK2 knockdown on kidney function, semi-quantitative analysis
of urinary content was performed and a moderate increase in protein expression level in
urine collected from 1, 3, and 6 month-old shGRK2 mice was observed when compared
with age-matched control mice (Tab. 3.2).
Quantitative analysis of urine revealed a significant increase in total protein content
in urine of 3 month-old shGRK2 mice when compared with control (13.5 ± 1.7 vs.
7.2 ± 2 g/l, p < 0.001). As well as an increase in blood urea nitrogen was recorded
(794 ± 29 vs. 732 ± 28 mg/dl, p < 0.001). The urinary electrolyte excretion was measured
and a significant decreased in urinary sodium content was observed for shGRK2 mice
across the all age-groups analyzed (Tab. 3.3).
With respect to blood biochemistry (Tab. 3.4), no plasma sodium variation was
observed among the all shGRK2 groups analyzed while an increase in potassium (5.2 ± 0.5
vs. 3.9 ± 0.38 mmol/l, p < 0.001) and phosphorous (8.5 ± 1.2 vs. 7 ± 0.8 mg/dl, p < 0.05)
can be observed in 6 month-old shGRK2 mice. In addition, an increased in blood urea was
recorded in plasma of shGRK2 mice when compared with control wild type mice (28 ± 1.4
vs. 22.7 ± 2 mg/dl, p < 0.001). Our data also indicate low serum albumin levels for
shGRK2 mice (25 ± 2.3 vs. 27 ± 2.9 g/l, p < 0.001).
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Table 3.2: Semi-quantitative analysis of urine

Samples were collected from shGRK2 and control C57Bl/6 mice (n = 6) and assessed by
urine analysis test strip. Expression level: negative (absent), modest (+), moderate (++).

Analyte (unit)
pH
Nitrate
Protein
Glucose
Ketones
Bilirubin
Leucocytes
Blood
Hemoglobin

1 month (n=6)
wt
shGRK2
5
6
Negative
Negative
Negative Positive(+)
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative
N/A
N/A

3 months (n=6)
6 months (n=6)
wt
shGRK2
wt
shGRK2
5
7
6
5
Negative
Negative
Negative
Negative
Negative Positive(++) Positive(+) Positive(++)
Negative
Negative
Negative
Negative
Negative
Negative
Negative Positive(+)
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative
N/A
N/A
N/A
N/A
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Table 3.3: Biochemical analysis of urine
Samples were collected from shGRK2 and control C57Bl/6 mice. Data represents the mean
± SD (n=6). (*) Significant at (p < 0.05); (**) Significant at (p < 0.01); (***) Significant
at (p < 0.001).

Analyte (unit)
Sodium (mmol/L)
Potassium (mmol/L)
Chloride (mmol/L)
Phosphorous (mg/dL)
Calcium (mg/dL)
Total Protein (g/L)
Albumin (g/L)
Blood Urea (mg/dL)
Creatinine (mg/dL)

1 month (n=6)
wt
shGRK2
199 ± 46
149 ± 44
72 ± 23
87 ± 4
198 ± 60
232 ± 61
47 ± 3
46 ± 0.4
5.2 ± 1.2
4.9 ± 1.3
2.2 ± 0.07
2.8 ± 0.6
0.15 ± 0.1
0.1 ± 0.01
823 ± 24
837 ± 9
25 ± 12
26 ± 5

3 months (n=6)
wt
shGRK2
214 ± 29
150 ± 22(*)
91 ± 6
104 ± 14
232 ± 43
245 ± 56
41 ± 3
47 ± 2
5.2 ± 1.3
6.6 ± 1.4
7.2 ± 2.3
13.5 ± 1.7(***)
0.7 ± 0
0.5 ± 0.34
732 ± 28
794 ± 29(***)
37 ± 4
30 ± 16
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6 months (n=6)
wt
shGRK2
175 ± 30
105 ± 53(**)
94 ± 6
83 ± 14
233 ± 31
165 ± 66
47 ± 1
46 ± 0.5
5.1 ± 0.2
5.9 ± 0.01
12.2 ± 2.4
12.9 ± 0.9
0.6 ± 0.1
0.7 ± 0.05
791 ± 11
788 ± 16
38 ± 2
40 ± 1

Table 3.4: Biochemical analysis of blood
Samples were collected from shGRK2 and control C57Bl/6 mice. Data represents the mean
± SD (n=6). (*) Significant at (p < 0.05); (**) Significant at (p < 0.01); (***) Significant
at (p < 0.001).

Analyte (unit)
Sodium (mmol/L)
Potassium (mmol/L)
Chloride (mmol/L)
Phosphorous (mg/dL)
Calcium (mg/dL)
Total Protein (g/L)
Albumin (g/L)
Blood Urea (mg/dL)
Creatinine (mg/dL)
Glucose (mg/dL)
Total Cholesterol (mg/dL)
Triglycerides (mg/dL)
HDL‐Cholesterol (mg/dL)
LDL‐Cholesterol (mg/dL)

1 month (n=6)
wt
shGRK2
149 ± 0.4
147 ± 2.1
4.4 ± 0.10
4.1 ± 0.07
114 ± 1.2
111 ± 1.6
10.5 ± 0.4
9.6 ± 0.4
9.6 ± 0.3
9.9 ± 0.1
44.2 ± 1.3
44 ± 0.3
26 ± 1.0
26.3 ± 0.7
22.3 ± 2.0
19.1 ± 1.3(**)
0.22 ± 0.02 0.18 ± 0.01(**)
213 ± 43
252 ± 26
95 ± 6.6
92 ± 8.5
148 ± 30
131 ± 13
44.7 ± 2.9
47.1 ± 3.0
7.5 ± 0.2
10.1 ± 0.6(***)

3 months (n=6)
6 months (n=6)
wt
shGRK2
wt
shGRK2
149 ± 3.2
151 ± 2.0
150 ± 2.8
146 ± 8.9
4.0 ± 0.32
4.1 ± 0.61
3.9 ± 0.38 5.2 ± 0.5(***)
113 ± 2.8
118 ± 2(*)
113 ± 2.4
113.2 ± 8.4
7.5 ± 1.2
7.8 ± 1.7
7.0 ± 0.8
8.5 ± 1.2(*)
8.9 ± 0.3
8.9 ± 0.2
9.1 ± 0.2
9.2 ± 0.4
47.0 ± 3.2
45 ± 2.3
49.2 ± 1.7
49.1 ± 1.7
27.0 ± 1.1
25.2 ± 0.7(*) 27.0 ± 1.5
25.1 ± 2.3(*)
24.7 ± 3.4 28.6 ± 2.67(**) 22.7 ± 2.9 28.0 ± 1.4(***)
0.22 ± 0.01 0.18 ± 0.03(**) 0.19 ± 0.01
0.20 ± 0.01
219 ± 38
234 ± 50
270 ± 38
256 ± 45
91 ± 18
90 ± 10.5
106 ± 17
89 ± 8.0(*)
141 ± 52
194 ± 97
171 ± 62
172 ± 41
53.0 ± 9.1
51.7 ± 3.7
59.4 ± 8.8 48.4 ± 3.6(***)
2.8 ± 0.6
4.5 ± 0.1(***) 3.2 ± 0.6
4.0 ± 0.6(**)
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3.3.3

Effects of GRK2 Knockdown on GPCRs Expression in Kidney

Microarray analysis confirmed that GRK2 gene expression is down-regulated in kidney
tissue of the transgenic mice. Consistent with previous observations that GRK2 downregulation increased lipolysis, our data indicate that several genes with role in lipid
metabolism are up-regulated: carboxylesterase gene with role in cholesterol hydrolysis,
adiponectin with role in lipid catabolism, and Apolipoprotein E which is a lipid transporter
and is the major ligand for LDL receptors (Tab. 3.5). One of the question to address was
whether GRK2 inhibition leads to up-regulation of other members of GRKs family as a
compensatory mechanism. In this regard, we found out that while GRK2 mRNA
expression is constantly maintained at decreased levels over time, GRK3, GRK4, and
GRK5 are significantly increased in kidney tissue collected from 3 and 6 month-old
shGRK2 mice (Fig. 3.3A). To assess whether alteration in GRK2 level have an impact on
the expression status of GPCRs, the mRNA level of several GPCRs with critical role in
blood pressure regulation was measured.
We found a significant shift/decrease in the mRNA expression of dopamine type 1
receptor (D1R) in kidney collected from shGRK2 mice when compared with age-matched
control. Dopamine interacts with AT1Rs and α1ARs in the proximal tubule to maintained
sodium homeostasis and any defect in dopaminergic system associates with an opposed
action of AT1R. Indeed, our data indicate a significant increase in both AT1R and α1ARs
mRNA expression in shGRK2 kidney. In addition, a distinct expression pattern of
serotonin 5-HT receptors was observed: while both types of receptors were significantly
increased in shGRK2 kidney tissues, the HT-1bR reach a peak of expression at 1 month
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Table 3.5: Microarray analysis of gene expression in kidney tissue
Top 25 significantly (A) increased and (B) decreased genes in kidneys harvested from
shGRK2 vs. C57Bl/6 mice at 3 months of age.

A)

B)
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Figure 3.3: Effects of GRK2 knockdown on GRKs expression in kidney
(A) Quantitative RT-PCR analysis of GRK 2, 3, 4, 5 and 6 mRNA expressions in kidney.
Expressions levels are normalized to actin (ACTB). (B) Quantitative RT-PCR analysis of
several GPCRs mRNA expression in kidney. Expressions levels are normalized to ACTB.
Data represents the mean ± SD (n=6). (*) Significant at (p < 0.05); (**) Significant at
(p < 0.01); (***) Significant at (p < 0.001).
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of age and then slowly decreased as mice aged. On the hand, the expression of HT-2bR
increased gradually with the development of high blood pressure (Fig. 3.3B).
3.3.4

Effects of GRK2 Knockdown on RAS Expression in Kidney

Our data indicate that the mRNA level of renal angiotensinogen increased significantly in
shGRK2 mice during the development of high blood pressure with a peak at six months of
age (Fig. 3.4A). In addition, the level of intra-renal renin mRNA expression increased
gradually starting with the pre-hypertensive shGRK2 mice and this increase was still
maintained at six months of age (Fig. 3.4B). On the other hand, no significant changes in
plasma renin concentration were noticed in pre-hypertensive and 3 month-old shGRK2
mice when compared with age-matched control wild type mice. However, the level of renin
emerged a significant increase in plasma of shGRK2 mice at six months of age (Fig. 3.4C).
In addition, renin mRNA expression correlates positively with renal renin protein
expression as visualized by immunochemistry staining (Fig. 3.4D).
3.3.5

Effects of AT1R Blocker on Blood Pressure and Kidney Function

To verify the involvement of AT1R axis in blood pressure modulation of the shGRK2 mice,
a selective AT1R blocker losartan was given orally (100mg/kg/day) to our shGRK2 and
wild type C57Bl/6 mice for four weeks. Water alone was used as a control. A gradual drop
in both systolic and diastolic blood pressures was recorded over the entire duration of
treatment for all aged shGRK2 groups analyzed (Fig 3.5A).
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Figure 3.4: Effects of GRK2 knockdown on RAS
Quantitative RT-PCR analysis of angiotensinogen (A) and renin (B) mRNA expressions in
kidney of shGRK2 and control C57Bl/6 mice (n=6). Expressions levels are normalized to
ACTB. (C) Plasma renin expression in shGRK2 and control mice as measured by enzymelinked immunosorbent ELISA assay. Standard curve as obtained by regression analysis (r2
= 0.99). Data represents the mean ± SD (n=6). (*) Indicates statistically significant
differences compared to control (p< 0.05). (D) Representative immunostaining of renin
protein expression in kidney sections of shGRK2 mice vs. control wild type.
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Figure 3.5: Effects of AT1R specific blocker Losartan on blood pressure
(A) Systolic pressures, diastolic pressures, and heart rates in response to 100 mg
losartan/kg/day and water control in shGRK2. Data represents the mean ± SD (n=9). (*)
Indicates statistically significant differences compared to control (p< 0.05). (B) Systolic
pressures, diastolic pressures, and heart rates in response to 100 mg losartan/kg/day and
water control in C57Bl/6. Data represents the mean ± SD (n=6).
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Blood pressure of the shGRK2 mice decreased significantly by the end of four weeks of
treatment when compared with water control (116/86 ± 12/15 vs. 163/130 ± 14/16 mmHg,
p < 0.01). No significant changes in blood pressures were observed for wild type mice
regardless if mice were on losartan treatment or water (119/84 ± 9/7 vs. 128/84 ± 8/12
mmHg) (Fig. 3.5B).
After a three-week wash out period, blood pressure recovered its pre-treatment
value supporting the observation that AT1R-mediated signaling is responsible for the blood
pressure elevation of the shGRK2 mice (152/114 ± 6/5 vs. 157/112 ± 8/6 mmHg). Since
the mRNA level of AT1 receptors is increased in kidney of shGRK2 mice (Fig. 3.6A), we
examined the effect of losartan on its expression and a significant decreased was recorded
for shGRK2 mice when compared with control-water group. On the other hand, a more
intricate pattern of expression was noticed for D1R and β2AR: while D1R expression is
unchanged and maintained at decreased levels, a pronounce increase in β2AR mRNA
expression was observed (Fig. 3.6B). In addition, a significant decreased in GRK2 and
GRK5 mRNA expression levels were observed for shGRK2 mice in response to losartan
treatment (Fig. 3.6C) while mRNA level of GRK3 and GRK4 expression was unchanged.
Blockade of AT1 receptor was associated with a significant increase in renin mRNA level
(Fig. 3.6D). Our data also indicate that the inulin clearance rate of shGRK2 mice was
rescued under losartan treatment to 178.29 ± 35.02 µl/min from 76.39 ± 20.79 µl/min,
value measured under basal conditions (Fig. 3.6E).
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Figure 3.6: Effects of AT1R specific blocker Losartan on kidney
(A) Quantitative RT-PCR analysis of AT1R and β2AR mRNA expressions in aortic tissue
of shGRK2 and control C57BL/6 mice. Expressions levels are normalized to ACTB (B)
Quantitative RT-PCR analysis of AT1R, β2AR, and D1R mRNA expressions in kidney
collected from shGRK2 mice under basal and 4 weeks of losartan treatment
(100mg/kg/day). Expressions levels are normalized to ACTB. (C) Quantitative RT-PCR
analysis of GRK2, GRK3, GRK4, and GRK5 mRNA expressions in kidney collected from
shGRK2 mice under basal and 4 weeks of losartan treatment (100mg/kg/day). Expressions
levels are normalized to ACTB. (D) Quantitative RT-PCR analysis of angiotensinogen,
renin, and TGFβ1 mRNA expressions in kidney of shGRK2 mice under basal and 4 weeks
of losartan treatment (100mg/kg/day). Expressions levels are normalized to ACTB. (E)
Renal inulin clearance (µl/minute) of shGRK2 mice under basal and 4 weeks of losartan
treatment (100mg/kg/day). Data represents the mean ± SD (n=6). (*) Significant at
(p<0.05); (**) Significant at (p<0.01); (***) Significant at (p<0.001).
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3.3.6

Effects of GRK2 Knockdown on Kidney Injury

One of the most common consequences of chronic hypertension is the injury of key target
organs including kidney. Therefore, we examined the expression level of pro-fibrotic
markers in kidney tissues of shGRK2 and age-matched wild type mice. We found that
TGFβ1, a key mediator of renal fibrosis through the activation of extracellular matrix
proteins such as collagen, is increased at both protein and mRNA levels (Fig. 3.7A, 3.7B,
and 3.7C). The expression level of TGFβ1 increase significantly in 3-month old shGRK2
mice, age that correspond with onset of hypertension and this increase was still maintained
at six months of age. Histological analysis of kidney sections revealed interstitial fibrosis
sights in 6-month old shGRK2 mice. In addition, Masson’ staining depicts increase
collagen deposition around the arteries. The total glomerular number was significantly
reduced in shGRK2 across the all age-analyzed when compared with control mice
(Fig. 3.7D, 3.7E, and 3.7F).

3.4

Discussion

The role of GRK2 in the embryonic development is essential since GRK2 gene ablation
reveals that no mice embryos survive post-embryonic day E15.5 (Jaber et al., 1996). GRK2
is expressed in multipotent and migratory cell populations during the early stages of
embryogenesis. From embryonic day E15.5, GRK2 is expressed in several organs and
tissues such as heart, liver, lung primordia and motor neurons supporting its broader role
in embryogenesis (Sefton et al., 2000). Recent evidences emphasize that GRK2 acts as a
positive regulator of Hedgehog (Hh) signaling with crucial roles in embryonic development
as well as physiological processes and many human disorders (Zhao et al., 2016).

169

Figure 3.7: Effects of GRK2 knockdown on kidney
(A) Representative immunoblot for TGFβ1 and GAPDH expression in kidney tissue
obtained from wild-type C57Bl/6 and shGRK2 mice. Quantitative RT-PCR analysis of
TGFβ1(B) and collagen IV(C) mRNA expression in kidney of shGRK2 and control
C57Bl/6 mice (n=6). Expressions levels are normalized to ACTB. (D) Representative
histological images of kidney sections stained with H&E collected from shGRK2 and agematched control mice. (D) Evaluation of glomerular number in H&E stained histological
kidney sections. Glomerular number from 160 microscopic fields (20X) is reported as a
mean per unit area of tissue sections. (E) Representative histological images of Masson’
trichrome staining of kidney sections from shGRK2 and control mice. Blue represents
collagen, red represents muscle fibers, and black nuclei.
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In our transgenic mouse model, the targeted knockdown of GRK2 expression has
translated into a growth-deficient phenotype with lower body mass indices and a significant
decrease of adipose mass. Indeed, microarray analysis revealed that shGRK2 mice exhibit
upregulations of several genes with role in lipid metabolism and this supports the past
observations that GRK2 plays an important role in the regulation of adiposity (VilaBedmar et al., 2012). Otherwise, our GRK2 heterozygote mice developed normally, with
no difference in organ weight-to-body weight ratio, the only exception being the kidneys
that were characterized by significant decreases in size and weight, as recorded at both
birth and adulthood. However, the reason for which shGRK2 mice had a kidney phenotype
with no other organ abnormalities remains to be determined.
The kidney has a central role among the organs with role in blood pressure
homeostasis. Among the various cellular defects associated with the inception of
hypertension, alterations in expression and function of GPCRs play a crucial role. The
cellular responses elicited upon activation of GPCRs are tightly regulated by
phosphorylation status of the receptors mediated by GRKs. According to the GRK
subtypes, phosphorylation can be regulated differentially, leading to distinct modulations
of receptor responsiveness or “signalling barcodes” (Butcher et al., 2011). Different
phosphorylation sites may provide different conformational changes of the receptor, since
the effect of various kinases under identical conditions can result in a different extent of
responses (Boughton et al., 2011). In our model, chronic inhibition of GRK2 expression
leads to differential increases of the other GRK subtypes (GRK3, GRK4, GRK5, and
GRK6) in both aortic and kidney tissue. These increases were synchronized with the onset
of the hypertensive state. Whether the activation of these kinases has a distinct role on the
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mechanisms of hypertension or their increase engenders a more compensatory role in the
attempt to balance the attenuation in GRK2-mediated receptor desensitisation, remains to
be determined.
Our data indicates that the blockade of the AT1 receptor was associated with a
significant downregulation in the level of GRK5 mRNA expression. Hypertension itself
has been shown to trigger the increase of GRK5 expression and Ca++ influx was a
prerequisite for this upregulation (Ishizaka et al., 1997). Indeed, our results indicate that
the blockade of AT1 receptor has normalized blood pressure that consequently led to GRK5
decreases, underscoring its counterbalancing role with respect to decreased GRK2mediated phosphorylation. On the other hand, the amount of GRK3 and GRK4 expressions
in response to AT1R blocker-losartan remained unchanged even though the increase in their
levels follows the development of high blood pressure in shGRK2 mice. This might imply
that a distinct mechanism other than hypertension was the underlying factor for their
upregulation.
Of note, GRK4 has been shown to phosphorylate and desensitize dopamine D1
receptor and to play a key role in dopaminergic-mediated natriuresis and thereby blood
pressure regulation(Yatabe et al., 2008). It seems that GRK2 inhibition can lead to a
possible disruption of D1R gene in the kidney of shGRK2 mice since a significant decrease
in D1 receptor mRNA expression level was measured across the entire lifespan. In addition,
the extent of D1R expression can be correlated to the development of hypertension since
its expression was significantly decreased in the pre-hypertensive state, but further dropped
after the onset of hypertension. The modulation of D1 receptor expression may be in part
explained through the activation of renal GRK4 since D1R is a better substrate for GRK4
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than GRK2 or GRK3. Thus, the increase in GRK4 expression observed in our shGRK2
transgenic mice can lead to an increase in desensitization of D1 receptors which in turn has
translated into a more pronounced antinatriuretic effect. Indeed, our results indicate that
D1R expression was associated with a decrease in urinary sodium excretion that was
markedly attenuated with the development of hypertension. As noted previously,
desensitization of D1R due to GRK4 associates with enhanced expression and activity of
AT1R in the proximal tubules leading to enhanced antinatriuretic effects (Jose et al., 2010;
Rayner and Ramesar, 2015).
Past works define the role of AT1 receptor in renal function and structure through
the modulation of glomerular filtration rate, facilitation of renal sodium retention and
regulation of cellular growth and differentiation. On the other hand, renal AT1 receptors
have unique and non-redundant actions in blood pressure homeostasis since blood pressure
can be regulated by direct effects of AT1 receptors on kidney cells (Crowley et al., 2006;
Wu et al., 2015). In line with these observations, our data indicate that the mRNA
expression of the AT1 receptor was augmented in both aortic and kidney tissue of shGRK2
mice and this increase positively correlates with the development of high blood pressure.
Treatment with a specific AT1R-blocker Losartan has significantly decreased the blood
pressure elevation that was brought down to the level of wild type mice. The reduction in
blood pressure was a direct consequence of interrupting the AT1 receptor signaling and this
was supported by our results showing that high blood pressure was completely reversed
after a three-week washout period.
The role of intra-renal RAS has emerged as pivotal in the management of blood
pressure regulation and electrolyte balances (Coffman and Crowley, 2008; Bader, 2010;
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Crowley and Coffman, 2012). Intra-renal angiotensin increases during the development of
hypertension and renal damage. The overexpression of angiotensinogen in the kidney could
lead to chronic hypertension and mice lacking the intra-renal angiotensinogen synthesis are
characterized by a lesser extent of hypertensive damage (Crowley et al., 2005; Susic and
Frohlich, 2011). We observed that the mRNA expression level of angiotensinogen was
augmented in kidneys of shGRK2 mice mainly due to the activation of intra-renal Ang II/
AT1R axis and this “feed-forward” system may alter sodium reabsorption and consequently
blood pressure. The control of renal sodium is the final conduit for chronic blood pressure
homeostasis. Previous studies have indicated that AT1 receptors in the kidney are primary
responsible for sodium homeostasis. AT1 receptors expressed in the proximal tubule
promote sodium reabsorption by controlling the Na-K ATPases. In the distal tubule and
collecting duct AT1 receptors directly stimulates epithelial sodium channel activation and
promote sodium reabsorption (Harrison-Bernard and Carmines, 1994; Kwon et al., 2003).
In addition, renal vasoconstriction mediated by AT1 receptors can affect the modulatory
flow by blunting the kidney excretory function for sodium (Crowley et al., 2006). In the
present study, GRK2 downregulation was associated with an enhance in AT1R signaling
and reduced renal sodium excretion. Moreover, the reduced urinary sodium excretion
parallels the development of high blood pressure in shGRK2 mice. Indeed, the urinary
sodium excretion was reduced by 60% in shGRK2 hypertensive mice, supporting the
observation that the control of renal sodium is an important pathway of blood pressure
homeostasis.
Renin is a rate-limiting enzyme and its expression/secretion is regulated at the
juxta-glomerular apparatus by renal baroreceptors and sodium chloride concentration at
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the macula densa (Lorenz et al., 1991; Bell et al., 2003). Our findings indicate that the
intra-renal renin protein and mRNA levels increase during the development of
hypertension and renal damage in shGRK2 mice. No significant changes were recorded for
plasma renin in the pre-hypertensive and three-month old hypertensive mice. However, the
level of plasma renin emerged a significant increase in shGRK2 mice at six months of age.
Thus, this data emphasizes the role of local RAS in the management of blood pressure. The
availability of renin affects the generation of Ang II that may control its own synthesis by
activating AT1R at the juxta-glomerular apparatus and thereby supressing the renin release.
The effect of AT1R blockers to increase the renin mRNA expression and to cause juxtaglomerular hypertrophy supports the “short-loop” feedback mechanisms (Shricker et al.,
1997; Oliverio et al., 1998). Our data suggests that the treatment with selective AT1Rblocker losartan has increased the renal renin mRNA expression more than tenfold above
baseline in shGRK2 mice when compared to water controls. The renal baroreceptors
mechanisms seem to be responsible for the marked stimulation of the renin associated with
the reduction of the AT1R signaling (Bock et al., 1992). Indeed, our findings indicate an
average reduction of 4 0 mm Hg in blood pressure of shGRK2 mice in response to losartan
that could trigger the baroreceptor mechanisms to activate the increase in renal renin
expression.
Along with its enzymatic properties, renin – through the activation of pro-renin
receptors in kidney glomerulus – stimulates pro-fibrotic and inflammatory pathways
(Balakumar and Jagadeesh, 2010; Nguyen and Muller, 2010). Moreover, one of the direct
effects of AT1 receptor activation is end-organ injury by inducing the expression of proinflammatory cytokines and fibrosis markers (Crowley et al., 2008). We found that the
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chronic activation of AT1 receptor signaling due to reduced receptor desensitization is
associated with elevated levels of TGFβ1 and collagen expression and thereby reflects the
effects on renal fibrosis observed in our shGRK2 mice. TGFβ1 is a key regulator of renal
fibrosis through the regulation of the extracellular matrix surrounding the renal cells
(Kagami et al., 1994). Thus, we found an increased collagen deposition, especially around
the renal arteries, with a significant reduction of the glomerular number.
The extensive loss of GRK2 expression through the activation of AngII/AT1
receptor axis not only promotes the renal pathological injuries but also the functional ones.
A significant impairment in glomerular filtration rates was noticed for GRK2 hypertensive
mice. The treatment with the ARB losartan markedly improved GFR indicating that the
activation of Ang II/AT1R axis could be responsible for renal functional injury. Our
findings also indicate low serum albumin levels for three-month old shGRK2 mice, age
that corresponds to the onset of hypertension. This pattern of expression was still
maintained at six months of age. In addition, the presence of proteinuria and the increase
in blood urea nitrogen in shGRK2 mice are direct reflections of the functional damage of
the kidney.
In summary, the kidney injury described in our model may promote and maintain
the hypertensive phenotype observed in shGRK2 mice and therefore emphasize the role of
target organ injury in the management of hypertension. The chronic activation of RAS not
only leads to defective renal-sodium excretion but also potentiates renal injury and thereby
could be responsible – at least in part – for the hypertensive phenotype. In addition, the
effect of GRK4 activation on dopaminergic-mediated natriuresis potentiates and further
sustains the alteration of kidney excretory function for sodium (Fig. 3.8).
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Figure 3.8: Schematic diagram of the proposed role of GRK2-targeted knockdown
expression in the mechanism of hypertension
Inhibition of GRK2 activity leads to chronic activation of AT1 receptor signaling due to
reduced receptor desensitization. In addition, the increased expression of renin and
angiotensinogen levels modulates the activation of Ang II / AT1 receptor axis with a strong
impact on the regulation of urinary sodium excretion. As the blood pressure increases, the
chronic activation of RAS not only leads to defective renal-sodium excretion, but also
potentiates renal injury by inducing alterations in glomerular filtration rates and
progression of renal fibrosis. In addition, the up-regulation of GRK4 expression leads to
an increase in desensitization of D1 receptors, which in turn translates into a more
pronounced anti-natriuretic effect. Thereby, this “feed-forward” system could be deemed
responsible – at least in part – for the hypertensive phenotype.
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Sodium Retention

Regardless of their initiating factor, decreases in sodium excretory capabilities lead to
elevation of blood pressure and this supports the observation that the control of renal
sodium is an important pathway of blood pressure homeostasis.
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CHAPTER 4:
MODULATION OF RAB4-GTPase ACTIVITY
RESULTS IN ALTERED VASCULAR GPCRs
SIGNALING AND HYPERTENSION
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4.1

Introduction

The amplitude of cellular responses depends in part on the number of functional receptors
available at the cell surface (Lefkowitz et al., 1998; Moore et al., 2007). GPCR expression
on the cell surface represents a dynamic, but coordinated balance between molecular
mechanisms governing: receptor internalization, endocytosis, degradation, and recycling.
GPCR internalization, initiated within seconds to minutes upon receptor activation, is one
mechanism by which cells can terminate cellular responses (Ferguson and Caron, 1998;
Krupnick and Benovic, 1998; Ferguson, 2001). To prevent the prolonged deactivation, the
internalized receptor are recycled back to the plasma membrane to restore the complement
of cell surface receptors and functional signaling (Anborgh et al., 2000; Li et al., 2000;
Seachrist et al., 2002; Marchese et al., 2008).
The vesicular transport of GPCRs through functionally distinct intracellular
compartments is regulated temporally and spatially by Rab GTPases. By serving as a

scaffold for binding unique effectors, Rab proteins regulate discrete and multiple steps in
endocytosis including: vesicular membrane budding, trafficking along the cytoskeleton,
and ultimately docking and fusion between donor and acceptor membranes (McLauchlan
et al., 1998; Gonzalez and Scheller, 1999; Mohrmann and van der Sluijs, 1999; Nielsen et
al., 1999). Rab GTPases are ubiquitously expressed, highly conserved in their structure,
and are regulated by GTP binding and hydrolysis as well as by effector protein interactions.
Given the low similarity (< 55% identical), a single activated Rab protein can selectively
bind to a multitude of effector proteins to coordinate distinct vesicular transport steps
(Takai et al., 2001; Rosenfeld et al., 2002; Seachrist and Ferguson, 2003).
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Rab4 modulates the fast recycling of cargo proteins directly from the early
endosomes to the plasma membrane. Emerging data indicate that Rab4 exhibits
overlapping distribution with Rab11 and also controls the slow recycling of cargo proteins
via fusion with Rab11-positive recycling endosomes (Sonnichsen et al., 2000; Zerial and
McBride, 2001; Seachrist and Ferguson, 2003; Duvernay et al., 2005). Rab4 influence the
intracellular trafficking and recycling of several GPCRs, including AT1R and β2AR with
main role in vascular tone and reactivity (Seachrist et al., 2000; Odley et al., 2004; Li et
al., 2008). The internalized AT1R through the last 10 amino acid residues of carboxylterminal tail domain associates in a dynamic manner with Rab4 proteins. Therefore, at the
early recycling stage, AT1R are observed in Rab4 positive compartments in the cytoplasm,
while during middle-recycling stage they are present in the perinuclear compartments in
association with both Rab4 and Rab11. Finally, in the late recycling stage AT1R-Rab4
complexes are present in both perinuclear compartments and the subplasma membrane area
(Seachrist et al., 2000; Li et al., 2008). The overexpression of either wild-type or
constitutively active Rab4-Q67L mutant promotes AT1R dephosphorylation and leads to
increased receptor re-sensitization (Esseltine et al., 2011).
Rab4 plays a central role in regulating the functional activity of the β2A receptors
by mediating the fast recycling route of internalized receptors directly from early
endosomes to the plasma membrane (Seachrist et al., 2000). Rab4 is a rate-limiting factor
for the recycling of endogenous β2AR by controlling the rate at which the receptor is
processed through the endosomal compartment. The dominant-negative Rab4-N121I
mutant blocks β2AR recycling and re-sensitization while the overexpression of wild-type
Rab4 neither alters the apparent rate of β2AR internalization nor accelerates the recycling
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of the receptor back to the cell surface (Seachrist et al., 2000). The expression of
constitutively active Rab4-Q72L accelerates β2AR reinsertion into plasma membranes but
had no effects on cardiac structure or function (Odley et al., 2004). On the other hand, the
dominant-inhibitory Rab4-S27N mutant prevents β2AR recycling, causing receptor
accumulation in early endosomes and impaired responsiveness to endogenous and
exogenous catecholamine (Odley et al., 2004; Filipeanu et al., 2006). Thereby, Rab4mediated recycling of β2AR is necessary for normal cardiac adrenergic responsiveness and
re-sensitization after agonist exposure. Previous studies indicated that endogenous Rab4
protein expression is augmented in a cardiomyopathy model of heart failure and the
overexpression of Rab4 in transgenic mouse hearts leads to alter β2A receptor resensitization and cardiac hypertrophy (Wu et al., 2001; Odley et al., 2004; Filipeanu et al.,
2006). Thus, alterations in Rab4 expression and activity have the potential to influence
β2AR signaling under both physiological and pathophysiological conditions, suggesting
that this protein may represent a viable target in the treatment of the cardiovascular disease.
However, the effects of Rab4 GTPase on the regulation of GPCR signaling in vascular
smooth muscle cells and hypertension have not been addressed, largely because suitable in
vivo experimental models do not exist.
In the present chapter, the main premise of the study was to test whether the
transgenic vascular expression of a dominant negative Rab4-S22N mutant leads to
alterations in vascular reactivity, vascular tone, and vascular smooth muscle cells signaling
that ultimately leads to vascular hypertension.
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4.2

Experimental Procedures

4.2.1

Isolation of Aortic Medial Layer and Primary ASMC Culture

Aortic smooth muscle cells (ASMCs) were prepared via collagenase (2000 U/ml) and
elastase (1 mg/ml) (Worthington Biochemical) incubation from freshly isolated thoracic
aortas obtained from 6 month-old wild type C57BL/6 mice. The full-length aorta was
excised, cut open longitudinally and endothelium was removed by abrasion. The medial
layer was then peeled off of the adventitia and subjected to enzymatic digestion. Following
isolation, ASMCs were grown in Dulbecco's Modified Eagle Medium with 4.5 g/l glucose
supplemented with 10% FBS, 50 μg/ml PDGF-B, 100 U/ml penicillin, and 100 g/ml
streptomycin in a humidified incubator with 5% CO2 at 37oC. Cells were maintained in
cultures for a number of seven passages. To address possible passage-specific changes in
ASMCs responses early and late passages were also used. ASMCs were characterized by
immunostaining and immunoblotting for smooth muscle-specific α-actin expression.
4.2.2

Adenoviral Infection

cDNA encoding GFP-Rab4, GFP-Rab4-N121I, and a control cDNA encoding only GFP
were used to generate adenoviral constructs (AdMax) as per the manufacturer's instructions
(Microbix Biosystems, Toronto, ON). All GFP-Rab4 DNA constructs were designed as
previously reported (Seachrist et al., 2000). Mouse ASMCs cultured in 60 mm dishes to
near confluence (80%) were subjected to infection with viral titers -100 MOI- of the above
mentioned adenoviral constructs. Post-infection (48 hours) the efficiency of transduction
was confirmed by immunoblot and confocal microscopy for GFP expression.
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4.2.3

Measurement of Cyclic Adenosine Monophosphate (cAMP)

ASMCs 48 hours post-infection were re-cultured on 96-well plate at a density of
1 x 104 cells/well and the dose response curves for isoproterenol-stimulated cAMP
formation (100 pM to 10 µM) were measured by means of a cAMP GLO assay (Promega,
Fitchburg, WI, USA) as described previously (Tutunea-Fatan et al., 2015).
4.2.4

Fura - 2 Florescence Ca2+ Imaging

Control-GFP, GFP-Rab4 and -Rab4-N121I expressing ASMCs were grown on 25 mm
round glass cover ships and loaded with 5µM Fura-2 acetoxymethyl ester (Invitrogen,
Mississauga, ON, Canada) for 20 minutes. Intra-cellular Ca2+ release in response to
stimulation with either AngII (100nM) or Serotonin/5-HT (100 µM) was measured as
described previously (Tutunea-Fatan et al., 2015).
4.2.5

Western Blot Analysis

ASMCs were cultured on six-well plates at a density of 2 × 105 cells/well and infected for
48 hours. Then, cells were starved for 24 hours and stimulated with isoproterenol (10 μM),
carvedilol (10 μM), 5-HT (100 μM), AngII (100nM), or [Sar1, Ile4, Ile8] AngII (100 μM)
for various time points. The reactions were terminated by the addition of 80 μl/well of MPER® Mammalian Protein Extraction Reagent (Thermo Scientific, Rockford, IL, USA).
Fifteen micrograms of total protein were electrophoresed per well on a 10% SDSpolyacrylamide gel and transferred onto Immobilon-FL PVDF membranes (Millipore,
Billerica, MA, USA). The membranes were probed with p44/p42 rabbit polyclonal
antibody (Cell Signaling Technology, Danvers, MA, USA) (1:500), phospho-p44/p42
rabbit polyclonal antibody (Cell Signaling Technology) (1:500), phospho-Retinoblastoma
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(Ser807/811) rabbit polyclonal antibody (Millipore) (1:1000), and GAPDH mouse
polyclonal antibody (Millipore) (1:500). Blots were probed afterwards with IRDye
polyclonal secondary antibodies (LI-COR Biosciences, Lincoln, NE, USA) (1:10000). The
signal was detected using an Odyssey infrared imaging system and the average density of
each band was quantified using the Image Studio software (LI-COR Biosciences, Lincoln,
Nebraska USA). Data were normalized to GAPDH or to corresponding total protein values,
and expressed as percentage over results obtained for untreated conditions.
4.2.6

Functional Assays

ASMCs migration was assessed with Boyden chambers using Transwell® inserts with 8µm pore size (Corning Life Sciences, Oneonta, NY, USA). Control or adeno-infected cells
were seeded at 2 × 105 cells/mL into the upper chambers. ASMCS migration was
stimulated with isoproterenol (10 μM) or AngII (100nM), added to the lower chamber of
the inserts. After 24-hour incubation, the transwell membrane were fixed in cold methanol,
stained with eosin-thiazine and fixed with mounting medium on a glass slide for
microscopy analysis. Digital microscopy images at 40 × magnification (Leica DFC 295,
Leica Microsystems, Germany) were taken and cells in ten random high power fields were
counted and a mean value for each sample was calculated.
ASMCs proliferation was assessed with a Trypan Blue exclusion assay. ASMCs 48-hour
post-infection were cultured on six-well plates at a density of 2 × 105 cells/well. After 48
and 72 hours, cells were harvested and suspended with Trypan Blue (1:1). Total cell
number, live cells, dead cells, and viability were calculated with an automated cell counter
(Invitrogen).
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4.2.7

Generation of Rab4-S22N Transgenic Mice

Transgenic mice expressing the Rab4-S22N inhibitory non-GTP binding construct were
generated under the control of a murine smooth muscle 22α (SM22α) promoter. The
original pUC57-SM22α construct (Gene Script, lot # 136526S) was subjected to a realtime PCR protocol for the amplification of the restriction enzyme sites with the following
primers: forward-AseI (5'-AAATTATTGGATTCAGGACGTAATCAGTGG-3') and
reverse-NheI (3'-AAGCTAGCGGCTTGGTCGTTTGTGGACTGG-5). Therefore, a final
linear SM22α construct of 1.4 Kb was obtained after enzymatic digestion. The resulting
SM22α fragment was sub-cloned into the pEGFP-Rab4-S22N-C2 construct (4.9 Kb)
digested with AseI and NheI (Thermo Scientific) and subjected to sequencing for integrity
(Fig. 4.5A). Then, the final circular construct (6.3Kb) was digested with ApalI/MluI
(Thermo Scientific) to linearize the DNA for microinjection and to remove as much as
possible vector sequences from the insert (Fig. 4.5B). The gene construct obtained after
backbone removal (3.6 Kb) was microinjected into the pro-nuclei of isogenic C57Bl/6J
single-celled oocytes using standard techniques (Transgenic Core Facility, University of
Michigan, USA). The putative transgenic mice were identified by real time-PCR analyses
of tail DNA for EGFP expression (Fig. 4.5C and 4.5D) to established homozygous mouse
colonies after ten generations (F10) of breeding.
4.2.8

DNA Isolation and Real-Time Polymerase Chain Reaction

DNA was extracted from mouse tail biopsies (3mm) by digestion with lysis buffer (5 mM
EDTA, 200 mM NaCl, 100 mM Tris, 0.2% SDS) supplemented with protein kinase K (0.4
mg/ml) (Sigma-Aldrich, Oakville, ON, Canada). After incubation at 55°C overnight,
follow by several centrifugation steps, DNA was finally eluted with 1xTE buffer (10 mM
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Tris-0.2 mM EDTA). cDNA was amplified by real-time PCR with Taq Polymerase
(Qiagen, Valencia, MD, and USA). A PCR reaction volume of 25 µl was prepared for
amplification with the following primer pair: EGFP, forward 5’-CGA AGG CTA CGT
CCA GGA GCG CAC-3’, and reverse 3’-GAC ATG GAT CTG AGT CCG GAC-5’, 300
bp-as design from the sequence of our DNA transgenic construct (Primer3Plus software).
PCR cycling conditions consist of initial denaturation at 94°C for 3 minute and then 28
cycles of denaturation at 94°C (30 seconds), annealing at 60°C (45 seconds), and extension
at 75°C (45 seconds). Real-time PCR products were separated by electrophoresis (85V for
50 minutes) on 1.5% agarose gel and visualized by GelRed Nucleic Acid Gel Stain using
a gel imaging system (GelDocTM XR System, Bio Rad).
4.2.9

Analysis of Copy Number Variation

Quantitative real-time PCR was performed in single micro capillary tubes with TaqMan
Universal PCR Master Mix (Roche Diagnostic, Laval, QC, Canada) for both the controlhousekeeping gene (Pre-Developed Assay Reagent, Mm ACTB) and target gene
expression primer probe (Custom Design Assay Reagent, Mm-PN4331348 EGFP, Applied
Biosystems, Foster City, CA, USA). The PCR profile consist of denaturation at 95°C for
15 seconds, annealing-extension at 58°C for 1 minute for 40 cycles. Delta-delta Ct (ΔΔCt)
method was employed to determine the fold difference (2–ΔΔCt) (Applied Biosystems).
4.2.10 Blood Pressure Measurement
Blood pressures and heart rates were recorded from conscious and lightly anesthetized
(Ketamine: 100 mg/kg body weight and Xylazine 5 mg/kg body weight) Rab4S22N C57BL/6 transgenic mice at 4 weeks, 12 weeks, and 6 months of age using the noninvasive CODA tail-cuff blood pressure system (Kent Scientific, Torrington, CT, USA) as
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described previously (Tutunea-Fatan et al., 2015). Third, forth , and fifth generation of
adult animals (1-6 months of age) were used for this study. All experiments involving
animals were approved by the Animal Use Subcommittee of Western University, according
to the guidelines of the Canadian Council on Animal Care.
4.2.11 Statistical Analysis
Statistical calculations were performed using GraphPad Prism software version 5
(GraphPad Software, La Jolla, CA, USA). All parametric data were analyzed with one-way
ANOVA followed by Bonferroni post hoc comparisons. Statistically relevant differences
between mean values were determined based on p < 0.05 criterion.

4.3

Results

4.3.1

Effects of Rab4 Modulation on Heterotrimeric G Protein Signaling

To assess the role of Rab4 in vitro, aortic smooth muscle cells obtained by enzymatic
digestion from 6 month-old C57Bl/6 mice were subjected to adenoviral infection with the
following constructs: control GFP, GFP-Rab4, or dominant negative mutant, GFPRab4N121I. The efficiency of transduction was assessed at the protein level for both GFP
and Rab4 expressions (Fig. 4.1A and 4.1B).
It is noteworthy that, the adenoviral expression of Rab4 constructs produced
different effects on mRNA expression level of vascular GPCRs (Fig. 4.2A). Whereas
mRNA expression of β2AR was not altered by wild type Rab4, adenoviral expression of
Rab1N124I inhibitory construct significantly augmented the level of its expression when
compared with control GFP-VSMCs. The expression level of AT1 receptor was
significantly increased in the presence of Rab4 construct while the dominant negative
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Figure 4.1: Assessment of adenoviral infection
(A) Representative confocal microscopy images of GFP expression in VSMCs 48 h postinfection. GFP tagged Rab4 and Rab4-N121I constructs are depicted in the form of
vesicular structures distributed all over the cytoplasm. GFP alone was used as a control.
Images were taken under 20X magnification (B) Western blot analysis of Rab4 and GFP
protein expression detected at 53kDa in VSMCs. GAPDH was used as a loading control.
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Figure 4.2: Assessment of heterotrimeric G protein signaling
(A) Quantitative PCR analysis of vascular GPCRs mRNA expression in VSMCs subjected
to: GFP, Rab4, and Rab4N121I adenoinfection. Expression levels are normalized to actin
(ACTB). (B) Dose response curves for cAMP production in response to treatment with
increasing concentrations of isoproterenol. Data points are represented as the mean ± SD
of 3 independent experiments. (C) Representative Ca2+ tracers for changes in intracellular
Ca2+ concentration in VSMCs cultures 48 h post-infection in response to treatment with
AngII and 5-HT. Graph shows the area under the curve (AUC) for integrated Ca2+
responses to agonist treatments. Data are represented as the mean ± SD of 4 independent
experiments and the total number of cells analyzed is shown in the graph.
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Rab1N124I mutant had no effect when compared with cells infected with adenovirus
control. On the other hand, the mRNA expression of serotonin-HTR2b-receptor was
significantly increased in cells subjected to both Rab4 and Rab4N121I constructs. No
effects were noticed for α1d-AR receptor regardless if cells were infected with Rab4 or
Rab4N121I mutant.
To determine whether the manipulation of Rab4 expression and activity could
modulate β2AR signaling, cyclic adenosine monophosphate (cAMP) accumulation in
response to the β2AR agonist-isoproterenol was assessed. The overexpression of wild type
Rab4 did not alter the apparent rate of cAMP production. The expression of dominant
inhibitory Rab4N121I markedly impaired β2A receptor responsiveness and consequently
cAMP production when compared with control GFP expressing cells (EC50:0.27 vs.
EC50:0.08) (Fig. 4.2B). Thus, a loss of Rab4 activity appears to lead to decreased of Gαsmediated receptor signaling.
The release of Ca2+ from intracellular stores in response to treatment with 100 nM
Ang II elicited a significantly greater increase in VSMCs overexpressing the Rab4
construct when compared to control cells. Expression of dominant inhibitor Rab4N121I
had no effects on Ca2+ concentration in response to stimulation with AngII (Fig. 4.2C). On
the other hand, treatment with serotonin significantly augmented the release of Ca2+
whether cells were infected with Rab4 or Rab4N121I mutant (Fig. 4.2D). These results
indicate that Rab4 expression not only played a significant role in regulating GPCR
expression in VSMCs but receptor signaling is also significantly altered.
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4.3.2

Effects of Rab4 Modulation on G Protein-Dependent and Independent
ERK1/2 Signaling

To determine whether Rab4 is capable of regulating β2AR signaling, ERK1/2 activation in
response to stimulation with β2AR agonist-isoproterenol was evaluated by measuring its
level of phosphorylation. While the presence of ERK1/2 phosphorylation was detected in
VSMCs overexpressing Rab4, the extent of phosphorylation status was unchanged
regardless the duration of treatment. In addition, the phosphorylation signal observed for
untreated, 48-hour-serum starved cells suggests that ERK1/2 might be constitutively
activated in VSMCs overexpressing the Rab4 construct. The depletion of Rab4
significantly increased the phosphorylation status of ERK1/2 when compared with control
GFP cells (Fig. 4.3A). Isoproterenol treatment elicited a rapid increase in ERK1/2
phosphorylation with a peak of activation observed at 5 and 15 min of agonist stimulation.
Adenoviral expression of wild type Rab4 augmented ERK1/2 phosphorylation in
response to stimulation with β2AR biased agonist carvedilol. In contrast, carvedilolmediated ERK1/2 activation was attenuated by Rab4N121I, suggesting that augmentation
of Rab4 function by overexpressing Rab4 may selectively regulate the β-arrestindependent mechanism (Fig. 4.3B).
A significant increase in the extent and duration of ERK1/2 activation was observed
in response to the treatment of VSMCs expressing the wild type Rab4 with AngII.
However, Rab4N121I did not affect the level of Ang II mediated ERK1/2 phosphorylation
when compared with control GFP infected cells (Fig. 4.3B).
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Figure 4.3: Assessment of Gαs-and Gαq-mediated Erk1/2 signaling
Representative immunoblots and densitometric analysis showing time course for ERK1/2
phosphorylation with corresponding total ERK1/2 immunoblots from VMSCs-GFP, GFPRab4, and GFP-Rab4N121I in response to: (A) 10 µM isoproterenol, (B) 10 µM carvedilol,
(C)100 nM AngII, (D) 100 µM [Sar1, Ile4, Ile8] AngII (SIIAngII), (E) 100 µM serotonin.
Data are represented as the mean ± SD of 3 independent experiments expressed as
percentage of basal ERK1/2 phosphorylation.
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A similar response profile was observed in response to treatment with the biased
angiotensin receptor agonist [Sar1, Ile4, Ile8] Ang II whether cells were expressing the wild
type Rab4 or dominant negative Rab4N121I (Fig. 4.3C).
Serotonin treatment of either control, wild-type or Rab4 inhibitory VSMCs elicited
a rapid increase in ERK1/2 phosphorylation at 5 and 15 min of agonist treatment, activation
that was also prolong over the entire duration of stimulation. Thus, the activation of
ERK1/2 signaling was unaffected by alteration in Rab4 expression/activity (Fig. 4.3C).
4.3.3

Effects of Rab4 Modulation on VSMC Migration

To assess whether Rab4 modulates long term cellular responses, such as VSMCs
migration, a Boyden chamber assay was performed using trans-well inserts. VSMCs
subjected to Rab4 expression showed a reduction in cell migration in response to
isoproterenol treatment when compared to SFM media. In VSMCs subjected to Rab4N121
inhibitory construct, isoproterenol-stimulated cellular migration was significantly
increased when compared with isoproterenol-stimulated migration of VSMCs expressing
either the control GFP or Rab4 adenoviral constructs. VSMCs subjected to stimulation with
Ang II exhibited a significant increase in migration rate in the presence of Rab4N121I
when compared with both control and Rab4 expressing cells (Fig. 4.4A). Thus, Rab4N121I
increased VSMCs migration in response to both Gαs- and Gαq/11-coupled GPCR activation.
4.3.4

Effects of Rab4 Modulation on VSMC Proliferation

VSMCs expressing Rab4 or Rab4N121I exhibited a significant impairment in the
proliferation rate in complete (10% FBS) media when compared with control GFP
expressing cells.
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Figure 4.4: Assessment of migration and proliferation responses
(A) Representative images and quantification of the migration of VSMCs adenoinfected
with control-GFP, GFP-Rab4, and GFP-Rab4N121I constructs, in response to treatment
with 10 M isoproterenol, or 100 nM Ang II for 24 hours. SFM only was used as a control.
Bar graph data represents the mean ± SD of 3 independent experiments expressed as
percentage of basal-untreated cells (SFM). (B) Representative immunoblots and
densitometric analysis showing the phosphorylation status of retinoblastoma protein in
response to isoproterenol (10 µM), AngII (100 nM), and serotonin (100 µM), or FBS
(10%). GAPDH was used as a loading control. Data are represented as the mean ± SD of
3 independent experiments expressed as percentage of basal-untreated cells (SFM). (C)
Growth curves over 72-hour course time of primary VSMCs adenoinfected with controlGFP, GFP-Rab4, and GFP-Rab4N121I constructs. Data are represented as the mean ± SD
(n = 3). (*) Indicates statistically significant differences compared to control (p < 0.05).
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Isoproterenol-stimulated VSMCs proliferation was unaffected regardless if cells were
infected with Rab4 or Rab4N121I mutant since the extent of retinoblastoma
phosphorylation (p-RB) was almost the same. However, Rab4-overexpressingVSMCs
subjected to AngII treatment exhibited an increased proliferation rate as indicated by the
high phosphorylation level of retinoblastoma protein. On the other hand, Rab4-depleted
VSMCs did not significantly alter the phosphorylation status of retinoblastoma protein in
response to Ang II treatment then control VSMCs (Fig. 4.4B and 4.4C). Thus, the
overexpression of Rab4 wild-type or mutant has proved a role for Rab4 in G proteinmediated long term migration and proliferation of VSMCs responses.
4.3.5

SM22α-Rab4S22N Mice Develop Hypertension with Age

The pathophysiological effects of modulated Rab4 expression/activity in the hypertension
have not been defined, largely because suitable in vivo experimental models do not exist.
To establish the relevance of Rab4 activity in the regulation of the vascular GPCRs
signaling in vivo, we have used mutation and transgenic expression of a dominant negative
Rab4S22N to attenuate endogenous Rab4 function. We generated transgenic mice that
specifically overexpress GFP-Rab4-S22N in VSMCs under the control of a murine SM22α
promoter (Fig. 4.5). SM22α was used as a promoter since is exclusively expressed in
smooth muscle of adult animals and it is one of the markers of differentiated smooth muscle
cells. No phenotypic changes or embryonic and neonatal mortality were observed among
the SM22α-Rab4S22N transgenic mice when compared with non-transgenic littermate
controls. Our observations document a gradual onset of hypertension (Fig. 4.6A).
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Figure 4.5: Development of the SM22α-Rab4S22N DNA transgene construct and
genotyping analysis
(A) Schematic representation of the final 6.3Kb size DNA plasmid construct obtained after
sub-cloning the SM22α promoter (1.4Kb) into the pEGFP-Rab4S22N-C2 vector. (B)
Agarose gel electrophoresis of Sm22alpha-pEGFP-Rab4S22N-C2 linear construct (3.6Kb)
after digestion with restriction enzymes ApalI/MluI and backbone removal (2.7Kb) (C)
Copy number of the Sm22alpha-pEGFP-Rab4S22N-C2 transgene construct spiked into
C57Bl/6 tail DNA as measured by Real-time PCR assay. (D) Genotyping results as
depicted by quantitative and semi-quantitative real-time PCR assays. A custom design
EGFP-FAM tagged primer probe was used for quantification of the copy number of the
Rab4 transgene. Both, beta globin and ACTB were used as an internal control.
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Figure 4.6: Assessment of blood pressure
(A) Blood pressures and heart rates of C57Bl/6-Rab4S22N and control littermate mice, as
measured by non-invasive tail cuff CODA method at 4 weeks, 12 weeks, and 6 months of
age. (B) Blood pressures and heart rates in lightly anesthetized 4 weeks, 12 weeks, and 6
month-old mice using the tail-cuff CODA method. Data are represented as the mean ± SD
of 4 independent experiments (n=6). * Indicates statistically significant differences
(p < 0.05).
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Therefore, hypertension was established in 3 month-old SM22α-Rab4S22N mice with a
significant increase in both systolic and diastolic blood pressures (168/132 ± 10/6 vs.
142/113 ± 8/11mmHg, p < 0.05, n=8). The elevated blood pressures were still maintained
at 6 months of age (160/125 ± 9/7 vs. 139/106 ± 7/10 mmHg, p < 0.05, n=8). Heart rate
was unchanged between the groups. To eliminate the possibility of stress-induced
elevations, blood pressure was assessed in anesthetized mice and both systolic and diastolic
were increased at 6 months of age when compared with control littermates (135/104 ± 5/7
vs. 105/69 ± 7/6 mmHg, p < 0.05, n=8) (Fig. 4.6B).
So far, our preliminary data suggest that the loss of Rab4 activity may favor an
increase in peripheral resistance with an increased sensitivity to stress-anxiety leading to
the activation of the sympathetic responses. These observations seem to be in agreement
with previous work that Rab4-mediated recycling of βAR is necessary for normal cardiac
catecholamine responsiveness and receptor re-sensitization after agonist exposure.

4.4

Discussion

Blood pressure homeostasis is tightly regulated by a delicate balance of vasoconstrictive
and vasodilatatory signaling inputs and any alterations brought to this “unstable
equilibrium” state can trigger a domino effect to tilt the balance in either direction. The
most consistently described vascular GPCR-defect in hypertension is the impaired
relaxation due to alterations in Gαs-mediated receptor signaling (Marcil et al., 1997;
Feldman and Gros, 1998; Ferguson and Feldman, 2014). Indeed, a decrease in GPCR
signaling can lead to an increased blood pressure via reductions in β2-adrenergic mediated
dilatation.

211

Cell surface expressions of β2A receptors linked to vasodilatatory mechanism are
preferentially regulated by modulations of Rab4 GTPase activity (Seachrist et al., 2000;
Odley et al., 2004; Li et al., 2008). Rab4 is a rate-limiting factor in the regulation of the
functional activity of β2ARs. This is attained through the control of the rate at which the
receptor is processed through the endosomal compartments and then recycled back to the
plasma membrane. Emerging data indicate that dominant-inhibitory Rab4 mutants prevent
β2AR recycling, causing receptor accumulation in early endosomes. Indeed, confocal
studies reveled abnormal vesicular structures and increased accumulation of β2AR in
caveolae and early endosomes (Seachrist et al., 2000; Odley et al., 2004). Aligned with
these findings, our data indicate that the expression of a dominant inhibitory Rab4N121I
has significantly increased the β2AR mRNA expression level in VSMCs. The increased
gene transcriptional activity of β2AR may in turn compensate for the impaired recycling of
internalized receptors to the plasma membrane. Thereby, Rab4-mediated recycling of the
internalized β2AR plays more of a “housekeeping” role in maintaining the number of
functional receptors.
The classical pathway regulating β2AR signaling involves Gαs-mediated activation
of adenylyl cyclase and subsequent activation of the cyclic AMP production (Neer, 1995).
We found that the transient expression of Rab4N121I in VSMCs has significantly impaired
β2A receptor responsiveness and consequently isoproterenol-stimulated cAMP production,
when compared with control GFP expressing cells. Thereby, the low level of cAMP may
function as a positive feedback regulator of β2A receptor gene that ultimately will increase
the receptor population.
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On the other hand, the overexpression of wild type Rab4 neither alter the apparent
rate of cAMP production nor the mRNA expression level of β2AR in VSMCs. Our results
are in alignment with previous studies outlining that an increase in Rab4 expression level
did not cause increases in the rates of receptor internalization and re-sensitization
(Seachrist et al., 2000). Moreover, cardiomyocyte-specific expression of constitutively
active Rab4Q72L had no effect on β2AR signaling and cardiac function (Odley et al.,
2004).
Although AT1R is not readily dephosphorylated and efficiently recycled (Anborgh
et al., 2000; Dale et al., 2004) recent evidences indicate that the overexpression of either
wild-type or constitutively active Rab4 in human embryonic (HEK) 293 cell line promotes
AT1R dephosphorylation and recycling back to the plasma membrane (Esseltine et al.,
2011). Indeed, our data indicate that while vascular transient expression of wild type Rab4
significantly increases the release of Ca2+ from intracellular stores, the expression of
inhibitory RabN1221 had no effect on Ca2+ concentration in response to AT1R stimulation.
One possible explanation for these different outcomes could be related to the fact that AT1R
seems to not be able to distinguish between GTP-and GDP-bound forms of Rab4 (Esseltine
et al., 2011). Additionally, AT1R trafficking is regulated by Rab4 and Rab11 coordinated
model of interaction according to which Rab4 facilitates the early recycling stage, while
Rab11 regulates the slow recycling route from perinuclear endosomes to plasma membrane
(Sonnichsen et al., 2000; Zerial and McBride, 2001; Seachrist and Ferguson, 2003;
Duvernay et al., 2005). Therefore – as AT1R internalizes as a complex with β-arrestin and
is retained in the endosomal compartment in a non-dephosphorylated state – AT1R might
be preferentially recycled via the slow Rab11-mediated pathway. This could explain why
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Rab4 inhibition has no effect on AT1R levels and activity. Thus, taken together these results
indicate that alterations in Rab4 expression and activity might differently regulate the
recycling of β2AR and AT1R to the plasma membrane as well as their subsequent functional
cellular responses.
An increased body of work has showed that Rab4 regulates endothelial cell
migration, proliferation, and angiogenesis (Jopling et al., 2014; Talaber et al., 2014). In
addition, Rab4 performs an autophagy function and is also involved in the inhibition of
endothelial cells autophagy under laminar shear stress conditions (Nagy et al., 2006;
Fernandez et al., 2009; Caza et al., 2014). The loss of endothelial autophagy promotes
reactive oxygen species generation and thereby dysregulation of vascular function
(Lavandero et al., 2015). Aligned with these observation, our data indicate that inhibition
of Rab4 activity has significantly increased the isoproterenol-stimulated smooth muscle
cell migration. However, depletion of Rab4 activity level has an inhibitory effect on VSMC
proliferation. VSMCs subjected to AngII treatment showed a significant increase in both
proliferation rate and peak-phosho ERK1/2 levels upon Rab4 overexpression.
Isoproterenol-stimulated ERK1/2 activation was increased upon Rab4 inhibition in
VSMCs (Fig. 4.7). The activation of ERK1/2 was unaffected by β2AR biased agonist
carvedilol. In contrast, Rab4 overexpression augmented ERK1/2 phosphorylation in
response to stimulation with β2AR biased agonist suggesting that Rab4 may selectively
regulate the β-arrestin dependent signaling. However, other components of signaling
pathway that localize to the endocytic pathway may be also disrupted by Rab4 inhibition,
such as Akt or PDK1. These findings suggested key differences in the mechanism of Rab4
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Figure 4.7: Schematic diagram of the proposed role of Rab4 in the mechanism of
hypertension
Rab4 is a rate-limiting factor in the regulation of expression and function of both β2A and
AT1 receptors. Primary VSMCs subjected to Rab4 inhibition show activation in ERK1/2
signaling and migration responses to Gαs-mediated receptor stimulation. On the other hand,
Rab4 overexpression leads to an increase in Ca2+ release from intracellular store and
alteration in ERK1/2 signaling and proliferation and migration responses to Gαq/11-coupled
GPCR activation.
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GTPase action on β2A and AT1 receptor-mediated signaling linked to both short and longterm cellular responses. These two opposing but highly interlinked signaling pathway
likely affect each other and this has direct consequences on vascular smooth muscle cell
function.
However, the effects of Rab4GTPase on the GPCR recycling and signaling on the
vascular function have not been studied mainly because suitable in vivo experimental
models do not exist yet. Herein, we have developed a vascular specific dominant inhibitory
Rab2S22N transgenic mice to enable definition of the functional role of Rab4 in the
hypertension. We observed an age-dependent onset of hypertension in Rab4S22N mice
that is maintained throughout the lifespan of the animals. The development of an in vivo
model of vascular-targeted Rab4 inhibition and the documentation of the hypertensive
phenotype in these transgenic mice is the first evidence for the existence of a causal
relationship between alteration in Rab4 activity and vascular GPCR signaling. Further
characterization of this mouse model is needed in order to establish the molecular
mechanisms responsible for alterations in vascular GPCR signaling. Overall, our in vitro
and in vivo models indicate that the loss of Rab4 function is positively correlated with β2adrenergic stimulated adenylyl cyclase activity and inversely correlated with blood
pressure elevation.
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CHAPTER 5:
DISCUSSION
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5.1

Summary

An important component in the regulation of GPCR signaling cycle is represented by the
agonist-induced receptor desensitization and internalization from the plasma membrane to
the internal endosomal compartments of the cell where GPCRs are dephosphorylated and
recycled back to the plasma membrane as functional receptors. However, these processes
do not occur in isolation, but rather simultaneously with each cycle of ligand-receptor
interaction (Fig 5.1). Since GPCRs play an essential role in the regulation of cardiovascular
function, a better understanding of their activity and intracellular trafficking through
endosomal compartments can provide insights on the complex mechanism of
cardiovascular disease.
Among the various cellular defects associated with the inception of hypertension,
alterations in expression and function of GRK2 play an important role. In this thesis, we
have attempted to determine whether the genetic knockdown of GRK2 expression leads to
a selective sensitization of GPCR-Gαq/11 protein-mediated signal transduction that is
potentially responsible for the hypertensive phenotype. Furthermore, our goal was to
elucidate whether Rab4-dependent regulation of GPCRs trafficking plays a significant role
in the development of the hypertensive state.
Chapter 2 has clarified the link between changes in GRK2 expression and altered
vascular reactivity. Since the targeted disruption of the GRK2 gene in mice is known to
result in an embryonic lethal phenotype (Jaber et al., 1996), we had universally knockdown
but not knockout GRK2 expression in vivo. The shGRK2 mice displayed intrauterine
growth-deficient phenotype with lower body mass indices. Our time course observations
documented an age-dependent onset of hypertension. The pre-hypertensive phase begins
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Figure 5.1: Schematic diagram of the GPCR recycling-cycle
Agonist (A) induced GPCR-desensitization starts off with receptor phosphorylation by the
GRK2 and the newly added large phosphates will interfere with G protein-coupling and
will facilitate the recruitment of adaptor proteins with role in internalization. Once
internalized, GPCRs can traffic from clathrin-coated vesicles to early endosomes from
where Rab4 promotes their reinsertion into the plasma membrane through a process called
resensitization.

GRK2

Rab4
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with a significant increase in systolic blood pressure for 8 week-old shGRK2 mice with a
full onset of hypertension observed at 3 months of age. The elevated blood pressure was
maintained throughout the lifespan of the animals and it was not confounded by stress or
anxiety.
Our findings indicate that the extensive loss of GRK2 expression favors an increase
in vasoconstriction associated with an increase in peripheral resistance likely due to
reduced Gαq/11-coupled receptor desensitization. Whereas vasodilatation in response to
GαS-coupled receptor stimulation was also enhanced in the shGRK2 mice, the hypertensive
phenotype was the consequence of the extent of reduction of the Gαq/11-selective GPCRs
uncoupling.
In terms of downstream signaling pathway, we have found that GRK2 inhibition
modulates the AKT and ERK1/2 pathways and these responses are altered with age and
progress with the generation of hypertensive phenotype as the pre-hypertensive mice do
not exhibit a generalized alteration in response to both Gαq/11- dependent and –independent
β-arrestin-mediated signaling. Further, our data indicate that Gαq/11- but not GαS-coupled
receptor activation leads to increased proliferative and migratory responses of VSMCs and
thereby it could be responsible for the increase in peripheral resistance associated with the
hypertensive phenotype. Taken together, these data indicate that the balance between the
mechanisms regulating vascular tone is shifted to favor vasoconstriction in the absence of
GRK2 expression and this leads to the development of hypertension.
In Chapter 3, we have learned that GRK2 inhibition not only contributes to blood
pressure elevation – through the activation of vascular AT1 receptors with consequent
vasoconstriction in early stages – but also that the activated intra-renal AT1 receptors are
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capable to maintain the high blood pressure by altering the renal function and further
stimulation of the pro-hypertensive mechanisms. Our data indicate that hypertension was
initiated through the reduced desensitization of both systemic and intra-renal Gαq-mediated
vasoconstriction mechanisms as a consequence of decreased GRK2 expression.
Intra-renal injury develops over time with local activation of the RAS components,
with a reduction in glomerular filtration rate and dysregulation of renal sodium excretion.
Indeed, as blood pressure increases, the expression of renal RAS components increases
correspondingly in shGRK2 mice. The chronic activation of RAS not only leads to
defective renal-sodium excretion but also potentiates the functional damage of kidney as
supported by the presence of proteinuria and low serum albumin levels. In addition, the
increased collagen deposition observed especially around renal arteries along with
significant reduction in glomerular number reflect the pathophysiological injuries of
kidney noticed in our shGRK2 mice.
The treatment with ARB-losartan markedly improved the glomerular filtration rate,
supporting the involvement of Ang II-AT1R axis in the progression of renal injury.
Moreover, chronic inhibition of GRK2 expression was associated with differential
increases of GRK subtypes, increases that synchronized with the onset of hypertension. In
this regard, while GRK5 activation engenders a more compensatory role in attempt to
counterbalancing the reduced GRK2-mediated receptor desensitization, GRK4 activation
seems to potentiate and further sustain the alteration of kidney excretory function for
sodium. Overall, our findings presented in Chapter 3 open up avenues for previously
undocumented roles for GRK2 in the pathophysiology of hypertension.
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In Chapter 4, we have investigated whether Rab4 and has a distinct role in the
regulation of vascular GPCR signaling and thereby on blood pressure homeostasis. We
used mutation and transgenic expression of a dominant negative Rab4S22N to define
effects of Rab4 on vascular function. The SM22α-Rab4S22N transgenic mice display an
age-dependent hypertension phenotype. Hypertension was established in 3-month old mice
with significant increases in both systolic and diastolic blood pressures. Moreover, these
mice exhibited increased sensitivity to stress-anxiety, implying the activation of the
sympathetic responses.
Our data indicate that Rab4 is a rate-limiting factor in the regulation of expression
and function of β2A receptors. Since we showed that the expression of a dominant
inhibitory Rab4N121I increased gene transcription activity of β2A receptors, it can be
inferred that Rab4-mediated recycling of the internalized β2AR plays somewhat of a
“housekeeper” with role in the preservation of the number of functional receptors.
Alteration of Rab4 activity appeared to lead to decreased of Gαs-mediated receptor
signaling. Primary VSMCs subjected to Rab4N121expression show alterations in ERK1/2
signaling, which were linked to altered cellular proliferation and migration responses to
Gαs-coupled GPCR activation. In brief, the developed in vitro and in vivo vascular specific
dominant inhibitory Rab4 models represents one of the first and comprehensive attempt to
establish causal relationships between the alteration of Rab4 activity and vascular GPCR
signaling.
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5.2

Physiological Relevance of GPCR Signal Transduction in Blood
Pressure: Consequences of Altered GRK2 Expression on
Hypertension

Since GRK2 gene ablation translates into fatality of the mouse embryos beyond E15.5 day
(Jaber et al., 1996), it can be inferred that GRK2 plays a cardinal role during the embryonic
development. This kinase is expressed in multipotent and migratory cell populations during
the early stages of embryogenesis and since after E15.5 day GRK2 was found in heart,
liver, lung primordia and motor neurons, its significant contribution to the embryogenic
process becomes more than apparent (Sefton et al., 2000). Furthermore, GRK2 is a positive
regulator of Hedgehog (Hh) signaling with important effects on the embryonic
development as well as multiple pathophysiological processes (Zhao et al., 2016).

In our transgenic mouse model, the targeted knockdown of GRK2 gene expression
has translated into a growth-deficient phenotype with lower body mass indices and a
significant decrease of adipose mass. The shGRK2 mice show indications of intrauterine
growth retardation since the positive transgene pups at E17.5 were significantly smaller in
size and had lower body with a significant post-natal loss. Otherwise, our shGRK2
transgenic mice developed normally with the exception of a significant decreased in kidney
weight-to-body weight ratio. However, the reason for which shGRK2 mice had a kidney
phenotype with no other organ abnormalities remains to be determined. Emerging
evidences suggest the existence of a direct correlation between kidney size-nephron
number and disease susceptibility in humans (Nyengaard and Bendtsen, 1992; Keller et al.,
2003; Hoy et al., 2006; Matsuoka et al., 2006).
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According to the Barker-Brenner hypothesis (Brenner et al., 1988; Barker et al.,
1989), the onset of hypertension could be a consequence of certain in-utero events. This
theory is supported by the fact that infants with low birth weight are more prone to develop
hypertension and metabolic pathologies (obesity, diabetes) at adulthood (Barker et al.,
1989; Eriksson et al., 2000). Animal models have also shown that maternal malnutrition
leading to small birth weights can be linked to elevated blood pressure and salt sensitivity
develop during adult life (Woods et al., 2004). Based on these findings, Brenner and his
colleagues (Brenner et al., 1988) have proposed that hypertension is the result of
congenitally low nephron numbers that are common in newborns with low weight as well
as those characterized by intrauterine retardation (Zandi-Nejad et al., 2006). This
correlation between low nephron numbers and hypertension has been later reinforced by
studies performed on both animals (Woods et al., 2004) and human subjects (Keller et al.,
2003; Hughson et al., 2006).
However, while the existence of the correlation was verified, its underlying
mechanisms remain more or less obscure. One of the known implications of low nephron
count in offspring of malnourished mothers are the pre-glomerular arteriolar disease and
tubule-interstitial inflammation (Tapia et al., 2003; Woods et al., 2004). The experimental
models involving spontaneously hypertensive rats showed that in addition to the low
nephron count and the consequential elevated blood pressure (Woods et al., 2004), animals
were also characterized by reductions in afferent arteriolar lumen leading to renal hypoxia
and interstitial inflammation (Welch et al., 2001; Rodriguez-Iturbe et al., 2002). These
suggest that hypertension might be an outcome of a preexisting renal microvascular injury
and inflammation. Along this line of thoughts, low nephron count becomes a
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catalyst/accelerator, rather than the root cause of hypertension that might be a consequence
of the renal microvascular disease.
In terms of ethnical background, it was shown that low nephron count correlates
well with essential hypertension in young Caucasians (Keller et al., 2003). Since similar
observations can be extended to White Europeans, White Americans (but not African
Americans) and Australian Aborigines (Douglas-Denton et al., 2006; Hughson et al.,
2006), it might be inferred that while low nephron number might constitute a strong risk
factor for hypertension in young Caucasians, its effect might be superseded by other
mechanisms in other populations (e.g., African American).
GRK2 modulates multiple cellular responses through GPCR desensitization and
alterations in GRK2 expression have been associated with hypertension. Consequently,
alterations in GRK2 expression are proposed to induce a shift in the balance between
vasoconstrictor and vasodilator mechanisms suggesting that GRK2 may function as a
potential molecular mediator contributing to the induction of hypertension. Previous
studies indicate that GRK2 protein expression is elevated in lymphocytes from
hypertensive patients and is correlated with reductions in the β2A-receptor stimulated
vasodilation (Gros et al., 1997; Gros et al., 2000). In addition, vascular specific
overexpression of GRK2 results in mice that display moderate increases in blood pressure
(20%) due to impaired β2AR-mediated vasodilation (Eckhart et al., 2002). Surprinsingly,
when these mice were chalanged with a vasoconstrictor agonist (AngII), GRK2overexpression reduced blood pressure elevation. On the other hand, our data indicate that
global knockdown of GRK2 expression results in a mouse that spontaneously develops
hypertension (40%), due to alterations in the balance between mechanisms regulating
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vasodilatation and vasoconstriction. We observed that vasodilatation is enhanced in the
shGRK2 mice but – consistent with the hypertensive phenotype – vasoconstriction was
also increased and tends to be physiologically predominant (Fig 5.2).
To explain these apparently counterintuitive evidences, we would need to account
the following observations: the animal models of altered GRK2 expression are
characterized by a gene-targeted mechanism that is not necessarily a “mirror copy” of the
pathological GRK2 accumulation. The increased GRK2 protein expression in human
hypertension reflects a post-translational mechanism. By contrast, the mechanism of
GRK2-targeted alteration of gene expression has more to do with alterations in GRK2
stability such as ubiquitination and phosphorylation (Gros et al., 1999; Penela et al., 2001).
On the other hand, GRK2 is a multivalent and multipotent kinase with multiple regulatory
roles which has been demonstrated to interact and regulate several substrates through its
kinase activity, RGS and PH domains. GRK2 mediates the RGS homology domain
phosphorylation-independent desensitization of Gαq/11-coupled GPCRs only. As such,
GRK2 may have the unique capacity to block Gαq/11-coupled GPCR signaling via its
interaction with Gαq/11.
Thus, the behavior of the analyzed shGRK2 hypertensive phenotype could be the
result of GRK2 suppression that might – in turn – reduce the Gαq/11-selective uncoupling
of Gαq/11-coupled GPCRs by the GRK2 RGS homology domain, a pattern that is not
observed for Gαs-coupled GPCRs (Ferguson, 2007). Gαs-coupled GPCRs might be more
responsive to small increases in GRK2 expression due to the loss of phosphorylationdependent desensitization whereas reductions in GRK2 expression will upregulate both
Gαs- and Gαq/11-GPCR signaling.
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Figure 5.2: Schematic diagram of the role of GRK2 in the mechanism of hypertension
Alterations in GRK2 expression are proposed to induce a shift in the balance between
vasoconstrictor and vasodilator mechanisms regulating vascular tone and this leads to the
development of hypertension. GRK2 overexpression shifts the balance towards decreased
vasodilatation with intact vasoconstrictor responses. In the absence of GRK2, the balance
is shifted to favor vasoconstriction, but with enhanced vasodilatation responses.

Vasodilatation (Gαs) = Vasoconstriction (Gαq)
Normotensive
GRK2

Gαq
Hypertensive

Gαs
GRK2

Gαq
Hypertensive

Gαs

GRK2
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Our observations suggest that the loss of GRK2 expression favor an increase in
vasoconstriction likely due to reduced Gαq-mediated receptor desensitization since GαScoupled GPCRs that control vasodilatation are regulated slowly by GRK2-dependent
phosphorylation whereas Gαq-coupled GPCRs are regulated by both GRK2
phosphorylation-dependent and -independent mechanisms. Along these lines, it appears
that since both increases and reductions in GRK2 levels are not desirable – due to their
negative influence on cell functions – newer therapies will need to attempt to restore GRK2
functionality by accounting for its widely dissimilar roles in various cellular compartments.
Regardless of the avenues to be pursued in the future, it is reasonable to expect that
therapies to target GRK2 activity, rather than receptor inhibition, will be more effective in
the treatment of hypertension.
Since Gαq represents a common driving force behind both cardiac hypertrophy and
hypertension, it is possible that the selective inhibition of Gαq will provide new avenues in
the treatment of cardiovascular disease. It is important to note that the activated Gαq will
interact with the N terminus of GRK2 that – under in vitro conditions – is capable to inhibit
the Gαq-mediated activation of PLCβ (Carman et al., 1999). The characteristics of this
inhibition (enhanced by the presence of the agonist, occurs not only after GPCR stimulation
but also in the presence of constitutively activated Gαq) suggests that it might be a
consequence of the direct interaction with Gαq (Carman et al., 1999). In turn, this
interaction might be caused by a crucial proline residue that is present in Gαq, but not in
Gαi or GαS (Day et al., 2004; Tesmer et al., 2005). Because of this particularity, GRK2 is
prone to bind with the effector binding domain of Gαq that is responsible for Gαq
associations with PLC proteins as a prerequisite for downstream signaling (Tesmer et al.,
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2005; Lyon et al., 2014). Therefore, it is possible that a more in-depth investigation of
distinct protein-interacting domains of GRK2 will suggest new GRK2-based therapies
capable to prevent hypertension and heart failure and thereby will highlight the functional
relevance of GRK2 interactions.
The complexity of cellular responses elicited upon activation of GPCRs are tightly
regulated by phosphorylation status of the receptors mediated by GRKs. According to the
GRK subtypes, phosphorylation can be regulated differentially leading to distinct
phosphorylation profiles or “signalling barcodes” (Butcher et al., 2011). In this way, the
patterning of receptor phosphorylation determines the conformation of the bound βarrestins and, subsequently, its functional capabilities. Therefore, by adopting a specific
“phosphorylation profile,” a receptor could encode a particular signaling pathway (Kim et
al., 2005; Ren et al., 2005; Zidar et al., 2009). Members of the GRK family can
phosphorylate different sites on the same receptor whereas some receptors are actually
regulated by a single GRK (Torrecilla et al., 2007; Tobin et al., 2008). In our model,
chronic inhibition of GRK2 expression was associated with differential increases in the
other GRK subtypes (GRK3, GRK4, GRK5, and GRK6), increases that were synchronized
with the onset of the hypertensive state. Thereby, the follow-up question is whether the
activation of these kinases has a distinct role on the mechanisms of hypertension or their
increase induces a compensatory role in the attempt to balance the attenuation in GRK2mediated receptor desensitisation. Interestingly, while increased GRK5 levels positively
correlates with increased blood pressure, GRK3 and GRK4 seems to further sustain and
potentiate the GRK2-dependent mechanism of hypertension. As such, changes in GRKs
levels may reduce or enhance GPCR phosphorylation and thereby subsequently altering
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the downstream signaling pathway. It is worth to emphasise that even though GRKs
isoforms are expressed at low levels in basal conditions, their expression might be
important and relevant under pathological conditions. The challenge will remain to fully
comprehend the role played by GRKs in the disease state.

5.3

Future Directions

We have learned that shGRK2 transgenic mice are characterized by an intrauterine growth
restriction with a significant post-natal loss. Therefore, future studies could seek to
determine if GRK2 mice can be used as a model of intrauterine growth restriction (IUGR)
phenotype for studying of the mechanisms linking birth weight and hypertension.
From a strict diagnosis standpoint, IUGR is usually defined through a fetal weight
that falls under the 10th percentile of the normal body weight. However, this rather simple
definition tends to include – in addition to the targeted pathologies – underweight
individuals whose occurrence is normal in a population. IUGR is a complex phenomenon
caused by the intricated effects of multiple maternal, fetal, placental and environmental
factors. While the intrinsic correlation between the low oxygen/nutrients supply and IUGR
is widely acknowledged, the mechanistic substrate of this link is still largely unknown.
Since in addition to nutritive, placental and hormonal factors, IUGR dysregulations are
often associated with gene mutations and expressions (Mukhopadhyay et al., 2010; Chen
et al., 2011; Mando et al., 2011; Chelbi et al., 2012; Borzsonyi et al., 2013), it can be
inferred that the investigation of the related pathways by means of engineered transgenic
models might shed some light on the underlying molecular mechanisms.
Importantly, the use of a mouse model of IUGR will allow us to address novel
hypotheses related to the developmental origins of hypertension. Since the relationship
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between GRK2 levels and impaired vasoconstriction responses is causal for hypertension,
it would be interesting to decipher if this trait is also present in the fetal placental
vasculature. At early development stages, GRK2 is express in cells that are multipotent,
undifferentiated that undergo shape changes and are associated to migratory processes
(Sefton et al., 2000). At later development stages, GRK2 is present in several organs and
tissues supporting is broader role in embryogenesis. GRK2 is unique among the GRK
family members in that no embryos survived past embryonic day E15.5 under GRK2
knockout phenotype (Jaber et al., 1996; Matkovich et al., 2006). A greater understanding
of the essential function of GRK2 in the developing embryo would be of significant interest
especially since limited data are available. Therefore, future studies could seek to
determine what is the exact relationship between GRK2 downregulation and renal
development. Further, since our preliminary data indicate a loss in the number of nephrons
during embryonic development, it would be important to determine the conditional genetic
modifications involved in the cessation of nephrogenesis in shGRK2 mice. The
investigation of the complex role of GRK2 on embryogenesis could grant us a better
understanding of the role played by GRK2 under pathological conditions.
We have observed that down-regulation of GRK2 expression significantly decreases
age-related adiposity in shGRK2 mice compared to wild type littermates. Moreover, the
shGRK2 mice display higher respiratory exchange ratio and significant increases in both
total and ambulatory activity measurements. One possible future study could attempt to
investigate the molecular mechanisms responsible for these outcomes and it would be
interesting to evaluate whether the lean phenotype observed in the shGRK2 mice is caused
by a direct effect of GRK2 on energy homeostasis. Our data also indicate that several genes
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with role in lipid catabolism are upregulated in shGRK2 mice. In support of this idea, there
is evidence that GRK2+/− mice display an increase in gene expression related to
thermogenesis as well as enhanced lipolysis rate. Moreover, the overexpression of GRK2
can suppress lipolysis in white adipose tissue and energy burning in brown adipose tissue
(Vila-Bedmar et al., 2012). As such, future studies could analyze the specific role of GRK2
on cellular metabolism with potentially relevant targets in the treatment of obesity and
associated metabolic disorders.
The availability of animals models makes possible the study of molecular
mechanisms that influence the function of genes implicated in disease and disorders. The
development of a transgenic mouse model of specific vascular-targeted Rab4 inhibition
presented in Chapter 4 and the documentation of the hypertensive phenotype highlights a
number of interesting questions that could be pursued in the future. A greater
characterization of this model would enable us to understand the pathophysiological role
of Rab4 modulated GPCR internalization/recycling. Therefore, it would be of significant
interest to assess vascular reactivity in response to vasodilator and vasoconstrictor agonists.
We could further investigate the Gαs, Gαi, Gαq signaling via G protein and β-arrestinmediated pathways in primary cultures of VSMCs derived from Rab4S22N transgenic
mice. Since differences in Rab4 protein expression levels can vary from on cell type to the
other might be interesting to assess intracellular trafficking and signaling patterns of
GPCRs in primary cultures of endothelial cells obtained from the Rab4S22N transgenic
mice. To enable definition of the functional role of Rab4 on long term cellular responses,
3D scaffold methods can be employed to assess cellular proliferation, differentiation,
migration, and adhesion responses.
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